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11.1 AIMs And OutlIne Of thIs thesIs
Aims
1. To establish the production of HAdV-5 particles decorated with protein IX-fused 
polypeptide ligands that have proven potential for tumor targeting, such as single-
chain antibody fragments, single-chain T-cell receptors, or Affibody molecules.
2. To investigate the targeting efficacy and specificity of protein IX-ligand decorated 
HAdV-5 vectors to tumor cell lines.
3. To investigate the targeting of HAdV-5 to cancer-testis antigens through fusing 
a single-chain T-cell receptor with protein IX or fiber molecules.
4. To analyze the effect on transduction of incorporating cathepsin-cleavage sites in 
between HAdV-5 protein IX and its fused targeting ligand.
5. To obtain insight into the biological consequences of protein IX modification.  
Outline
Chapter 1 provides a general introduction on HAdV-5, which is the best-studied 
adenovirus serotype and the serotype most-often used for the construction of 
oncolytic vectors for cancer gene therapies. Important aspects on the biology of 
HAdV-5 are summarized, including the virion architecture, the infection route, and the 
replication mechanism. A separate paragraph is devoted to the minor capsid protein 
IX of HAdV-5, taking into account the important role of this protein in this thesis. 
Chapter 1 also provides a general overview on oncolytic adenovirus vectors. Vector 
modification strategies aiming at improved efficacy are described, as well as strategies 
for reducing transduction of non-target tissues. The ins and outs are provided for 
replication-deficient HAdV-5 vectors, as well as for the more recently developed 
Conditionally Replicating Adenoviruses (CRAds).
In Chapter 2 the most recent advances in oncolytic adenovirus technology are 
described, focusing on vectors for prostate-cancer treatment. The most prominent 
bottlenecks for successful cancer gene therapy with oncolytic viruses are reviewed, 
and potential solutions to overcome these hurdles are outlined.
Chapters 3, 4, and 5 describe the usability of the adenovirus minor capsid protein 
IX as an anchor for genetically fusing tumor targeting ligands.
The feasibility of fusing large and complex polypeptides to protein IX is described 
in Chapter 3. As a model ligand the hyper-stable single-chain antibody fragment 13R4 
was chosen, which binds with high affinity to β-galactosidase. Incorporation of protein 
IX-13R4 polypeptides in the virus capsid was achieved with our previously developed 
“protein-IX screening” system, encompassing the transduction of a protein IX-13R4 
producing helper cell line with a protein IX gene-deleted HAdV-5 vector, followed 
by harvesting and purification of the progeny viruses. Incorporation efficiency and 
functionality of 13R4 in the capsid of the HAdV-5 vector is discussed.
As a next step, using the same ligand incorporation strategy, a tumor-targeting 
ligand was fused with protein IX (Chapter 4). Since cancer-testis (CT) antigens have 
been described to be truly tumor-specific (except for their expression in the testis) 
it was decided to fuse protein IX with a single-chain T-cell receptor (scTCR) directed 
9
CHAPTER 1
against the CT antigen MAGE-A1, in complex with HLA-A1. Efficacy of targeting to 
HLA-A1/MAGE-A1 positive melanoma cell lines is described, as well as various assays 
to analyze the specificity of targeting. 
Chapter 5 describes the results on HAdV-5 viruses targeted to tumor cells through 
fusion of a high-affinity binding Affibody molecule to protein IX, and the effects of 
incorporating a cathepsin-cleavage site (ccs) in between protein IX and the Affibody 
molecule. Previous findings by us and by others suggested that protein IX-mediated 
targeting using ‘high-affinity binders’ (like Affibody molecules) as ligand is limited 
by inefficient release of protein IX-fused ligands from their cognate receptors in the 
endosome. This would result in inefficient endosomal escape of the virus particles. 
Chapter 5 comprises an extensive comparison between HAdV-5 viruses containing 
either wild type protein IX, protein IX-Affibody, or protein IX-ccs-Affibody in the 
capsid. The transduction efficiency is compared in monolayer cultures, 3-dimensional 
spheroid cultures, and in SKOV-3 tumors grown on the chorioallantoic membrane of 
embryonated chicken eggs.
In addition to the analyses of the protein IX-scTCR loaded HAdV-5 vectors, as 
described in Chapter 4, the usability of the HLA-A1/MAGE-A1 specific scTCR for 
HAdV-5 targeting was also tested in the context of fusion with the fiber protein 
(Chapter 6). The adenoviral fiber knob, which is responsible for attachment to the 
Coxsackie virus and Adenovirus Receptor (CAR) on target cells, was replaced by the 
scTCR molecule and an extrinsic trimerization motif in a replication-competent HAdV-5 
vector. The efficacy and specificity of targeting is presented through comparison of 
cell killing in a panel of melanoma cell lines.
Functional consequences of deleting the protein IX gene from HAdV-5 vectors 
are described in Chapter 7. The findings provide novel insights into the biological 
role of protein IX, and may be of relevance for future development and clinical 
implementation of protein IX-modified HAdV-5 vectors.
Chapter 8 provides a general discussion on the potency of protein IX-mediated 
tumor targeting for the development of improved oncolytic HAdV-5 vectors. 
Recommendations for further preclinical studies are included. Also, an overview is 
given on the newest insights and developments in preclinical testing of oncolytic AdV 
vectors in general. The anticipated essence of various model systems for future vector 
analyses is described. 
1.2 bIOlOGy Of huMAn AdenOVIrus tyPe 5 
Adenovirus was first isolated in the 1950s from adenoid tissue-derived cell cultures. 
These primary cell cultures were often noted to spontaneously degenerate over 
time, and human adenoviruses (HAdV), (belonging to the family Adenoviridae, genus 
Mastadenovirus) are now known to be a common cause of asymptomatic respiratory 
tract infection that produces in vitro cytolysis in these tissues. Based on serological 
parameters, hemagglutination parameters, restriction enzyme digestion patterns, 
and nucleotide sequence analyses, 55 types of HAdV have been described (51 
‘serotypes’ identified by traditional immunochemical methods, and 4 ‘types’ defined 
by genomics). These have been classified in seven species, A to G. Most HAdV 




can cause considerable morbidity, especially in individuals who are compromised 
immunologically (e.g. transplant patients) or nutritionally (e.g. gastrointestinal 
infections in children in the developing world).
Adenoviruses are icosahedral, non-enveloped viruses of approximately 90 nm 
in size, belonging to the largest non-enveloped viruses. Recently, the structure of a 
HAdV has been solved at the atomic level, providing the largest high-resolution model 
ever.1,2 Research on adenoviruses has yielded ample knowledge on various cell biology 
mechanisms, such as RNA splicing.3 Also, laboratory experiments on adenoviruses and 
their derived vectors has come along with the development of important molecular-
biological techniques like the calcium-phosphate DNA transfection method.4
Various aspects, including the relative safety, the well-known biology, and the 
suitability for genetic modification, have made vectors derived from HAdV type 5 
(belonging to the species C HAdVs) the currently most-often used vehicles for viral 
gene-delivery. HAdV-5 vectors have been used extensively as vaccine, and have 
shown great potential for ex vivo and in vivo gene therapies for treatment of hereditary 
diseases or cancer.
1.2.1 Virion architecture
A fully mature HAdV-5 particle, with an approximate mass of 150 MDa, consists of an 
icosahedral capsid of 20 facets and a core, as schematically depicted in Fig. 1. The 
pentons, hexons and fibers form the so-called major proteins of the adenovirus capsid. 
The minor proteins of the capsid are proteins IIIa, VI, VIII and IX. The core consists 
of a double-stranded linear DNA genome (36 kb in size) and of several proteins: 
proteins IVa2, V, VII, terminal protein (TP), mu, and the adenovirus protease.5,6 The 
HAdV-5 genome contains transcriptional units referred to as early (regions E1 to E4), 
intermediate (regions pIX and IVa2) and late (regions L1 to L5) depending on their 
temporal expression, relative to the onset of viral DNA replication.
The fiber protein in the capsid has been identified as the main cell binding protein, 
with the cell surface protein bound being the coxsackievirus and adenovirus receptor 
(CAR).7 CAR binds to the fiber knob domain, which is located at the carboxyl-terminus 
of the fiber shaft domain. The fiber tail is mounted on the vertex protein penton 
base. Penton base is located on each vertex and has protruding arginine-glycine-
aspartic acid (RGD)-domains that are involved in secondary cell binding and the 
initiation of virus endocytosis through integrin binding.8,9 Penton base has also been 
suggested to play a role in endosomal escape of virus particles, evidenced by the 
blocking of adenovirus induced endosomal lysis by α-penton antibodies and addition 
of soluble penton.10,11 The bulk of the capsid consists of 240 copies of trimeric hexon, 
contributing to approximately 50% of the mass of the capsid.12 The hexon content of 
a capsid can be divided in two subgroups. The groups of nine (GON) are a group of 
hexons that is frequently observed after dissociation of the capsid.13 The non-GON 
belonging hexons are the peripentonal hexons. These are, as the name suggests, 
the hexons in direct contact with the penton bases. Each trimeric hexon has three 
towering structures on top, with a cavity in between that can be bound by coagulation 
factor X in HAdV-5.14,15
Most minor capsid proteins have an assigned capsid localization, but their mechanism 
of function has often not yet been fully resolved. Protein IIIa was found to be important 
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for packaging the viral DNA as well as capsid maturation and localizes on the inner side 
of the pentons.16 Protein VI has been localized to the inner cavity of hexons and has 
a function in hexon transport into the nucleus during virus assembly, as well as being 
involved in the lysis of endosome membranes.17-19 Protein VIII (assigned to the inner 
capsid) is thought to provide the capsid stability but the exact functions remains to be 
solved.20 A description on the smallest but most abundant minor capsid protein, protein 
IX, is provided in more detail below, since this protein plays a major role in this thesis. 
1.2.2 Cellular infection route
Different receptors are involved in adenovirus cell binding.21 The main receptor 
for adenoviruses is CAR, which binds to the fiber knob.7 Alternatively, species B 
adenoviruses utilize different receptors, that is, CD46 for species B1 (serotypes 16, 21, 
35, 50), desmoglein 2 for species B2 (serotypes 3, 7, 14), and CD46 or desmoglein 2 for 
species B3 (serotype 11).22 Furthermore, cell surface sialic acid molecules can be utilized 
as a receptor by various serotypes, such as HAdV-37 from species D.23,24 Recently, a 
new mechanism of cellular uptake was discovered for HAdV-5, via the interaction of 
hexon with coagulation factor X (FX). This mechanism appears to be a major cause for 
the uptake of systemically introduced HAdV-5 vectors in the liver, through the binding 
of virus-bound FX to heparan sulphate molecules on hepatocytes.14,15,25 However, it 
Figure 1. Schematic representation of 





remains to be established how important the latter mechanism is for transduction 
of liver cells in humans. After the initial docking of a HAdV-5 particle to its primary 
receptor, various secondary interactions can occur, the most prominent one being 
the interaction of RGD domains of penton base with integrins αvβ3 or αvβ5.
8,9 Also 
heparan sulphate proteoglycans have been identified as cell surface molecules for 
secondary interactions, through binding to the fiber shaft.26 Shortly after cell binding 
the fiber is shed.27,28 The interaction of penton base RGD domains with cellular 
integrins induces a conformational change of penton base monomers, suggested 
to be necessary for fiber release or for breaking contacts with the surrounding 
hexons, allowing the fiber or the penton base to be released.29 Integrin aggregation 
through penton-base binding localizes the virus to clathrin coated endosomes, the 
main entry route for adenovirus.30 Integrin binding also activates various intracellular 
signaling routes, including the MAPK/p38 and the p85/p110 PI(3) kinase routes, which 
is thought to influence susceptibility of adenovirus uptake by the canonical routes 
and by other endocytosis pathways such as macropinocytosis.31,32 Once the virus is 
in the clathrin-coated endosome and the environment acidifies, the release of pVI 
triggers endosomal escape.18,19 Once in the cytosol, HAdV-5 binds molecular motors 
that move over microtubules; a minus end directed motor (kinesin) and a plus end 
directed motor (dynein). These motors are engaged in a tug of war principle, resulting 
in speeds of movement of micrometers per minute.33,34 Hexon seems to be the protein 
responsible for binding kinesins and dyneins.35 Whether the movements of the viral 
particle occur according to a stochastic tug of war principle or whether all movements 
are coordinated is still subject of debate.36 Alternatively, microtubule independent 
transport has been reported, suggesting other cytosolic transport mechanisms.37,38 
When the partially dismantled HAdV-5 particle reaches the nucleus, it binds the nuclear 
pore complex and is further dismantled.39 Subsequently, the viral DNA is imported and 
transcription of genes can be initiated.
1.2.3 Replication
The adenoviral genes can be classified in three groups, based on their time 
of transcription after infection: the early genes (E1A, E1B, E2, E3, and E4), the 
intermediate genes (pIX and IVa2), and the late genes (L1 to L5).40 Genes are 
transcribed from both DNA strands and the majority of RNA transcripts are subject 
to complex splicing patterns. The first messengers to be transcribed after infection 
are the E1A transcripts. The E1A proteins induce the cell to enter the cell cycle, 
necessary for replication of the adenoviral DNA, through binding cellular proteins 
including the retinoblastoma gene product Rb. The E1B-55kD protein binds p53, 
thereby preventing apoptosis or blockage of the cell cycle. The E2 proteins (terminal 
protein, DNA-polymerase, and single-stranded DNA binding protein) are involved 
in viral DNA replication, the E3 proteins play essential roles in down-regulating the 
host immune response against HAdVs, and the E4 proteins have multiple functions in 
the regulation of viral transcription, replication and mRNA transport. The late genes 
encode the capsid proteins, with the exception of capsid protein IX, which is a product 
from an intermediate gene.   
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1.2.4 Capsid protein IX
The 14.3 kDa protein IX is the smallest of the HAdV capsid proteins. Protein IX is 
unique to the Mastadenoviruses and is, in contrast to the other capsid proteins, absent 
in the other adenovirus genera. During the viral replication cycle, the transcription of 
protein IX messenger RNAs is, for unknown reasons,  initiated relatively early after 
infection, as compared to the mRNAs of the other capsid proteins.40 Each virus facet 
contains 12 molecules of protein IX, resulting in a total of 240 molecules per virion. 
The protein has three conserved regions, as shown by amino acid alignment, located 
at the amino-terminus, the middle part, and the carboxyl-terminus of protein IX. 
The amino-terminal regions of protein IX are positioned in the cavities between the 
hexon tops of hexons that belong to a GON. Each cavity contains the amino-termini 
of three molecules of protein IX.41 The recent determination of the HAdV-5 structure, 
by means of cryoelectron microscopy and x-ray analyses, has revealed the carboxyl-
terminus of protein IX to be present in the capsid as quadrimeric coiled-coils, at a 
location previously assigned to the minor capsid protein IIIa.1,2,42,43 The orientation of 
the four coiled-coils is parallel for three of the coils, originating from one facet of the 
capsid, and anti-parallel for one coil, originating from a neighbouring facet.1,2,43 Taken 
together, these assignments result in a large network of protein IX, spanning the entire 
capsid (Fig. 2).
Despite many years of research the definite function of protein IX is still to be 
assigned. The protein highly likely acts as capsid cement, since deletion of the protein 
causes thermal instability.44 The amino-terminus appears to be exclusively responsible 
for incorporation of protein IX in the virus capsid and for providing the capsid its 
thermal stability, probably through stabilizing the GONs.45 Besides its postulated role 
in providing the virion stability, protein IX seems to play a role in viral DNA packaging, 
as suggested by the finding that viruses lacking protein IX have a strong reduction 
in infectivity if the genome is larger than 95% of wild-type size (>35 kb).46,47 The 
carboxyl-terminus of protein IX, which can be deleted from HAdV-5 without affecting 
thermostability, has been suggested to be essential for post-infection interactions 
of protein IX with cellular factors, resulting in a stimulatory effect on promoters of 
early viral genes.48 However, this effect, which was found in a non-viral context, was 
subsequently toned down by another study, showing no significant effect of protein IX 
on viral transcription in the context of viral infection.49
Interestingly, protein IX was reported to form clear amorphic bodies in the 
nucleus, strongly resembling the so-called PML (promyelocytic leukemia protein) 
bodies in terms of size and protein contents (including PML and sp100).50 Deleting 
the carboxyl-terminus of protein IX abrogated the capacity of protein IX to form PML 
bodies. Appreciating the importance in cellular biology of PML bodies, for example 
functioning in regulation of cell cycle and cell growth, it was tempting to speculate on 
a role of (the carboxyl terminus of) protein IX in host cell modulation.50 However, such 
a role has not been confirmed in subsequent experiments. The relevance of the PML-
protein IX bodies in HAdV-5 biology is questionable, based on results obtained in our 
laboratory (De Vrij, unpublished data, Fig. 3). To our surprise, expression of protein 
IX in normal diploid cells (VH10 cells (primary foreskin fibroblasts) and mesenchymal 
stem cells (MSCs)) results in protein IX localization in both cytoplasm and nucleus, 











Figure 2. Capsid structure of HAdV-5. (a) Protein density on an exterior region of the capsid, roughly 
corresponding to one icosahedral facet. The model was created through overlaying a cryo-electron 
microscopy model of the entire virus particle (at 6-Å resolution) with X-ray crystallography structures 
of individual proteins. Penton base monomers are indicated in yellow, and hexons are indicated in 
green (position 1), cyan (position 2), blue (position 3), and magenta (position 4). Protein IX densities, 
as four trimeric regions and three helical bundles, are indicated in red. Hexons belonging to a group 
of nine (GON) are marked with an asterisk (*). Figure adapted from Saban et al.42 (b) CryoEM (at 3.6-Å 
resolution) reveals a physical network of protein IX in the capsid, lashing together hexons into GON 
tiles. Left insets: Ribbon models of the N-terminal domains of three protein IX monomers (blue, green, 
and red), overlaying the models of three adjacent hexon monomers (H2, H3, and H4) (gray). The 
N-terminus of protein IX is in close proximity to the FG2 region of a hexon monomer (lower left inset). 
Right insets: Ribbon models of the C-terminal domains of protein IX. Four C-terminal domains form a 
bundle consisting of three parallel α-helices and one antiparallel α-helix. The helices are linked by a 
ladder of hydrophobic residues (leucines and valines) (magenta). Bottom inset: Ribbon model of protein 
IX showing three distinguished domains as well as the N-joint region. Figure adapted from Liu et al.1
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IX appeared not to co-localize with PML. In the context of HAdV-5 infection in these 
primary cell cultures, protein IX localizes to the nucleus, regularly forming ring-like 
structures. In contrast, and in line with the results published by Rosa-Calatrava et al.,50 
protein IX formed nuclear bodies in transformed cell lines like A549 alveolar epithelium 
cells. These observations argue against a role of protein IX in nuclear sequestration of 
PML in non-transformed cells.
1.3 AdenOVIrus VeCtOrs fOr CAnCer therAPy
Genetically modified adenoviruses have been explored extensively as gene-transfer 
vehicle for the purpose of gene therapy or vaccination.53 Several characteristics 
make adenoviruses highly suitable as gene-transfer vehicle: a relatively low level 
of pathogenicity; a high stability of the viral DNA genome, thereby preventing the 
Figure 3. Subcellular localization of protein IX in mesenchymal stem cells, as visualized by 
immunohistochemistry. (a) Detection of protein IX and promyeolocytic leukemia (PML) protein after 
establishing lentiviral vector-mediated heterologous expression of protein IX. The cells were fixed with 
acetone-methanol (1:1). Staining was performed by means of primary incubation with the antibodies 
α-protein IX (rabbit, polyclonal)51 and α-PML (5E10; mouse, monoclonal),52 followed by secondary 
incubation with  α-rabbit-FITC and α-mouse-Alexa594, respectively. (b) Detection of protein IX after 
infection with HAdV-5. Infection was performed with 10 virus particles per cell. The cells were fixed 
with acetone-methanol (1:1), at 72 hours post infection. Staining was performed through subsequent 





development of heterogeneous populations of ‘quasispecies’; the ability to transduce 
dividing as well as quiescent cells; the well known biology and uncomplicated genetic 
modification; the availability of technologies for production of clinical-grade virus 
batches with high titers and high purity. Adenoviruses can be used either as replication-
deficient or replication-competent vectors. The replication-deficient vectors can be 
used as gene delivery vehicle for gene augmentation therapy (e.g. through delivery of 
genes that are mutated in the vector-receiving patient) or cancer therapy (e.g. through 
delivery of prodrug-activating genes). Also, replication-deficient vectors are being 
used (with proven efficacy and safety) as vaccine vector to induce immune responses 
against antigenic polypeptides that are displayed on the viral capsid or encoded 
for by the viral vector.54 More recently, replication-competent adenovirus vectors, or 
Conditionally Replicating Adenoviruses (CRAds), have been developed, exploiting 
the lytic infection cycle of the virus to kill tumor cells. Various modifications can be 
introduced to CRAds to provide tumor cell selective replication.
Currently, the large majority of adenovirus vectors for cancer therapies are derived 
from HAdV of serotype 5, mainly as a result of its well known biology and its proven 
safety. In the next paragraphs a general overview is given on the development of 
HAdV-5-derived vectors for cancer therapy, describing replication-deficient as well 
as replication-competent vectors. An extensive outline is provided on rational design 
approaches towards improved oncolytic HAdVs, such as capsid modifications for 
targeting and detargeting purpose. Preclinical developments on random approaches, 
such as bioselection with mutagen-induced viral libraries, are summarized as well.
1.3.1 Replication-deficient vectors
Different types, or ‘generations’, of replication-deficient HAdV-5 vectors have been 
developed. The first-generation vectors have the E1 region deleted.55 This deletion 
renders the recombinant virus replication-defective, providing an important safety 
feature. The production of E1-deleted vectors is dependent on specialized helper 
cells that provide the E1 functions in trans. The most frequently used helper cell lines 
are the 293 cell line (human embryonic kidney cells transformed with sheared HAdV5 
DNA)56 and the 911 and PER.C6 cell lines (human embryonic retinoblasts transformed 
with a plasmid carrying a defined portion of the adenovirus genome).57,58 By combining 
removal of the E1 region with removal of the E3 region, which encodes for proteins 
involved in evasion of the immune system and is dispensable for vector growth in 
vitro, approximately 7500 base pairs of heterologous DNA can be accommodated in 
HAdV-5 vectors.
The first-generation HAdV-5 vectors appeared to be suboptimal for certain gene-
delivery applications, mainly as a result of the induction of a strong cell-mediated 
immune response.59 These responses appeared to be a result of viral protein expression. 
As a consequence second-generation HAdV-5 vectors were made in which deletions 
or mutations were introduced in the E2 and E4 region. These modifications resulted 
in a substantial reduction of the cellular immune response and, as a consequence, 
prolonged transgene expression.55 Also third-generation or ‘high-capacity’ HAdV-5 
vectors have been developed, which are devoid of all viral genes and can accommodate 
up to 35 kilo bases of heterologous DNA.55,60 The only remaining viral sequences are 
the inverted terminal repeats (ITRs) and the packaging signal. Production of high-
17
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capacity vectors requires the usage of a helper virus to provide all viral functions 
and structural proteins in trans. Elegant systems have been developed to prevent the 
presence of helper virus contaminants in the final high-capacity vector preparation. As 
intended, high-capacity HAdV vectors have a strongly improved duration of transgene 
expression as compared to first- or second-generation HAdV vectors, as a result of 
a reduced cellular immune response.55
As evidenced by various studies, the first-generation HAdV-5 vectors are inferior to 
the higher-generation vectors in these gene-delivery applications that require the in 
vivo expression of large heterologous genes for prolonged times. However, the usage 
of replication-deficient vectors for the (short-term) expression of oncolytic genes in 
cancer cells not necessarily requires the usage of higher-generation vectors. First-
generation vectors can perfectly accommodate the majority of anti-tumor transgenes 
and, importantly, induce immune responses that might be of benefit for the efficacy 
of the therapy (e.g. through induction of a cellular immune response against tumor 
antigens). Examples of anti-tumor transgenes are genes encoding for prodrug 
converting enzymes (e.g. the Herpes Simplex Virus thymidine-kinase (HSV-TK) for 
activating gancyclovir, the bacterial nitroreductase for activating CB1954), immune 
stimulatory cytokines (IL-2, IL-12, GM-CSF, IL-24), or apoptotic proteins (e.g. p53).61 
Specificity of transgene expression can be provided through the inclusion of tissue-
specific promoters.
To improve the specificity and efficacy of AdV vectors, a large variety of capsid 
modifications is being pursued. Such modifications aim, on one hand, on the 
enhancement of tumor cell transduction (e.g. through fusing tumor-targeting 
polypeptides to the viral capsid) and, on the other hand, on reduced transduction of 
non-target cells or tissues. Transductional targeting and detargeting approaches will 
be discussed in Paragraph 1.2.3.    
1.3.2 Conditionally-Replicating Adenoviruses (CRAds)
Past clinical trials have defined major limitations of replication-deficient vectors for 
cancer gene therapy, as a result of their inability to infect the majority of cells within 
a clinically presented three-dimensional solid tumor mass.62 Conditionally Replicating 
Adenoviruses (CRAds) are designed to overcome this limitation by making use of the 
natural ability of HAdV-5 to kill their host cells upon its spread throughout a tissue. 
To provide specificity of cell killing, CRAds are designed in such a way to restrict 
their replicative ability to tumor cells. Besides the direct lytic effect of CRAds, their 
induction of cell death might cause anti-tumor immune responses as a positive 
bystander effect.63,64 Future research is necessary to fully delineate the effects of CRAd 
therapies on the patient’s immune system.
CRAds are rendered tumor-specific by taking advantage of cancer-specific cellular 
changes. It was found by Berk et al. that disruption of the HAdV-5 E1B-55K gene in 
the mutant dl1520 yielded specific replication in cancer cells.65 Based on previous 
experiments showing an ability of E1B-55K to interact with the tumor-suppressor protein 
p53, it was initially thought that the tumor selectivity of dl1520 was due to p53 being 
mutated in cancer cells. However, dl1520 was found to replicate in p53-expressing 
cancer cells as well.66,67 Despite the controversy on the mechanism behind the tumor 




vectors. The dl1520 virus has been tested in a variety of cancer clinical trials (under 
its commercial name ONYX-015) including head and neck cancer,68 oral carcinoma,69 
colorectal carcinoma metastases to the liver,70 hepatocellular carcinoma71 and glioma.72 
These studies have demonstrated safety, with well tolerated doses of up to 2 x 1012 
particles (by various routes of injection) and tumor-selective replication. The efficacy 
as a single agent has been relatively limited to date (0-14% local tumor regression 
rates), but encouraging anti-tumor activity has been demonstrated in combination with 
chemotherapy.73 A very similar virus, H101, has been registered for clinical use in China.
Cancer cell-specific CRAds can also be made by mutating the E1A gene.74 A 24-bp 
deletion was found to prevent E1A from binding to the cellular protein Rb for induction 
of the cellular S-phase. As a consequence, replication depends on the inactivation 
of Rb through other means (e.g. hyperphosphorylation) which is the case in most 
types of cancer. Clinical safety and efficacy of E1AD24 CRAds is subject of current 
research. Recently, the maximum tolerated dose, toxicity spectrum, clinical activity, 
and biological effects were evaluated for a E1AD24 CRAd (named Ad5-Δ24-RGD) in 
patients with ovarian cancer.75 Besides having the 24-bp deletion, to establish tumor-
selectivity, this CRAd also contained an RGD-domain fused to the fiber, to enhance 
efficacy of the treatment. The approach appeared to be safe, and a minor antitumor 
response was found.
As an alternative to the E1 deletions, CRAds can be created through the 
incorporation of tissue-specific promoters to control the expression of essential viral 
genes. As an example, expression of the viral E1A gene can be controlled by the 
recombinant prostate-specific PPT sequence, which is composed of a prostate-specific 
antigen (PSA) enhancer, a prostate-specific membrane antigen (PSMA) enhancer and 
a T cell receptor gamma-chain alternate reading frame protein (TARP) promoter.76 
As a result, the AdV vector replicates exclusively in normal and neoplastic prostate 
epithelial cells.
A large variety of modifications is being explored, to further improve the efficacy 
and specificity of CRAds. Similar to the replication-deficient vectors, the CRAd 
genome can be armed with ‘cell killing transgenes’, which may improve the efficacy 
of tumor eradication. As an example, arming the dl1520 virus with the HSV-TK/
Ganciclovir system results in increased survival rates in mice with subcutaneous colon 
cancer xenografts.77 Alternatively, CRAds with improved clinical performance may be 
obtained by the insertion of genes coding for proteins with antitumor effect on the 
tumor micro-environment, such as angiogenesis inhibition or immune activation.78 To 
improve the specificity and safety of CRAds, their replication can be blocked in non-
target cells by incorporating microRNA (miRNA)-binding sequences in viral genes. 
In this way, multiple binding sites for a hepatocyte-specific miRNA, mir-122, have 
been placed in the 3’ untranslated region of the E1A gene of a CRAd, leading to the 
absence of E1A gene expression (and viral replication) in murine hepatocytes and a 
significant reduction in hepatotoxicity.79,80
Furthermore, capsid modifications for targeting and detargeting approaches are 
pursued, as will be discussed in the next paragraph.
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1.3.3 Capsid modifications for targeting and detargeting
Studies on oncolytic HAdV-5-based vectors, in preclinical- as well as early phase 
clinical settings, have demonstrated the necessity of introducing modifications in 
the viral capsid to improve the efficacy and safety in the complex environment of 
a patient’s tumor.
One important efficacy-limiting aspect is the low-level expression of the CAR 
receptor on many tumor cells, necessitating capsid modifications to alter the wild-
type tropism of HAdV-5.81,82 Development of modified vectors that can infect CAR-
negative cells has mainly focused on the genetic incorporation of heterologous 
ligands in the fiber protein, or on ‘fiber-swap’ strategies in which the HAdV-5 fiber is 
replaced by a fiber from another HAdV serotype.83 Although effective, the applicability 
of incorporating large and complex ligands (e.g. single-chain antibody fragments) into 
fiber locales might be limited, since such modifications in many cases result in virus 
replication with low titers.21 This drawback has prompted the identification of other 
capsid proteins (hexon, penton base, protein IIIa, and minor capsid protein IX) as 
usable locales for incorporating heterologous peptides (reviewed by Vellinga et al.5).
An interesting locale for the fusion of polypeptides is the minor capsid protein 
IX. Fusing polypeptides to the carboxyl-terminus of protein IX does not reduce the 
viral titers upon in vitro production, and has no effect on the stability of the virus 
particles.45 It was found that the presentation of protein IX-fused peptides can be 
improved through incorporating a 75-Ångstrom alpha-helical spacer in between 
protein IX and the peptide.84 Using the protein IX-spacer sequence as anchor, highly 
efficient coverage of the virions with heterologous peptides can be obtained with 
incorporation efficiencies close to the theoretical maximum of 240 molecules per 
virion, depending on the size and complexity of the polypeptide. The feasibility of 
targeting HAdV-5 to tumor cells through fusing tumor-targeting ligands to protein IX 
has subsequently been investigated, as described in detail in this thesis.     
Nowadays, elegant systems are available for creating genetically modified HAdV-5 
vectors, which enable cloning and recombination steps in a bacterial context instead 
of in human cell lines. Still, genetic modification of the HAdV-5 genome is a time- 
and effort consuming process, limiting the rapid screening of polypeptide moieties 
for their capsid incorporation ability. For this reason, screening-facilitating systems 
have been developed based on the propagation of HAdV-5 vectors on cell lines 
expressing heterologous peptides fused to a capsid protein. Such systems have been 
used successfully for expedited functional assessment of modified variants of protein 
IX and fiber.85,86  
An alternative to genetically modifying the viral vector for transductional purposes 
has been provided by ‘adapter strategies’, applying bispecific targeting moieties 
that on one hand bind to the virus (in general to the fiber knob domain), and on 
the other hand to a molecule on the target cell. As an example, HAdV-5 vectors 
have been efficiently retargeted to HER2/neu expressing tumor cells through using 
designed ankyrin repeat proteins (DARPins) as bivalent adapter molecules.87 The 
adapter technology has several potential advantages with respect to the genetic 
modification technology, in that it enables the relatively rapid screening of targeting 
ligands, and provides a production platform for the preparation of high-titer batches 




ligands. However, special care will be required to ensure the preparation of clinical 
batches with defined characteristics, for example assuring low variability of ligand 
incorporation efficiencies between different vector preparations.      
The above described modifications aim at enhanced transduction of tumor cells 
through coupling tumor-targeting ligands to the HAdV-5 capsid. Another strategy to 
improve the potency of oncolytic HAdV-5 vectors is by detargeting the vector from non-
target tissues. As discussed in more detail in the next chapter, last years have witnessed 
an enhanced understanding on the in vivo mechanisms behind the disappointing anti-
tumor efficacies of oncolytic HAdV-5 vectors in early-phase clinical trials. One aspect 
thwarting effective therapy is the high prevalence of pre-existing humoral immunity 
against HAdV-5 in the human population, resulting in rapid clearance of the vectors 
from the blood. Additionally, strong innate immune responses, e.g. by natural killer 
cells, are observed after intratumoral or systemic injection of oncolytic HAdV-5 vectors. 
Another bottleneck, especially hampering the efficacy of systemically delivered 
oncolytic HAdV-5 vectors, is the rapid clearance from the blood stream as a result of 
sequestration in the liver. It has recently been found that binding of HAdV-5 to blood 
coagulation factor (F) X, results in uptake of the vectors by hepatocytes in the liver.14,15 
FX appears to bind to viral capsid epitopes of the hexon protein, and bridges the 
virus to heparan sulphate proteoglycans on hepatocytes. Besides the FX-hepatocyte 
mediated removal of oncolytic HAdV-5 vectors, the vectors are also cleared form 
the blood by liver-residing macrophages (Kupffer cells).88 Binding of the vectors to 
complement proteins, natural antibodies and platelets seems to play an important 
role in the uptake by these scavenging macrophages.89,90 Another problem to tackle is 
the binding of HAdV-5 vectors to erythrocytes.91,92 This binding appears to be specific 
for human erythrocytes, and has therefore not been noticed previously during vector 
analyses in rodent models. Last years have seen enormous pre-clinical improvements 
in the efficacy of HAdV-5 based oncolytic vectors, through applying novel types of 
modifications leading to improved transductional targeting and detargeting. One 
highly promising example is the ability to genetically modify viral hexon sequences to 
abolish uptake of virus particles by hepatocytes, thereby enhancing gene transfer to 
target cells.93,94
Additionally, strategies have been developed to reduce off-target binding by 
shielding the adenovirus vector particles with chemical polymers.95 In animal models, 
this technology significantly increases the circulation time of HAdV-5 vectors in the 
blood stream, and simultaneously reduces liver toxicity.96,97 Similar to targeting of 
the ‘naked’ vector particles, the polymer coatings can also be modified to achieve 
targeting to tumor cells.98 Research is ongoing to further improve the polymer coating 
technology, for example aiming at ‘low pH triggered de-shielding’ to facilitate 
proper intracellular routing of polymer coated virus particles after their uptake in the 
endosome. As an alternative to the polymer coatings, ‘carrier cells’ might be utilized to 
shield HAdV-5 vectors from efficacy-limiting moieties. Various cell types with intrinsic 
tumor-homing properties, such as mesenchymal stem cells, T cells, and monocytes, 
are currently under investigation.99
Taken together, a large array of new targeting and detargeting approaches has 
been developed to facilitate improved performance of oncolytic HAdV-5 vectors. The 
most up-to-date developments in the field of oncolytic HAdV-5 vector engineering, 
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as well as prominent aspects that require further optimization, are outlined in more 
detail in Chapter 2. 
1.3.4 Random approaches to vector development
As described in the previous sections, a plethora of rational design approaches is being 
pursued to develop AdV vectors with improved performance. However, last years 
have witnessed a renewed interest in the more traditional ‘directed evolution’ method 
of oncolytic vector development; the random creation of virus mutants followed by 
bioselection of the best-performing viruses. This approach has yielded improved 
oncolytic HAdVs with genomic mutations that would have never been picked up using 
rational design approaches. These findings not only benefit to the development of 
improved oncolytic HAdVs, but also enhance our knowledge on HAdV biology.
Following a mutagenesis and bioselection approach, Yan et al. plaque purified 
two mutants, ONYX-201 and ONYX-203, from a pool of randomly mutated HAdV-5 
that was repeatedly passaged in the human colorectal cancer cell line HT29.100 The 
mutants replicated more rapidly in HT29 cells than wild-type HAdV-5, and lysed HT29 
cells up to 1,000-fold more efficiently. The enhanced cytotoxicity was also observed 
in other human cancer cell lines, but not in a number of normal primary human cells, 
indicating a strong enhancement of the therapeutic index of ONYX-201 and ONYX-
203. Although the virus mutants contained multiple single-base-pair mutations, 
they shared a mutation at nucleotide 8350, which was shown to be essential for the 
observed phenotype. This mutation was mapped to the i-leader sequence of the 
HAdV-5 genome, which is (for unknown reasons) present as a 440-nucleotide leader 
sequence in the majority of HAdV-5 major-late transcripts. The i-leader contains an 
open reading frame encoding for a 16 kDa-sized protein.101 The mutation at nucleotide 
8350 introduces a stopcodon, resulting in a truncation of 21 amino acids from the C 
terminus of the i-leader protein. In parallel to these results, another i-leader mutant 
HAdV-5 was isolated by Subramanian and coworkers in a screen for large plaques on 
A549 alveolar epithelium cells.102 Although the exact mechanism behind the improved 
oncolytic performance of i-leader mutated HAdV-5 remains to be investigated, the 
potential of this type of mutation was recently underscored by Van den Hengel et al., 
who demonstrated enhanced cytopathic activity of i-leader mutated HAdV-5 in glioma 
cell lines and primary glioma cultures.103
Using similar mutagenesis and bioselection approaches, another type of HAdV-5 
mutant with enhanced antitumor efficacy was found by Gros et al.104 The propagation 
of a mutagenized HAdV-5 stock in human tumor xenografts led to the isolation of a 
mutant virus displaying a large-plaque phenotype in vitro and an enhanced antitumor 
activity in vivo. A truncating mutation in the viral E3-19K gene, resulting in relocalization 
of the E3-19K protein from the endoplasmatic reticulum to the plasma membrane, 
appeared to be responsible for the mutant’s enhanced antitumor efficacy. The aberrant 
protein localization appeared to enhance the cellular influx of calcium ions, thereby 
deregulating calcium homeostasis and inducing membrane permeabilization.
Recently, Uil et al. presented another type of directed evolution, through serial 
passaging of HAdV-5 in cancer cells in the context of a ‘sloppy’ viral polymerase protein.105 
To this aim, the authors first identified mutations in the viral polymerase protein that lead 




having a mutation in the single-strand DNA binding region of the exonuclease domain, 
were exploited to generate HAdV-5 mutants with improved cytolytic activity in tumor 
cells. A common mutation was identified, located in a splice acceptor site preceding the 
gene for the adenovirus death protein (ADP). Accordingly, high and untimely expression 
of ADP was observed, presumably causing the enhanced cytotoxicity.
Kuhn and coworkers have used a directed evolution approach to obtain chimeric 
oncolytic adenoviruses, that consist of components from different HAdV serotypes.106 
An array of serotypes, representing HAdV species B to F, was pooled and passaged on 
tumor cell lines under conditions that invite recombination. By using this methodology, 
a highly potent oncolytic HAdV-3/HAdV-11p chimeric virus (named ColoAd1) was 
obtained. ColoAd1 demonstrated greatly enhanced potency and selectivity, as 
compared to its parent serotypes and ONYX/015, in colon cancer cell cultures and in 
a mouse tumor model.   
The proven potential of random selection approaches has triggered researchers to 
combine this type of approach with rational design. As such, improved HAdV vectors 
targeted to prostate cancer cells have been isolated after genetically incorporating 
random peptides at viral capsid locales flanking the tumor-targeting polypeptide 
sequence.107
Directed evolution approaches are expected to lead to the isolation of novel and 
improved oncolytic HAdVs. Performing such strategies in clinically relevant model 
systems will be of great interest, acknowledging the large repertoire of efficacy-
limiting in vivo aspects of oncolytic viral therapy, with many aspects having non-
resolved mechanisms of action.
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CHAPTER 2
AbstrACt
Prostate cancer is a leading cause of death among men in Western countries. Whereas 
the survival rate approaches 100% for patients with localized cancer, the results of 
treatment in patients with metastasized prostate cancer at diagnosis are much less 
successful. The patients are usually presented with a variety of treatment options, 
but therapeutic interventions in prostate cancer are associated with frequent adverse 
side effects. Gene therapy and oncolytic virus therapy may constitute new strategies. 
Already a wide variety of preclinical studies has demonstrated the therapeutic 
potential of such approaches, with oncolytic prostate-specific adenoviruses as the 
most prominent vector. The state of the art and future prospects of gene therapy 
in prostate cancer are reviewed, with a focus on adenoviral vectors. We summarize 
advances in adenovirus technology for prostate cancer treatment and highlight areas 
where further developments are necessary.
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IntrOduCtIOn 
Although many viruses are being evaluated as oncolytic agents, human adenoviruses 
(HAdVs) are among the most popular to be developed. There are several good 
reasons for making HAdV vectors such a popular choice. Recombinant HAdV vectors 
have a good safety profile as a gene therapy vector, can be produced under GMP 
conditions, and various commercially operating manufacturing facilities are available, 
allowing research groups access to batches of HAdV vectors that meet the required 
quality standards. In addition, the wild-type HAdVs from which vectors are derived are 
only mildly pathogenic.1 Although HAdV genomes are stable enough to prevent the 
rapid development of heterogeneous populations of so-called quasispecies, they are 
easily amendable by genetic modification. Genetically modified HAdVs with altered 
host range (‘‘targeted viruses’’) have been generated by engineering new polypeptide 
ligands in the capsids of the particles, yielding viruses that preferentially infect specific 
cell or tissue types. In parallel, by engineering mutations at known receptor-binding sites 
in the capsid, ‘‘detargeted’’ HAdV vectors have been generated to reduce transduction 
of nontarget tissues. Also, HAdVs can be modified to carry therapeutic or reporter 
transgenes.2 Numerous and diverse transgenes have been inserted in E1-deleted 
HAdVs to be exploited as cytolytic agents. Such therapeutic transgenes include genes 
encoding prodrug-activating enzymes (e.g., herpes simplex virus thymidine kinase for 
activating ganciclovir, cytosine deaminase for activating 5-fluorocytosine, bacterial 
nitroreductase activating CB1954), genes encoding immune-stimulatory cytokines 
(interleukin [IL]-2, IL-12, granulocyte-macrophage colony-stimulating factor [GMCSF], 
and IL-24), or genes encoding proteins inducing apoptosis (e.g., p53). More recently, 
conditionally replicating adenoviruses (CRAds) have been developed. Such viruses 
rely on the lytic replication cycle of HAdVs for tumor cell killing. Viral replication in 
the tumor increases the local vector concentration and may lead to spread of the virus 
within the tumor. In addition, HAdV may provide a danger signal that stimulates an 
antitumor immune response.3 Successful preclinical studies have led to various phase 
I clinical trials of replication-defective as well as conditionally replication-competent 
HAdV vectors in prostate cancer.4,5 So far these studies have confirmed the good 
safety profile of HAdV vectors. Taken together, these factors have made adenoviral 
vectors a prime candidate for developing viral oncolytic agents.
GettInG the VIrus tO the tuMOr
Intratumoral injection
An important lesson learned from preclinical and clinical research in cancer gene 
therapy is that efficient transduction of the cancer cells in the tumor is essential for 
efficacious treatment. Tumors are heterogeneous and contain a stromal compartment 
and extracellular matrix components that form physical barriers within the tumor 
(Fig. 1). Therefore even direct intratumoral administration of viral anticancer agents 
is often disappointingly inefficient. Expression of the receptor used by most HAdVs 
to enter the cell, that is, the coxsackievirus and adenovirus receptor (CAR), is often 
scanty. The high interstitial fluid pressure within most tumors causes a convective flow 
from the tumor. This inhibits the passive diffusion of viral particles into the tumor. The 
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extracellular matrix may form physical barriers that prevent efficient spread of viral 
vectors.6-8 In elegant studies, Jain and co-workers demonstrated that destruction of 
the matrix by collagenase treatment or overexpression of matrix metalloproteinases 
(MMP)-1 and -8 increases the volume distribution of oncolytic herpesviruses.9,10 The 
volume distribution can also be increased by multiple injections, or by convection-
enhanced delivery procedures.
Vascular delivery
Theoretically, vascular delivery of vectors may lead to a larger distribution of viruses 
within the tumor. Also, it could provide an option for transducing (micro)metastatic 
tumors. However, vascular delivery, too, has been frustratingly inefficient so far. This 
is attributable to a wide variety of factors. Direct contact between malignant cells and 
the oncolytic HAdV may be difficult to obtain. Often blood vessels are confined to 
the tumor stroma, and therefore several layers of stromal cells must be passed before 
malignant cells are reached by vascularly applied therapeutic agents.6,7
HAdV vectors may become unavailable to the tumor by promiscuous association 
with nontarget tissues such as the liver. The primary receptor of many HAdVs is the 
CAR. After ligation of the adenoviral fiber with the CAR an integrin-binding RGD 
motif in the penton base binds αvβ3- or αvβ5-integrins. This promotes adenovirus 
circulating
tumor cells











Figure 1. Schematic representation of the tumor structure and the hurdles to efficient adenoviral 
vector-mediated prostate cancer gene therapy. Several efficacy-lowering aspects are encountered on 
systemic or intratumoral delivery of adenoviral vectors to prostate cancer. Systemic delivery of vector 
particles to the primary tumor site and to metastasized tumor cells is hampered by innate and humoral 
immunity, sequestration from the blood stream through the binding of blood cells or plasma proteins, 
and limited permeability of blood vessels. The heterogeneous composition of the primary tumor mass 
results in inefficient penetration into the tumor and insufficient transduction of the neoplastic cells.
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internalization. Both CAR and the integrins are widely expressed on cells in the human 
body, resulting in transduction of nontarget tissues.11 Intriguingly, mutation of the 
CAR-binding site of the fiber and the RGD motif in the penton base was found not 
to reduce liver transduction, and on intravascular administration adenoviruses were 
still efficiently sequestered by Kupffer cells in the liver.12 Subsequently it became 
evident that the interaction of the virus with host blood cells and plasma proteins is 
critical. Studies suggest that these interactions dictate the particle biodistribution of 
adenovirus in vivo. Various plasma proteins and in particular vitamin K-dependent 
coagulation factors IX and X can bind to hexon proteins in the capsid, and bridge the 
virus to receptors in the liver.13,14 In this respect there is variability between human 
adenoviral serotypes. Whereas the serotypes commonly used as vector, that is, 
HAdV-5 and -2, strongly bind factor X, others such as serotype 26 and 46 do not.15,16 
Therefore (hexons of) different serotypes, or non-clotting factor-binding derivatives of 
the HAdV-5 hexon, can be used to decrease the loss of vector particles in the liver and 
to improve bioavailability to the tumors. Indeed, such mutations significantly decrease 
liver transduction of HAdV-5 vectors in mice.15,16 The HAdV-5 fiber harbors a site with 
high affinity for heparan sulfate proteoglycans; however, mutation of the binding motif 
KKTK barely affects liver transduction in mice.12,17
Not only these interactions with clotting factors thwart efficient tumor cell 
transduction, but so do neutralizing immunoglobulins. A majority of humans have 
preexisting humoral neutralizing activity against HAdV-5 and HAdV-2 as a result of prior 
exposure to these viruses. Intravascular administration of adenovirus to recipients with 
preexisting humoral immunity will strongly reduce gene transfer. The use of vectors 
derived from HAdV with a low seroprevalence in the general population, or from 
nonhuman adenoviruses, may reduce the magnitude of the problem.18
An unexpected finding came with the observation thatbhuman, in contrast 
to murine, erythrocytes bind HAdV-5. Human erythrocytes present CAR at their 
surface, which stably interacts with HAdV-5 particles.19,20 Also human, but not murine, 
erythrocytes present complement receptor-1 (CR1), which binds HAdV-5 in the 
presence of antibodies and complement.19 Transplantation of human erythrocytes into 
immune deficient mice extended the blood circulation time of HAdV-5, reduced liver 
transduction, and decreased extravasation of the virus into human xenograft tumors. 
Similarly, HAdV-5 showed extended circulation and decreased liver transduction in 
transgenic mice presenting either CAR or CR1 on their erythrocytes. Erythrocytes 
may therefore restrict HAdV-5 infection in humans, independent of antibody status, 
presenting another challenge to HAdV-5-based anticancer viruses.19,20 Although much 
insight has been acquired on the interaction of adenoviruses with blood cells and 
plasma proteins, many other areas of virus-host interactions remain underexplored 
and in general we understand little of it.
Shielding vector particles from neutralizing immunity
Although formidable, the challenges of vascular delivery summarized previously may 
not be insurmountable. One approach potentially leading to improvements in delivery 
of adenoviral vectors for cancer gene therapy involves chemical coating of the vector 
particles. This approach is based on established and clinically applicable technology 
of packaging drugs or therapeutic biologicals in synthetic polymers. It is hoped that 
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this can lead to improved pharmacological parameters, such as improved solubility 
and stability, reduced dosing frequency, potentially reduced toxicity, and extended 
circulation time. Amongst others, poly[N-(2-hydroxypropyl)-methacrylamide] and 
polyethylene glycol (PEG) are often used to covalently coat therapeutics.21
Coating with multivalent polymers based on poly[N-(2-hydroxypropyl)-
methacrylamide] abrogated normal HAdV-5 infectious tropism.22 In addition, 
neutralization by antibodies was decreased up to 50-fold, and the resulting polymer-
coated adenoviral particles have a greatly extended plasma circulation time in mice.22,23 
Although normal tropism was blocked, polymer-coated adenovirus accumulated 
within a solid subcutaneous tumor 40 times more efficiently than unmodified virus, 
and mediated higher levels of transgene expression within tumors. This has been 
attributed to the enhanced permeability and retention effect, which leads to the 
nonspecific accumulation of circulating macromolecules within tumors.24
After blocking, infectivity can be restored by linking targeting peptides onto the 
surface of the polymer-coated viruses. Addition of a synthetic -SIKVAV- peptide, 
which binds α 6-integrin, can restore viral infectivity of PC-3 cells. Competition assays 
confirmed that entry of retargeted viruses was mediated via the incorporated ligand. 
Intravenous administration of retargeted viruses to tumor-bearing mice resulted 
in slower plasma clearance and greatly reduced liver tropism, and hence toxicity 
compared with unmodified virus, while maintaining reporter gene expression in the 
tumor.25 Similarly, polymer-coated HAdV could be targeted with cetuximab to target 
the epidermal growth factor (EGF) receptor.26 The data demonstrate that the polymer-
coating technology is compatible with peptide-based tumor targeting.
Other groups used coating of adenoviral particles with polyethylene glycol 
(PEG) molecules for particle shielding, and showed that this allows escape from 
neutralizing antibodies and to some extend allowed vector readministration. In this 
respect the size of the PEG molecules matters. With the use of large PEG molecules 
(e.g., 20-kDa PEG), vector particles were detargeted from muscle after local delivery 
and from liver after systemic delivery in mouse models. Surprisingly, fully detargeted 
PEGylated adenoviral vectors still induced strong cellular and humoral immune 
responses to vector-encoded transgene products. PEGylation does not affect the 
kinetics of transgene product-specific cytotoxic immune responses.27 These data have 
been corroborated by Barry and collaborators, who demonstrated that PEGylation 
with 20-kDa PEG was as efficient at detargeting adenovirus from Kupffer cells and 
hepatocytes as virus predosing and warfarinization.28-31 Bioluminescence imaging of 
viral distribution in a xenograft model in nude mice demonstrated that PEGylation 
with 20-kDa PEG reduced liver infection 19- to 90-fold. Tumor transduction levels 
were similar for 20-kDa PEGylated and un-PEGylated vectors. Anticancer efficacy 
after a single intravenous injection was retained at the level of unmodified vector 
in large established LNCaP prostate carcinoma xenografts, resulting in complete 
elimination of tumors in all animals and long-term tumor-free survival.31 It should 
be noted that the protective effects of PEGylation could be more pronounced in 
the presence of human erythrocytes, as PEGylation will also reduce association with 
CAR and complement receptor I. Taken together, these data suggest that chemical 
shielding of HAdV particles is a powerful approach to prevent interaction of HAdV 
particles with blood proteins, erythrocytes, and nontarget tissues, and thereby may 
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increase the bioavailability, and as a result the uptake of viruses into tumors, by 
enhanced permeability and retention. 
Vascular permeability
To further stimulate extravasation of vector particles, new physiological regulators of 
vascular permeability (i.e., vascular endothelial growth factor [VEGF]) may be used. This 
strategy allows enhanced transduction of striated muscle by combining intravenous 
AAV6-vector administration with infusion of VEGF.32 Alternatively, strategies are being 
developed that employ the endothelial receptor-mediated transcytosis pathway. The 
transferrin receptor is an example of a receptor that binds transferrin and its associated 
iron, resulting in caveolar uptake of the complex. Via a series of vesicles these 
complexes are transported across the endothelium and released at the basolateral 
side. Curiel and co-workers provided evidence that this pathway can be used by 
adenoviruses. By using a bifunctional adaptor, for example, a soluble CAR-transferrin 
fusion protein, the particles could be taken up by Caco-2 cells and transported across 
a polarized monolayer.33 These data suggest that adenoviruses can be redirected to 
the transcytosis pathway, although it remains to be established how efficiently this 
route can be recruited in the tumor endothelium. 
Targeting adenoviruses
Many strategies have been pursued to improve gene transfer into CAR-negative 
cells. In addition to the use of non-CAR-binding serotypes and fiber-swap vectors,34,35 
recombinant HAdV vectors with altered tropism have also been generated 
by engineering new ligands for cellular receptors into surface loops of capsid 
components. The favorite locations have been the C terminus and the HI loop of the 
knob domain of the fiber, the RGD loop of the penton base protein, and the L1 loop 
of the hexon. Although effective, the applicability of this approach was initially limited 
by the restricted tolerance for inserting new ligands at these positions.11 In addition, 
new ligands that are to be incorporated genetically into adenoviral vectors must be 
able to fold correctly in the reducing environment of the mammalian cell cytoplasm. 
This excludes most ligands dependent on disulfide bond formation for proper folding 
such as epidermal growth factor and most single-chain variable fragments.36 Promising 
candidate ligands are Affibody molecules (Affibody AB, Bromma, Sweden), which are 
affinity proteins based on a 58-amino acid three-helix bundle structure, termed ‘‘Z,’’ 
that is derived from the immunoglobulin-binding domain of staphylococcal protein 
A. Display libraries have been constructed on the basis of randomization of 13 
surface accessible amino acids in the Z domain, from which novel Affibody molecules 
to desired targets have been selected. These Affibodies can be efficiently used for 
genetic retargeting of adenovirus.36,37 Although initial experiments were thwarted by 
structural constraints, Lindholm and collaborators managed to insert two Affibodies 
in tandem in the HI loop, by connecting them via small flexible linkers. This resulted 
in HAdV-5 vectors genetically retargeted with a HER2/neu-specific Affibody molecule 
inserted in the HI loop of the fiber knob of a CAR-binding-ablated fiber.38 With this 
technology, vectors can be generated by incorporating two Affibody molecules with 
different specificities.39 Camelid and human single-domain antibody fragments may 
be applicable in a similar manner.40
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In another approach, the knob and shaft of the fiber have been replaced by an 
artificial trimerization domain, which was linked to an heterologous receptor-binding 
ligand.41-43 Via this strategy Willemsen and co-workers managed to retarget HAdV-5 
to tumor cells by replacing the shaft and knob of HAdV-5 by a single-chain T cell 
receptor specific for HLA-A1 molecules that present a MAGE-A1 peptide.44 Similar 
single-chain T cell receptors have been fused to the C terminus of the minor capsid 
protein IX.45 Immunoaffinity studies suggested that the C termini of protein IX 
molecules are positioned near the capsid surface.46,47 This has been confirmed by 
cryoelectron microscopy studies, which suggest that the C termini are located near 
the peripentonal hexons. Here the leucine zipper domain in the C-terminal part of 
protein IX interacts with the zipper of other molecules, forming a coiled coil.48-50 These 
protein IX-protein IX associations are not necessary for pIX-capsid incorporation and 
thermostability of the particles.51
If ligands are to be fused with pIX, a spacer may expose the ligands above the 
outer surface of hexon capsomers to ensure its accessibility to cellular receptors. 
Vellinga and co-workers have demonstrated that linkers up to a length of 75 Å can 
be added to the C terminus of protein IX without affecting the incorporation of 
protein IX into the capsid.52 Indeed, a wide variety of targeting polypeptides could 
be functionally incorporated by genetic fusion at the C terminus of protein IX. In this 
way small targeting peptides, a hyperstable single-chain Fv, and a single-chain T cell 
receptor could be functionally incorporated into the capsid.45,52-54 In addition, other 
functional proteins were incorporated in the adenoviral capsid through linkage to pIX, 
such as fluorescent proteins that allow particle tracing by fluorescence microscopy.55,56
An elegant combination of genetic modification and chemical modification 
has been developed by Kreppel and co-workers. HAdV-5 vectors were genetically 
modified to contain cysteines at solvent-exposed positions in the capsid.57 The 
introduced thiol groups are highly reactive, and procedures were established for their 
controlled covalent coupling to protein and nonprotein ligands. Depending on the 
chemistry used, ligands could be coupled by formation of thioether or disulfide bonds. 
The latter method yields viruses that release the coupled ligand in the endosome. In 
addition, thiol groups in the fiber knob were still accessible after amino PEGylation, 
allowing PEG shielding to be combined with targeting by ligand coupling to the thiol 
groups.57 Coupling of transferrin to engineered cysteine residues at the C terminus 
of protein IX allowed targeting of HAdV particles in mice in vivo.58 This validates the 
applicability of the technique in procedures involving intravenous administrations of 
adenoviral vectors.
Taken together, these data show that HAdV vector technology has matured and 
constitutes a functional and robust platform for generating shielded, retargeted vectors 
that can be used for developing oncolytic HAdV vectors for cancer gene therapy.
Targetable receptors in prostate cancer
With the targeting platform in place, a key question concerns which receptors could be 
targeted in prostate cancer. Extensive target exploration has yielded several cell surface 
receptors that are expressed preferentially or specifically in prostate cancer cells.
A prime candidate is prostate-specific membrane antigen (PSMA). It is expressed 
both on benign and malignant prostate cells. It is a type 2 membrane receptor, which 
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can be efficiently internalized. The ligands that trigger internalization remain to be 
identified.59 Nearly all prostate tumors and prostate cancer cells express PSMA and 
increased expression correlates with aggressive tumors.60 PSMA is also upregulated 
after androgen deprivation in model systems whereas other markers such as prostate-
specific antigen (PSA) are decreased after androgen withdrawal.61 PSMA can serve as 
a tissuespecific target for adenoviral vectors.62 Retargeting of viral particles to prostate 
cancer cell lines was obtained through the attachment of bispecific molecules, which 
consisted of conjugates between an anti-adenoviral fiber knob Fab’ fragment and 
anti-PSMA monoclonal antibodies.62
Besides PSMA, various other cell surface molecules have been demonstrated to be 
upregulated in prostate cancer, such as prostate stem cell antigen (PSCA). Successful 
targeting to PSCA-expressing prostate cancer cells has been achieved for genetically 
engineered T cells that have been equipped with a chimeric T cell receptor recognizing 
PSCA.63 These findings support the exploration of PSCA targeting in the context of 
prostate cancer-targeted oncolytic viruses.
The urokinase-type plasminogen activator receptor (uPAR) has also been exploited 
for targeting of oncolytic viruses to prostate cancer cells. uPAR is overexpressed in 
tumors as well as in stromal cells of multiple malignancies, including prostate cancer.64,65 
uPAR is involved in tumor angiogenesis. For example, tumor cell-conditioned media 
can upregulate endothelial uPAR expression.66 The principle of targeting tumor 
endothelium by aiming at uPAR, rather than at the cancer cells themselves, is highly 
attractive, because such an approach may lead to improved viral trafficking from the 
bloodstream into the tumor tissue. HAdV targeting to uPAR is feasible.67 More recently, 
tumor and vascular targeting of an oncolytic measles virus has been achieved.68
In addition, other cell surface molecules are upregulated in the tumor vasculature, 
including members of the vascular endothelial growth factor receptor (VEGFR) family. 
Both VEGFR1 (Flt-1) and VEGFR2 (Flk-1) are selectively expressed on endothelial cells 
and are highly upregulated in proliferating (angiogenic) capillary cells of numerous 
types of prostate tumor.69 The potential of VEGFR2 as a target has been shown in 
studies on systemic targeting of drug-loaded microspheres to subcutaneous prostate 
tumors in mice, which demonstrated significant inhibition of tumor growth after 
conjugation of anti-VEGFR2 antibodies to the microspheres.70
One class of potentially specific receptors is the group of tumor-specific cancer 
testis (CT) antigens.71 Peptides of these CT antigens are presented on the cell surface 
in complex with major histocompatibility class (MHC) I molecules. With the exception 
of their expression in the testis, an immune-privileged site due to the absence of 
MHC expression, the CT antigens are expressed exclusively in cancer cells. Proof-of-
principle of targeting adenoviral vectors to CT antigens has been shown by genetically 
fusing viral capsid proteins with single-chain T cell receptors, which could specifically 
recognize the melanoma-specific CT antigen MAGE-A1 in complex with HLA-A1.44,45 
Multiple cancer CT antigens have been found in patients with prostate cancer, including 
SSX-2 and MAD-CT-1 and -2.72,73 A peptide present in the majority of MAGE-A gene 
family members could serve as an ideal target as most tumors, both solid and blood-
borne, express at least one member of this MAGE-A gene family.74 In addition to cell 
surface antigens, intracellular antigens, for example, PSA, have now become available 
for targeting and warrant further exploration as targets for gene therapy vectors.72,73 
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Combining the selective power of phage display, which allows for the testing of tens 
of billions of individual clones, with high-throughput selection of Fabs with peptide-
MHC complex-binding capacity will yield new human ‘‘T cell receptor (TCR)-like’’ Fab 
fragments that specifically target viruses to tumor cells expressing intracellular tumor 
antigens.75 
Prostate-targeted conditionally replicative adenoviruses
HAdVs have been generated that replicate specifically in certain cell types. In HAdV 
infection, the E1A gene acts as the master switch that activates the viral gene 
expression cascade. Therefore, by controlling E1A expression with a tumor- or tissue-
specific promoter, viral replication can be restricted to certain cell types. Along these 
lines, Essand and collaborators developed a series of prostate-specific adenoviruses 
that replicate exclusively in normal and neoplastic prostate epithelial cells.76-78 In 
these vectors expression of E1A is controlled by the recombinant prostate-specific 
PPT sequence. The PPT sequence is composed of a prostate-specific antigen (PSA) 
enhancer, a prostate-specific membrane antigen (PSMA) enhancer, and a T cell 
receptor γ-chain alternate reading frame protein (TARP) promoter. The PSMA enhancer, 
which upregulates PSMA expression in androgen-depleted prostate cancer cells, 
also ensures that the PPT sequence is active under androgen-deprived conditions. 
The mouse H19 insulator (I), with enhancer-blocking activity, was placed upstream 
of PPT to protect it from interfering signals from the adenoviral backbone.76,77 The 
most advanced version, the so-called Ad[i/PPT-E1A, E3] virus, induced regression of 
aggressively growing LNCaP tumors, and yielded significantly prolonged survival for 
treated mice compared with the control groups.78
Not only can E1 regulation be used to restrict replication to cancer cells, 
but the strategy has also been used to prevent expression of E1A, and thereby 
expression of other viral genes, in sensitive nontarget tissues. HAdV5 vectors can 
mediate significant hepatotoxicity. To prevent viral gene expression in hepatocytes, 
multiple binding sites for a hepatocyte-specific microRNA, miR-122, were placed 
in the 30 untranslated region of the E1A gene.79,80 miR-122 is highly and selectively 
expressed in hepatocytes and this modification might prevent expression of E1A 
within hepatocytes, and hepatotoxicity, while maintaining its replicative capacity in 
tumor cells. Animals receiving a lethal dose of wild-type Ad5 (5x1010 viral particles/
mouse) showed substantial hepatic genome replication and extensive liver pathology, 
whereas inclusion of miR-122 binding sites decreased replication 50-fold and virtually 
abrogated liver toxicity, demonstrating the efficiency of the approach.80 These 
examples demonstrate that we can endow replicating HAdV vectors with tumor cell 
selectivity, while protecting sensitive nontarget tissues. 
new dIreCtIOns
A robust technology platform for cancer-targeted and oncolytic HAdV vector 
generation has been established. Many elegant tools and techniques have been 
developed with well-chosen experiments to show their proof-of-concept. However, 
it seems fair to state that most improvements have been incremental and only a few 
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of the vectors that showed promise in preclinical studies have reached the stage of 
clinical evaluation. So, where do we go from here? In what fields are new developments 
necessary to fulfill the promise of efficacious prostate cancer-targeted HAdV vectors? 
It may be useful to step back, reflect, and place our activities in perspective.
Rational design or evolution of new oncolytic viruses?
So far, most vectorologists have followed a ‘‘rational design’’ or reverse-genetics 
approach for building new therapeutic vectors. In other words, on the basis of a 
priori knowledge of virus biology, tumor cell biology, and pharmaceutical parameters, 
we have built our new vectors to have the desired phenotype and to perform as 
anticipated. This approach has been most useful and has delivered most of the vectors 
that are in use in clinical gene therapy to date. Nevertheless, one should realize that 
this is not the classical approach in microbiology.
Classical virology studies viruses by employing selection strategies to isolate 
mutants with desired phenotypes and to study these to obtain insight into viral 
genetics and virus biology. There has been a revival of interest in the classical, more 
evolutionary approaches involving bioselection strategies for developing improved 
HAdV oncolytic vectors. Yan and co-workers have provided a fine example of the 
power of this approach.81 In vitro chemical mutagenesis of HAdV-5 was combined with 
a bioselection strategy. This yielded a mutant virus that replicated more efficient in the 
HT29 colorectal tumor cells that were used for selection. The mutation truncates an 
open reading frame in the late i-leader transcript. Not only in HT29, but also in several 
other tumor cell lines, replication was enhanced by the causative i-leader mutation at 
nucleotide 8350 of the HAdV-5 genome.81 Along similar lines, Gros and co-workers 
used in vivo bioselection and obtained an E3/19K mutant with enhanced antitumoral 
potency.82 By selecting for HAdVs with large-plaque phenotypes, Subramanian and 
coworkers isolated a series of mutants, including mutants in the i-leader and in the 
E3/19K gene.83 Taken together, these data suggest that the oncolytic activity of wild-
type HAdV-5 can be enhanced by mutations.
Hermiston and collaborators took this approach a step further.84 On the basis of 
the notion that there is no evidence that HAdV-5 is the optimal start point for selecting 
more potent oncolytic HAdVs, they pooled an array of HAdV serotypes. These pools 
were passaged under conditions that invite recombination between serotypes. They 
isolated a mutant, designated coloAd1, which replicates more efficiently than any wild-
type virus in human colon cancer cells. Characterization of coloAd1 revealed that it is a 
complex hybrid between HAdV-3 and -11p.84 It is evident that none of the bioselected 
viruses would have been created on the basis of preexisting knowledge. In fact, we 
have no clear understanding why these mutants replicate so much better in the cell 
systems that were used for their isolation. This underscores the potential of the classical 
strategy. It is to be expected that evolutionary approaches involving bioselections 
will become more widely applied. These approaches will yield new viruses, and the 
characterization of these viruses may provide new insights concerning critical aspects 
of virus and tumor cell biology. Uil and co-workers reported an approach that employs 
modified adenoviral polymerases with deficits in the polymerase proofreading 




Taken together, it seems reasonable to anticipate that adenoviral mutations that 
have been isolated by bioselection procedures will soon be incorporated in clinically 
applicable oncolytic adenoviruses. 
Cellular delivery of viruses
Many studies have demonstrated that the delivery of vector particles into tumors 
is inefficient. Both intratumoral and vascular delivery are thwarted by a variety of 
factors (see above), and therefore new delivery methods are essential. An attractive 
option is to use cells with the capacity to migrate to tumors as delivery vehicles for 
oncolytic viruses. In this strategy the tumor-targeting cells are loaded with viruses 
and administered to the patient. After migration the cells should hand off the cell-
associated viruses or, if the virus replicates in the delivery cells, their progeny. In 
this way viruses should bedelivered to tumor cells. Several cell types can migrate 
to tumors in vivo, including cytokine-induced killer cells, tumor antigen-specific T 
cells, macrophages, endothelial progenitor cells, and mesenchymal stem cells.86 In 
addition, virus-loaded dendritic cells have been used to eradicate tumor cells from 
tumor-draining lymph nodes.87
Cellular delivery of viral anticancer agents may also circumvent the effects of 
neutralizing immunity.88 This is evidenced in a study employing human reoviruses 
as the oncolytic agent. In reovirus-immune mice with B16tk lymph node melanoma 
metastases, in vivo delivery of free reovirus to the melanoma was ineffective, whereas 
effective antitumor responses and long-term tumor clearance were obtained if mature 
dendritic cells as well as T cells were used as carriers.87 This and other studies suggest 
that cellular delivery is feasible and may be applicable for the delivery of viral oncolytic 
agents at tumor sites. It should be noted that cellular delivery adds a new level of 
complexity to clinical gene therapy studies and is logistically challenging.
Tumor stem cells as new targets?
With the aid of such new technologies, that is, the bioselection-based strategies for 
vector improvement, and cell-based methods for vector delivery, new cancer gene 
therapeutics and therapeutic strategies may be developed that ensure efficient vector 
delivery into the tumors. It is known that tumors are usually markedly heterogeneous, 
consisting of complex mixtures of cancer cells with various grades of differentiation. A 
cell type that has attracted much attention is the tumor-initiating cell, or cancer stem 
cell. The tumor-initiating cell is a cell with the capacity to self-renew and differentiate 
into any of the lineages of cancer cells that comprise a tumor.89 Presumably the tumor-
initiating cells are derived from organ stem cells.90 The latter are long-lived and change 
over the course of time by accumulating (epi)genetic alterations. In this model, the 
characteristics of a cancer-initiating cell, and therefore of the resulting tumor, depend 
(in part) on these alterations. The cancer stem cell population in a tumor may govern 
crucial tumor processes such as progression, invasion, and metastasis. Therapy 
resistance may be the consequence if a particular treatment does not effectively 
eradicate the cancer stem cell population. It may therefore be important to ensure 
that new oncolytic agents have the capacity to transduce and kill cancer stem cells.
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Nonviral delivery of viral genomes
Systemic approaches for cancer gene therapy have been focused on delivering viruses 
to the tumor. With advances in the field of nonviral gene delivery, an alternative 
approach became feasible.91 Rather than delivering intact viruses to the tumor cells, 
a strategy is followed in which viral genomes are delivered. If transferred into cells, 
HAdV DNA can yield replicating virus. Although not particularly efficient, infectious 
HAdV can be reproducibly recovered from cell cultures on transfer of naked DNA.
The field of nonviral gene transfer has seen impressive advances in increased tumor 
accumulation of transgenes,92 but so far the therapeutic consequences remain to be 
improved. Individual steps in gene delivery need further improvement, especially those 
relating to intracellular trafficking of the complexes. This includes the timely release 
of the DNA complex from the targeting ligand, efficient escape from the endosomal 
compartment, and proper delivery of the genes into the nucleus.93-95 Furthermore, 
innate immunity must be evaded. Integration of controlled-release technologies into 
targeted gene delivery systems will provide more effective gene delivery systems.96-98
With the delivery of viral genomes we could benefit from the best of two worlds. 
Nonviral vectors may be easier to produce and formulate, and may deliver their 
payload more reproducibly at the tumor site than viral vectors. If used for the delivery 
of viral genomes, tumor-selective replicating viruses may be generated on site, which 
can spread in the tumor and exert their therapeutic action, without causing collateral 
damage to nontarget tissues. It remains doubtful, however, that HAdV is the best 
choice of virus for such strategies.
New therapeutic genes
New transgenes in the vectors may enhance therapeutic efficacy. An intriguing class 
of prodrug-activating genes is based on deoxyribonucleoside kinases (dNKs). These 
enzymes catalyze the phosphorylation of deoxyribonucleosides to deoxyribonucleoside 
monophosphates and thereby provide the cell with deoxyribonucleoside triphosphates. 
The dNKs catalyze the first, and often rate-limiting, step of nucleoside analog activation. 
These enzymes are therefore promising candidates to be used in combination with 
nucleotide analogs as prodrug-enzyme combinations. Bioselection yielded mutants 
of the Drosophila melanogaster-derived dNK with enhanced sensitivity to a range of 
clinically approved nucleotide analogs, such as 30-azido-30-deoxythymidine (AZT), 
arabinosylcytosine (AraC), ddA, and ddC.99,100 These mutants efficiently sensitized 
glioblastoma, osteosarcoma, and breast cancer cells to clinically accepted drugs.100 
The use of approved nucleoside analogs may facilitate swift acceptance of the strategy.
future PrOsPeCts 
We have witnessed an enormous expansion of the gene transfer technology required 
for cancer gene therapy. Initial clinical safety studies have demonstrated the validity of 
the concept, and the feasibility of current approaches.101 The viral vectors used in the 
clinical studies reported so far have been well tolerated and safe. Robust technology 
platforms have been established and many of the factors currently thwarting prostate 
cancer gene therapy have been identified. New platforms for preclinical evaluation of 
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new oncolytic vectors are available.102 Combining the technologies and building on 
new insights from prostate cancer biology and virology will facilitate the generation of 
new vectors that will, it is hoped, be as safe as current vectors, but more efficacious. 
With these we may keep the promise of gene therapists to provide new and effective 
treatment for malignant neoplastic disease in general and prostate cancer in particular.
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EFFICIENT INCORPORATION OF A FUNCTIONAL 
HYPER-STABLE SINGLE-CHAIN ANTIBODY FRAGMENT 
PROTEIN-IX FUSION IN THE ADENOVIRUS CAPSID
CHAPTER 3
AbstrACt
Recombinant adenoviruses are frequently used as gene transfer vehicles for 
therapeutic gene delivery. Strategies to amend their tropism include the incorporation 
of polypeptides with high affinity for cellular receptors. Single-chain antibodies have 
a great potential to achieve such cell type specificity. In this study, we evaluated the 
efficiency of incorporation of a single-chain antibody fused with the adenovirus minor 
capsid protein IX in the capsid of adenovirus type 5 vectors. To this end, the codons 
for the single-chain antibody fragment (scFv) 13R4 were fused with those encoding 
of pIX via a 75-Angstrom spacer sequence. The 13R4 is a hyper-stable single-chain 
antibody directed against β-galactosidase, which was selected for its capacity to fold 
correctly in a reducing environment such as the cytoplasm. A lentiviral vector was used 
to stably express the pIX.flag.75.13R4.MYC.HIS fusion gene in 911 helper cells. Upon 
propagation of pIX-gene deleted HAdV-5 vectors on these cells, the pIX-fusion protein 
was efficiently incorporated in the capsid. Here, the 13R4 scFv was functional as was 
evident from its capacity to bind its ligand β-galactosidase. These data demonstrate 
that the minor capsid protein IX can be used as an anchor for incorporation of single-
chain antibodies in the capsids of adenovirus vectors.
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IntrOduCtIOn
Human Adenovirus (HAdV)-derived vectors are among the most frequently used 
gene delivery vehicles for human gene therapy and vaccination.1 Much effort has 
been devoted to improve the cell-type specificity of gene delivery. Whereas the use 
of bispecific antibodies has been employed with considerable success, retargeting of 
adenovirus vectors by genetic incorporation of cell-specific ligands and single-chain 
antibodies proved more difficult. Many attractive ligands for insertion into the virus 
capsid elements for retargeting purposes are molecules that are normally excreted 
from the cells, such as epidermal growth factor (EGF), antibodies, and their derivatives, 
for example, single-chain antibody fragments (scFv).2,3 An important hurdle is that many 
of such polypeptide ligands are normally routed via the protein secretory pathway, 
whereas the adenovirus particles assemble in the nucleus. Hence, the ligands fused 
with capsid proteins lack the post-translational modifications that may be essential 
for their function.2,4 The reducing environment in the cytoplasm, which prevents the 
formation of disulphide bridges, and the absence of accessory factors to help these 
proteins to fold correctly, avert their maturation to functional proteins.5 Indeed, studies 
in which scFv were fused with capsid proteins were not very successful.2,6,7 However, 
some antibodies can be produced in a soluble form in the cytoplasm and retain 
their activity. These are called hyper-stable single-chain antibodies.8-12 Recently, such 
hyper-stable scFv have been incorporated in HAdV particles on de-knobbed, fibritin-
foldon trimerized fibers.4 Although the exact location of pIX in the adenovirus capsid 
is under revision,13-16 we and others have shown that this minor protein is an efficient 
platform for retargeting and imaging moieties.17-21 Here, we demonstrate efficient and 
functional incorporation of the hyper-stable scFv 13R4 that was fused with the minor 
capsid protein IX via a 75-Angstrom spacer. The scFv 13R4 originates from a naïve 
human phage display library22 and was isolated after random mutagenesis by error-
prone polymerase chain reaction, and selection for increased cytoplasmic solubility.9 
We show that 13R4 fused with pIX via the 75-Angstrom spacer is accessible on the 
surface of purified viruses. Moreover, the 13R4 is functional in the capsid as evidenced 
from its capacity to bind E.coli β-galactosidase.
results
For incorporation of the 13R4 scFv in the adenovirus capsid a fusion gene was 
constructed in which the coding region of pIX was fused via the flag epitope with the 
codons for a 75-Angstrom spacer, and with the codons for the 13R4 scFv (Fig. 1a). 
The resulting fusion gene coding for pIX.flag.75.13R4.MYC.HIS was inserted into the 
lentiviral expression vector pLV-CMV-IRES-NPTII.23 A schematic outline of the vector is 
provided in Fig. 1b. To test the pIX.flag.75.13R4.MYC.HIS production after lentivirus 
transduction, 911 cells were exposed to LV-CMV-pIX.flag.75.13R4.MYC.HIS-IRES-NPTII 
at 40 ng p24 per 105
 
cells (911-pIX.flag.75.13R4.MYC.HIS). Forty-eight hours post-
transduction, the 911- pIX.flag.75.13R4.MYC.HIS cells were fed fresh medium with 200 
mg ml-1 G418. No clonal cells were isolated, as the lentiviral transduction leads to a 
polyclonal cell line that produce homogenous levels pIX, sufficient to restore fully the 
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Figure 1. (a) Schematic representation of the pIX.flag.75.13R4.MYC.HIS fusion protein exposing the 
13R4 scFv above the hexon capsomers. (b) Schematic representation of the lentiviral system. The 
lentiviral vectors used in this study are so-called SIN vectors,35 and contain the Rev-responsive element 
sequence,36 the central poly-purine tract (cPPT)33,37,38 and the human hepatitis B virus-derived post-
transcriptional regulatory element. The encephalomyocarditis virus internal ribosomal entry site (IRES) 
was obtained from pTM3,39 the NPTII coding region was isolated from peGFPn2 (Clontech, Leusden, 
The Netherlands).
homogeneous amounts of the fusion proteins in the transduced cells (Fig. 2a). The 
pIX.flag.75.13R4.MYC.HIS amounts produced by the transduced 911 cells are similar 
to the pIX level produced by 911 cells during infection with a wt HAdV-5 (Fig. 2b).23
Next, we tested the incorporation of pIX.flag.75.13R4.MYC.HIS into the capsid of 
the HAdV-5 vector HAdV-5ΔpIX.CMV.GFP/LUC.23 This vector lacks a functional pIX gene 
and carries the enhanced green fluorescent protein (eGFP) and the firefly luciferase 
(LUC) reporter genes under control of two separate cytomegalovirus (CMV)-promoters. 
HAdV-5ΔpIX.CMV.GFP/LUC viruses were propagated on the 911-pIX.flag.75.13R4.
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MYC.HIS cell line, harvested and purified via the conventional CsCl purification 
method. During purification, particle-associated pIX molecules were separated from 
the non-associated pIX, as variants of pIX that cannot be incorporated into the capsid 
do not co-purify with the particles of CsCl gradients.19,24 To examine the amount of pIX.
flag.75.13R4.MYC.HIS in the particles, 5 x 109 CsCl-gradient purified particles were 
analyzed by Western analysis (Fig. 2c). The amount of pIX.flag.75.13R4.MYC.HIS in 
the pIX.flag.75.13R4.MYC.HIS-loaded HAdV-5ΔpIX.CMV.GFP/LUC particles is similar 
to the amounts in wt HAdV-5 particles.
To test if the 13R4.MYC.HIS fusion protein was accessible on the outside of the 
viral capsid, the purified pIX.flag.75.13R4.MYC.HIS-loaded HAdV-5ΔpIX.CMV.GFP/
LUC particles were subjected to immunoelectron microscopy. The presence of the 
13R4.MYC.HIS fusion protein was visualized using penta-HIS antibodies and gold-
conjugated prot.A (Fig. 2d). Wt HAdV-5 particles were used as negative control. There 
was no gold label found on the negative control, whereas viruses loaded with the 
13R4.MYC.HIS show specific binding of the gold-conjugated prot.A.
To study if incorporation of the pIX.flag.75.13R4.MYC.HIS could restore the heat 
stability of the pIX-gene deleted viruses, HAdV-5ΔpIX.CMV.GFP/LUC was propagated 
on 911-pIX.flag.75.13R4.MYC.HIS cells.  Similarly, HAdV-5ΔpIX.CMV.GFP/LUC and 
HAdV-5.CMV.GFP/LUC were propagated on 911 cells as negative and positive control, 
respectively. Heat-inactivation analysis demonstrated that although the particles were 
fully loaded, the pIX.flag.75.13R4.MYC.HIS protein could not restore heat stability of 
the pIX- gene deleted virus (Fig. 2e).
To study the functionality of the scFv in the capsid, we assayed the ligand 
(β-galactosidase)-binding capability of the 13R4 on the surface of the adenovirus. To 
this end, CsCl purified pIX.flag.75.13R4.MYC.HIS-loaded HAdV-5ΔpIX.CMV.GFP/LUC 
and wt HAdV-5 were separately mixed with 100 μg β-galactosidase. The viruses were 
purified using continuous CsCl density gradients to separate free β-galactosidase from 
the β-galactosidase bound to the 13R4 on the surface of the adenoviral particles. To 
examine if the 13R4 scFv was able to bind β-galactosidase, both viruses were analyzed 
by Western analysis (Fig. 3a) and immunoelectron microscopy (Fig. 3b). Both assays 
showed that β-galactosidase was bound specifically to viruses loaded with the 13R4 
scFv.
For another approach to study the ligand (β-galactosidase)-binding capability 
of the 13R4 on the surface of the adenovirus, the pIX.flag.75.13R4.MYC.HIS-loaded 
HAdV-5ΔpIX.CMV.GFP/LUC particles were trapped in DAKO IDEIA microwells and 
incubated with β-galactosidase. The DAKO kit was developed for demonstration of 
HAdV in clinical specimens. It contains microwell strips pre-coated with an anti HAdV 
antibody. After blocking and washing, the particles were exposed to the substrate 
(ONPG). Compared to wt HAdV-5, the particles that contain the pIX.flag.75.13R4.
MYC.HIS molecules showed significant β-galactosidase activity (Fig. 4), demonstrating 
that the 13R4 scFv can bind β-galactosidase on the surface of the virions. From the 
absorbance value of 0.5, a path length of 0.6 cm, and a molar absorption of ~4500 
M-1 cm-1,25 we can calculate that the concentration of o-nitrophenol formed is 1.85 x 
10-4 M, which corresponds to 37 nmoles in the sample volume. As the reaction was 
developed for one h, this is the equivalent of 37/60 = 0.6 Miller units.25 Since the 




















































































Figure 2. ( a) Immunohistochemistry assay for detection of the pIX.flag.75.13R4.MYC.HIS produced by 
the 911-pIX.flag.75.13R4.MYC.HIS cells. The production of pIX.flag.75.13R4.MYC.HIS was visualized 
using mouse anti-flag and FITC-labeled goat-anti-mouse antibodies. The nuclei were stained using 
propidium iodide. (b) Western analysis of pIX.flag.75.13R4.MYC.HIS levels in the 911-pIX.flag.75.13R4.
MYC.HIS cells. The pIX.flag.75.13R4.MYC.HIS amount in the complementing cell line 911-pIX.
flag.75.13R4.MYC.HIS was compared with the pIX amounts during wt HAdV-5 infection. The Western 
analysis was performed using anti pIX serum.23 (c) Western analysis of the incorporation efficiency of pIX.
flag.75.13R4.MYC.HIS. To test the incorporation efficiency of pIX.flag.75.13R4.MYC.HIS produced by 
the 911-pIX.flag.75.13R4.MYC.HIS cells, HAdV-5ΔpIX.CMV.GFP/LUC was propagated on the cell line, 
purified by CsCl centrifugation, and protein lysate of the purified virus sample was made for Western 
analysis. The amount of the pIX fusion proteins in HAdV-5ΔpIX.CMV.GFP/LUC propagated on 911-pIX.
flag.75.13R4.MYC.HIS was compared with wt HAdV-5, with anti-pIX serum and, as a virus-particle 
loading control, the 4D2 antibody directed against the fiber protein. (d) Immunoelectron microscopic 
analysis of HAdV-5ΔpIX.CMV.GFP/LUC loaded with pIX.flag.75.13R4.MYC.HIS. To test the accessibility 
of the HIS epitope on viruses loaded with pIX.flag.75.13R4.MYC.HIS were bound on copper grids. The 
HIS epitope was detected with penta-HIS antibody, followed by rabbit anti-mouse immunoglobulin 
and gold-labeled Prot.A. (e) Heat stability of HAdV-5ΔpIX.CMV.GFP/LUC with pIX.flag.75.13R4.MYC.
HIS in their capsid. HAdV-5ΔpIX.CMV.GFP/LUC was propagated on 911- pIX.flag.75.13R4.MYC.HIS 
cells. Similarly, HAdV-5ΔpIX.CMV.GFP/LUC and HAdV-5.CMV.GFP/LUC were propagated on 911 cells 
as negative and positive control, respectively. Freeze-thaw lysates were incubated at 45oC for various 
times. Residual infectious virus titers were estimated by determining the capacity of the virus to induce 
LUC activity in U2OS cells 24 h after infection. The results are presented as percentages of residual LUC 
activity. Each bar represents the cumulative mean ± s.d. of triplicate analyses.
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Figure 4.  DAKO IDEIA β-galactosidase binding 
assay. To measure the binding capability of 13R4 
on the surface of the virion to its native ligand 
β-galactosidase, the HAdV-5ΔpIX.CMV.GFP/
LUC loaded with pIX.flag.75.13R4.MYC.HIS were 
incubated with β- galactosidase and trapped on 
a DAKO IDEIA strip. The bound β-galactosidase 
was detected by measuring OD420 (left y-axis) 
after adding ONPG together with the Z-buffer (n 
= 3). As negative control an identical number of 














    
























Figure 3. To test if the HAdV-5ΔpIX.CMV.GFP/LUC particles loaded with pIX.flag.75.13R4.MYC.HIS 
were able to bind specifically β-galactosidase on the outside of the virion, viruses were mixed with 
β-galactosidase and purified via the standard CsCl purification protocol. (a) Western analysis. The 
captured β-galactosidase was detected using anti-β-galactosidase. Wt HAdV-5 was used as negative 
control. (b) Immunoelectron microscopic analysis of β-galactosidase bound to HAdV-5ΔpIX.CMV.GFP/
LUC loaded with pIX.flag.75.13R4.MYC.HIS. The β-galactosidase was only detected on the viruses that 

















in the well 0.61/58,000 = 1.05 x 10-5
 
nmoles of monomer, that is 2.6 x 10-6 nmoles of 
β-galactosidase tetramer, or 1.6 x 109 β-galactosidase tetramers. The DAKO wells used 
to capture the adenoviruses seem to be saturated between 1 x 106 and 5 x 106 viruses 
(data obtained from Dako Diagnostics; http://www.dako.co.uk/products). This means 
that about 1.6 x 109 / 5 x 106 = 320 to 1.6 x 109 / 106 = 1600 β-galactosidase tetramers 
would be bound to each particle. As each particle contains 240 pIX molecules in 
the capsid, this number suggests that the majority of the inserted scFv is active and 
accessible in the capsid.
dIsCussIOn
Here, we demonstrate the functional incorporation of a hyper-stable scFv (13R4), 
directed against β-galactosidase, fused with pIX into the adenovirus capsid. To test 
whether the pIX.flag.75.13R4.MYC.HIS (51.8 kDa) is able to incorporate into the 
viral capsid, a 911 cell line was created that produced the pIX.flag.75.13R4.MYC.
HIS proteins. To this end 911 cells were exposed to the lentiviral vector LV-CMV-
pIX.flag.75.13R4.MYC.HIS-IRES-NPTII. The production of pIX.flag.75.13R4.MYC.HIS 
proteins in the 911 cells was homogeneous as was seen earlier with pIX and pIX.
flag.75.MYC proteins.23 Propagation of HAdV-5ΔpIX.CMV.GFP/LUC on the 911-pIX.
flag.75.13R4.MYC.HIS cells did result in virus production levels that are similar to 
the levels obtained after propagation on the standard 911 helper cell line. Western 
analysis showed that pIX.flag.75.13R4.MYC.HIS was incorporated into the HAdV-
5ΔpIX.CMV.GFP/LUC as efficient as wt pIX (14.3 kDa) in wt HAdV-5 particles. Infection 
experiments using HAdV-5ΔpIX.CMV.GFP/LUC with or without pIX.flag.75.13R4.MYC.
HIS on 911 helper cells resulted in similar LUC levels 24 h post-infection (data not 
shown). Despite the complete loading, the particles that have the pIX.flag.75.13R4.
MYC.HIS incorporated in their capsid are not heat stable. This may be attributed to 
sterical hindrance, as we have seen similar effects with large pIX-fusion proteins (data 
not shown).
These data demonstrate that insertions of ligands up to at least 2.5 times the 
molecular weight of wt pIX can be incorporated into the capsid without decreasing the 
incorporation efficiency and without impairing the fiber and penton-base-mediated 
internalization. Retaining the capacity of the arginine glycine aspartic acid (RGD) motif 
in the penton-base to bind αv integrins may be important for retargeted viruses, and 
may depend on the ligand used for retargeting.
The 13R4.MYC.HIS fusion protein was located on the surface of the adenovirus 
capsid as shown by immunoelectron microscopy. The number of gold particles on the 
adenovirus particles appeared to be less than in previous studies using pIX.flag.75.
MYC.19,23 This might be due to the differences between the antibodies used for 
detection of the epitopes. Furthermore, the structure of the 13R4 scFv could have 
impaired the accessibility of the C-terminal HIS epitope. Alternatively, the positively 
charged HIS tag may have associated with the acidic-loop regions of the hexon 
molecules, making them less accessible to antibodies.
Both by Western analysis and by immunoelectron microscopy, we demonstrated 
that HAdV-5ΔpIX.CMV.GFP/LUC particles loaded with pIX.flag.75.13R4.MYC.HIS 
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bind β-galactosidase, whereas wt HAdV-5 does not. The detection of β-galactosidase 
in both assays was carried out using the GAL-13 antibody. This antibody does not 
recognize denatured or reduced β-galactosidase (data from Sigma–Aldrich; http://
www.sigmaaldrich.com/sigma/datasheet/g8021dat.pdf). Nevertheless, in our Western 
analysis, we were able to detect β-galactosidase using this antibody. The results of 
the DAKO IDEIA β-galactosidase binding assay using the HAdV-5ΔpIX.CMV.GFP/LUC 
particles loaded with pIX.flag.75.13R4.MYC.HIS show binding of native β-galactosidase 
tetramers. The capacity to bind β-galactosidase was specific for the particles harboring 
the pIX.flag.75.13R4.MYC.HIS molecules. We estimated that approximately 320-1600 
β- galactosidase tetramers are bound per virus particle. As the particle contains 240 
pIX molecules in the capsid, this number suggests that the majority of the inserted 
scFv is active and accessible in the capsid. This is the first time that it has been shown 
that pIX can be used as anchor to incorporate large targeting ligands such as the 
model scFv 13R4 into the HAdV-5 capsid.
Unfortunately, the β-galactosidase cannot be used as receptor on cell surfaces. This 
makes it difficult to show formally that the scFv can mediate adenovirus retargeting. 
Future studies using for retargeting biological relevant scFv, such as the scFv-αHER2,26 
will show the applicability of these retargeting moieties. Alternatively, 13R4 can be 
used as scaffold for loop grafting.27
Hyper-stable scFv can be produced without the need of stabilizing disulfide 
bounds. The development of techniques that facilitate the creation of large libraries 
of hyper-stable scFv will be of great importance for use in therapeutic agents such as 
gene transfer vectors described in this study. Traditional techniques involve isolation 
of VH and VL domains to construct scFv from an original hybridoma or in vitro display 
systems to screen and select for specific scFv that consequently should be tested for 
their ability to fold into functional scFv in the cytoplasm. Although these techniques 
have been shown effective for standard scFv, they rarely yield of the hyper-stable scFv 
variants. Other techniques such as intracellular antigen capturing and complementarity 
determining regions (CDR) grafting are promising approaches to create effective scFv 
that can be used for retargeting of adenoviruses to specific cells or tissues.28-30
The efficient incorporation of the relatively large 13R4.MYC.HIS fusion protein is 
promising for future retargeting strategies. The fact that the model scFv used in this 
study is biological active on the surface of the adenovirus is supporting the feasibility 
of retargeting adenovirus vectors by inserting of scFv that are directed against specific 
cellular receptors. However, it should be noticed that formal proof of effective retargeting 
via these pIX modifications still needs to be provided. In this light, it is important to be 
aware that the efficiency of retargeting can depend on the capsid protein to which 
the scFv is added.18 Therefore, it is necessary to compare side by side the retargeting 
efficiency with a single scFv fused with different capsid proteins (i.e. pIX and fiber).
MAterIAls And MethOds
Cells
The HAdV-5 E1-transformed cell line 91131 was maintained at 37oC in a humidified 
atmosphere of 5% CO
2 in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Breda, The 
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Netherlands) supplemented with 8% fetal bovine serum (Gibco-BRL) and 0.3% glucose 
(JT Baker, Deventer, The Netherlands). The 911 cells were used to propagate and titer 
adenovirus vectors. Infections of the cells with HAdVs were carried out in infection 
medium containing 2% horse serum.
Production of recombinant lentiviruses
The lentiviral vectors used in this study were described before.23 The lentivirus vectors 
were derived from the plasmid pLV-CMV-eGFP. Plasmid pLV-CMV-pIX.flag.75.13R4.
MYC.HIS-IRES-NPTII has been constructed by standard cloning procedures.23 The 
gene for pIX.flag.75 was obtained from the pCDNA3.1-based construct pAd5pIX.
MYC.flag.75.MYC.19 The gene encoding the scFv 13R4 was subcloned from the 
plasmid pPM163R4.9 The lentiviral vectors were produced and quantified as described 
previously.23,32 For titer estimations was assumed that 1 ng p24 equals to 2 x 103
 
transducing units in an infection assay.33
Lentiviral transduction
For transduction, the lentiviral supernatant was added to fresh medium together with 
8 μg ml-1 Polybrene (Sigma Aldrich, Zwijndrecht, The Netherlands). After overnight 
incubation, the medium was replaced with fresh medium. Cells transduced with 
lentiviral vectors containing the neomycin selection gene were cultured in medium 
supplemented with 200 mg l-1 G418 (Invitrogen, Breda, The Netherlands).
Adenovirus vectors
The HAdV-CMV.GFP/LUC and HAdV-5ΔpIX.CMV.GFP/LUC were made as described 
previously.19 The vectors carry a GFP and a firefly LUC transgene, each under the 
control of the human CMV immediate-early promoter. HAdV-5 was obtained from the 
virus collection of the Department of Molecular Cell Biology of the Leiden University 
Medical Center. The concentration of the adenovirus particles was measured by a 
standard OD260 protocol.34
 
Heat-inactivation studies of adenoviruses were performed 
as described previously.24
Western analysis
Cell lysates were made in radioimmunoprecipitation assay lysis buffer (50 mM Tris.Cl 
pH7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% DOC and 1% NP40). Protein 
concentrations were measured via the standard method with the bicinchoninic acid 
protein assay (Pierce, Perbio Science BV, Etten-Leur, The Netherlands). Virus lysates 
were prepared by adding 5 x 109 virus particles directly to Western sample buffer. The 
Western blotting and detection procedures have been previously described.19,23 For 
detection of β-galactosidase, the monoclonal anti-β-galactosidase clone GAL-13 was 
used (1:2000, Sigma Aldrich, Zwijndrecht, The Netherlands).
Immunohistochemistry assays
For immunohistochemistry assays, the 911-pIX.flag.75.13R4 cells were grown on 
glass cover slips in 6-well plates, fixed in methanol, washed with phosphate-buffered 
saline (PBS) containing 0.05% Tween-20, and incubated with primary antibody, anti-
flag (anti-FLAG
 
M2 Affinity Gel Freezer-Safe; Sigma Aldrich Chemie, Zwijndrecht, The 
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Netherlands) (1:1000 diluted in PBS, 3% bovine serum albumin (BSA)) for 60 min at 
room temperature. The cells were washed and incubated with secondary fluorescein 
isothiocyanatery (FITC)-conjugated goat anti-mouse serum (1:100 diluted in PBS, 3% 
BSA) for 30 min at room temperature. Nuclei were visualized using propidium iodide. 
Subsequently, the cells were washed and mounted on object glasses using Dabco / 
Glycerol (Glycerol, 0.02M Tris.Cl pH8.0 and 1 mg ml-1 2.4-diamidino-2-phenylindole). 
Cells were visualized with a Leica DM-IRBE microscope.
β-galactosidase binding
CsCl purified viruses (1 x 1011 particles per well) were incubated with 100 μg 
β-galactosidase (Sigma Aldrich, Zwijndrecht, The Netherlands) for 60 min on room 
temperature. Subsequently, the viruses were subjected to a continuous CsCl density 
gradient similar to the standard CsCl density gradient protocol during adenovirus 
purification. The purified viruses were further analyzed via Western analysis and 
immunoelectron microscopy. For the DAKO IDEIA β-galactosidase binding assay, 
purified viruses (5 x 109 particles per well) were trapped together with β-galactosidase 
(Sigma Aldrich, Zwijndrecht, The Netherlands) on DAKO IDEIA microwell strips (Dako 
Ltd, Ely, UK). After 60 min incubation on room temperature, the microwell strips were 
washed eight times according to the IDEIA kit instructions. After adding 60 μl ONPG 
(stock was 4 mg / ml in sodium-phosphate buffer, pH7.5) (Sigma Aldrich, Zwijndrecht, 
The Netherlands) and 60 μl Z-buffer (100 mM NaH2PO4 / Na2HPO4 pH7.5; 10 mM 
KCl; 1 mM MgSO
4 and 50 mM 2-mercaptoethanol), the reaction was stopped after 60 
min by adding 50 μl Na2CO3 (stock was 1 M Na2CO3). The ONPG incubations were 
performed at 37oC. The conversion of ONPG as a measurement for β-galactosidase 
activity was determined by assaying the OD420.
Immunoelectron microscopy
The presence of the modified pIX molecules in the viral capsids and the presence 
of β- galactosidase on the surface of the viral particles was visualized with antisera 
and gold- labeled protein-A as described.19 For the detection of the HIS epitope, the 
penta-HIS antibody was used (QIAGEN Benelux BV, Venlo, The Netherlands) (1:200 
diluted in PBS-2% BSA). For detection of β-galactosidase, the same antibody was used 
as for Western analysis (1:200 diluted in PBS-2% BSA). Subsequently, these samples 
were fixed in 1.5% glutaraldehyde in cacodylate buffer and negatively stained with 1% 
uranyl acetate for 15 min. The viruses were examined with a Philips CM-10 transmission 
electron microscope at 100 kV.
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ADENOVIRUS TARGETING TO HLA-A1/MAGE-A1-
POSITIVE TUMOR CELLS BY FUSING A SINGLE-CHAIN 
T-CELL RECEPTOR WITH MINOR CAPSID PROTEIN IX
CHAPTER 4
AbstrACt
Adenovirus vectors have great potential in cancer gene therapy. Targeting of cancer-
testis (CT) antigens, which are specifically presented at the surface of tumor cells by 
human leukocyte antigen (HLA) class I molecules, is an attractive option. In this study, 
a single-chain T-cell receptor (scTCR) directed against the CT antigen melanoma-
associated antigen (MAGE)-A1 in complex with the HLA class I molecule of haplotype 
HLA-A1, is fused with the C-terminus of the adenovirus minor capsid protein IX. 
Propagation of a protein-IX (pIX)-gene-deleted human adenovirus-5 (HAdV-5) vector 
on cells that constitutively express the pIXscTCR fusion protein yielded viral particles 
with the pIXscTCR fusion protein incorporated in their capsid. Generated particles 
specifically transduced melanoma cell lines expressing the HLA-A1/MAGE-A1 target 
complex with at least ten-fold higher efficiency than control viruses. Whereas loading 
of HLA-A1 positive cells with MAGE-A1 peptides leads to enhanced transduction 
of the cells, the efficiency of virus transduction is strongly reduced if the HLA-A1 
molecules are not accessible at the target cell. Taken together, these data provide 
proof-of-principle that pIXscTCR fusions can be used to target HAdV-5 vectors to 
tumor cells expressing intracellular CT antigens. 
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IntrOduCtIOn
Recombinant viral vectors hold great promise in the field of cancer gene therapy. Much 
effort is devoted to generating vectors that have the ability to specifically transduce 
tumor cells. In this respect it will be of major interest to develop vectors that are 
targeted to antigens that are specifically expressed at the surface of tumor cells to 
prevent transduction of noncancerous cells.
Intriguingly, in many cases cancer cells have been found to induce a tumor cell-
specific response of the immune system. Cytotoxic T lymphocytes (CTLs) have been 
discovered that eradicate tumor cells via the recognition of tumor-specific antigens, 
while leaving healthy tissue intact. Such tumor-specific antigens might belong to the 
group of so-called ‘cancer-testis’ (CT) antigens, which are presented at the tumor cell 
surface by major histocompatibility complex (MHC) class I molecules that are recognized 
by CTLs.1 CT antigens are expressed in a variety of cancerous tissues and are generally 
silent in normal tissues, except for the testis.2 To date, 89 CT genes or isoforms, which 
are organised into 44 families, have been described. From these, 19 families are 
testis restricted, 11 show additional expression in one or two somatic tissues, 9 are 
expressed in three to six tissue types besides testis and 5 are ubiquitously somatically 
expressed. With the exception of the testis-restricted CT antigens, the others also 
show expression in the pancreas but at levels as much as 10 times lower than in the 
testis.2 Expression of CT antigens was first shown in melanoma and all the classic CT 
antigens are expressed in this type of tumor, but since the 1980s, expression in various 
other tumors has been recognised.2 The highly specific expression profiles of the CT 
antigens make them interesting target molecules for cancer therapies. Importantly, CT 
antigens belonging to the melanoma-associated antigen (MAGE) A, B and C family 
seem to be involved in oncogenesis, providing protection against apoptosis in tumor 
cells.3 The expression of other tumor antigens, such as ‘overexpression’ antigens p53 
and HER-2/neu, or ‘differentiation antigens’ gp100 and Mart-1, is less restricted to 
tumor cells and their use for cancer-drug targeting may be associated with negative 
side effects.
The principle of targeting human MHC class I molecules (human leukocyte antigen, 
HLA class I), in complex with tumor-specific antigens, has been the subject of many 
studies on T-cell targeting to tumor cells.4 So far, HLA class I/peptide targeting of viral 
vectors has not been extensively explored. Promising results have been obtained by 
targeting measles virus particles to a specific HLA class I/peptide complex via fusion 
of a single-chain T-cell receptor (scTCR) to the attachment protein H of the virus.5 
Recently, adenovirus has been also retargeted to CT antigens by replacing the knob 
domain of the fiber protein with a CT antigen-specific scTCR.6
Adenoviral vectors are among the most promising viral vectors for cancer gene 
therapy for several reasons. They can be produced in large quantities, they do not 
lead to stable genetic modification of the transduced cells and they have a good 
safety profile.7 Genetic modification of adenoviral capsid proteins might lead to the 
development of vectors that are specifically targeted to tumor cells, thereby improving 
safety and efficacy. Cell binding of subgroup C-derived human adenovirus (HAdV) 
vectors (including HAdV-5 and HAdV-2), which are widely used in gene therapy, 
involves two distinct steps. First, they bind with high affinity to the coxsackie virus 
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and adenovirus receptor (CAR) at the cell surface. Second, interaction of penton 
base Arg-Gly-Asp (RGD) motifs with cellular integrins, including αvβ3 and αvβ5 leads 
to endocytosis.8 Many tumor cells are relatively refractory to infection by subgroup 
C-derived HAdV vectors due to the paucity of CAR receptors.9 Development of 
genetically modified vectors that can infect CAR-negative cells has mainly focused 
on incorporation of heterologous ligands in the fiber knob, or on replacement of 
the entire knob domain by a heterologous ligand.7 The complexity of incorporating 
ligands into the adenovirus fiber locale has prompted the identification of other capsid 
proteins amendable for ligand incorporation. These approaches have the potential to 
incorporate an increased number of complex ligands per virion. To date, the capsid 
proteins hexon,10,11 penton base,12 minor capsid protein IX (pIX),13-18 and protein pIIIa19 
have been explored as platforms for the incorporation of heterologous peptides 
(reviewed by Vellinga et al.20).
We have been exploiting the adenovirus minor capsid pIX as an anchor to 
genetically incorporate large proteins.17,18 Protein IX is a small (14.3 kDa) protein of 
unknown structure that acts as capsid cement, stabilizing the interactions between 
hexon trimers on each facet of the virion.21 Twelve molecules of pIX are associated 
with each facet of the icosahedron, with an overall stoichiometry of 240 pIX monomers 
per virion.22 Although the main mass of pIX is thought to be located in the cavities 
between the so-called group-of-nine hexon capsomers, the postulated position of pIX 
in the capsid is being challenged.23-26
Nevertheless, we have recently demonstrated efficient and functional incorporation 
of the hyperstable single-chain antibody fragment 13R4 that was fused with pIX via a 
75-Angstrom spacer.18 The 13R4 was functional in the capsid as was evidenced by its 
capacity to bind Escherichia coli β-galactosidase.
Here we report the production of an adenoviral vector which is targeted to tumor 
cells presenting peptides of the CT antigen MAGE-A1 on HLA class I molecules of 
haplotype HLA-A1, via a scTCR (TCRA1M1) fused with adenovirus minor capsid pIX. To 
ensure enhanced protrusion of the scTCR at the virus surface, a 75-Angstrom α-helical 
spacer was included between pIX and the TCR.17 We produced virus particles that were 
efficiently loaded with the pIX_TCRA1M1 fusion protein. The transduction efficiency of 
the HLA-A1/MAGE-A1-positive melanoma cell lines MZ2-MEL3.0 and MZ2-MEL43 was 
strongly increased upon incorporation of the fusion protein. These findings represent 
(1) the first demonstration of a pIXscTCR-mediated adenovirus targeting of a cell type 
that is normally refractory to HAdV-5, and (2) further proof-of-principle of targeting 
the highly tumor-specific CT antigen/HLA class I complexes at the surface of human 
tumor cell lines.
results
Establishment and characterization of the pIX_TCRA1M1 producing 
helper cell line
To establish a helper cell line stably expressing the pIX_TCRA1M1 fusion protein, 911 
cells were transduced with the recombinant lentivirus LV.pIX_TCRA1M1. A schematic 
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overview of the pro-lentiviral DNA construct and the sequence eventually incorporated 
in the 911 genome is provided in Fig. 1.
After growing the cells for several weeks in selection medium (containing 200 mg 
ml-1 G418), western analysis on cell lysate was performed. This revealed pIX_TCRA1M1 
protein amounts that were similar to the pIX level in 911 cells infected with HAdV-5.
LUC virus (Fig. 2a). The protein size of pIX_TCRA1M1 was as expected (65.8 kDa). The 
percentage of pIX_TCRA1M1-positive cells was determined by immunohistochemistry 
analysis (Fig. 2b). This showed more than 90% of the cells to be positive for pIX_
TCRA1M1. The pIX fusion protein appeared to be located mainly in the cytoplasm. 
Surprisingly, visualizing pIX_TCRA1M1 protein in the cells by using a conformation-
dependent antibody recognizing the variable domain of the scTCR (Vα12.1) was 
dependent on adenovirus infection of the cells (Fig. 2c). At 24 h post infection, a 
Vα12.1-mediated signal could be observed. Cells were infected with the viral vector 
HAdV-5.CMVLUCΔE1ΔE3ΔpIX (see next paragraph). Detection of pIX_scTCRA1M1 by 
Vα12.1 antibody was absent at earlier time points of infection and in pIX_TCRA1M1-
RSV-U3 R U5 RRE cPPT CMV pIX_TCRA1M1 PRE U5R
U3∆TATA
STOPATG
pIX NeoRIRESF 75A Vα Vβ Cβ
A1M1
R U5 RRE cPPT CMV pIX_TCRA1M1 PRE U5R
Co-transfection with packaging plasmids in 293T cells
Stable transduction 911 cells
LV.pIX_TCR
Figure 1. Schematic representation of the lentivirus system, used to establish the 911 helper cell line 
stably expressing pIX_TCRA1M1. The vector used in this study is a third-generation, self-inactivating 
(SIN) vector, with major part of the 3' U3 region deleted, including the TATA box.27 The Rev-responsive 
element (RRE),28 the central polypurine tract (cPPT)29-31 and the human hepatitis B virus-derived 
posttranscriptional regulatory element (PRE) are indicated. The encephalomyocardin virus internal 
ribosomal entry site (IRES) was obtained from pTM3.32 The NPTII coding region (NeoR), which mediates 
resistance to G418, was isolated from peGFPn2 (Clontech, Leusden, the Netherlands).
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negative 911 cells (result not shown). Confocal laser scanning microscopy was used to 
analyze the subcellular localization of the pIX_scTCRA1M1 protein after virus infection 
(Fig. 2c). Although the majority of the pIX_TCRA1M1 protein was observed in the 
cytoplasm, significant amounts were present in the nuclei of infected cells. In >90% of 
the infected cells the pIX_TCRA1M1 fusion protein was readily detectable in the nucleus.
Efficient incorporation of pIX_TCRA1M1 in the virus capsid
Next, we tested the incorporation of pIX_TCRA1M1 into the capsid of the vector 
HAdV-5.CMVLUCΔE1ΔE3ΔpIX. This vector lacks a functional pIX gene and carries the 
firefly luciferase reporter gene under control of the cytomegalovirus (CMV) promoter. 
After transduction of the 911/pIX_TCRA1M1 cells with the ΔpIX virus, the offspring 
virus particles were harvested and purified via the conventional cesium chloride 
Figure 2. Characterization of the 911/pIX_TCRA1M1 helper cell line. (a) Western analysis on lysates of 
the 911/pIX_TCRA1M1 cells. Production of pIX_TCRA1M1 was compared to the production of wild-type 
(wt) pIX in 911 cells infected with HAdV-5. Used antibodies were anti-pIX and horseradish peroxidase 
(HRP)-conjugated secondary antibody. The predicted size of 14.3 kDa for wt pIX and 65.8 kDa for pIX_
scTCRA1M1 was confirmed by the SDS–polyacrylamide gel electrophoresis (PAGE), as indicated in the 
figure. (b) Immunohistochemistry assay on 911/pIX_TCRA1M1 cells. The pIX_TCRA1M1 was visualized by 
using anti-pIX antibody. The nuclei were stained with propidium iodide. (c) Immunohistochemistry assays 
on 911/pIX_TCRA1M1 cells, infected with HAdV-5ΔpIX. Fixation was performed at 24 h postinfection. The 
upper panel shows wide-field microscopy images of anti-hexon and Vα12.1-stained cells. The lower 
panel shows confocal microscopy images of anti-pIX-stained 911/pIX_TCRA1M1. Infected 911 cells were 
included as negative control. To illustrate the presence of fluorescence signal in the nuclei more clearly, 
pseudocolor images of the cells are shown. Fluorescent intensities range from purple (low) to green 
(high).
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supernatant on MEL2a 
Vα12.1 Vβ1no a.b.
Figure 3. Analysis of pIX_TCRA1M1 incorporation in the virus capsid. (a) Schematic representation of the 
pIX_TCRA1M1 fusion protein exposing the single-chain TCRA1M1 above the hexon capsomers. A spacer of 
75 Angstrom is included to improve presentation of the single-chain T-cell receptor (scTCR). A flag tag 
is present in between the C terminus of pIX and the 75-Angstrom spacer. Additional linkers flank the 
75-Angstrom spacer (with amino-acid sequence ‘ser-gly-gly-gly’) to enhance the flexibility of the scTCR. 
(b) Western analysis on virus lysates of cesium chloride (CsCl)-purified viruses to analyze incorporation of 
pIX_TCRA1M1 in the particles. To compare incorporation efficiencies, virus lysates of HAdV-5 and HAdV-5/
pIX_13R4 were included. The anti-hexon antibody was included as a virus particle loading control. The 
predicted size of 14.3 kDa for wild-type pIX and 65.8 kDa for pIX_scTCRA1M1 was confirmed by the SDS-
PAGE, as indicated in the figure. (c) Spot-blot analysis to detect the presence of pIX_TCRA1M1 in intact 
virus particles. Virus was spotted onto a membrane followed by incubation with multiple antibodies. 
As a control to show integrity of the particles upon the spot-blot treatments, incubation with anti-pVII 
was included, directed against the core protein VII. Only after denaturation pVII could be detected. 
(d) Binding of pIX_TCRA1M1-loaded virus particles on beads containing anti-TCR antibodies (Vα12.1 
or Vβ1). After incubation of beads with the pIX_TCRA1M1 virus (containing the luciferase reporter as a 
transgene) plus a control virus (containing the Escherichia coli β-galactosidase gene as a transgene), 
the supernatant was applied to MEL2A cells. The ratio of luciferase to β-galactosidase expression in 








































































































































































(CsCl) purification method. This resulted in the virus HAdV-5/pIX_TCRA1M1. During 
purification, particle-associated pIX molecules were separated from the nonassociated 
pIX molecules, as nonassociated variants do not co-purify with the virus particles in the 
CsCl gradient.17,33 A schematic representation of the pIX_TCRA1M1 fusion protein, with 
its exposed single-chain TCRA1M1 positioned above the hexon capsomers, is depicted 
in Fig. 3a.
The presence of pIX_TCRA1M1 in the virus particles was detected by western assay 
(Fig. 3b). The amount of pIX_TCRA1M1 in the HAdV-5/pIX_TCRA1M1 particles is slightly 
lower than the amounts of pIX in wild-type (wt) HAdV-5 particles. Loading was similar 
to the loading of pIX_13R4 in the previously produced virus HAdV-5/pIX_13R4.18  The 
13R4 is a single-chain antibody fragment directed against β-galactosidase, which is 
approximately 14 kDa smaller than the scTCRA1M1.
Incorporation of pIX_TCRA1M1 in the virus capsid was also shown by spot-blot 
analyses (Fig. 3c). Virus particles were spotted on a nitrocellulose membrane, followed 
by incubation with various antibodies. Upon spotting, the virus particles remain intact, 
indicated by the inability to detect the adenovirus core protein VII (pVII). Only after 
denaturation of the virus particles the pVII could be detected. From the appearance 
of the anti-flag signal it can be concluded that flag epitopes of the pIX_TCRA1M1 fusion 
protein were accessible to immunoglobulins in the context of intact virus particles. For 
the anti-flag and the anti-pIX detection longer exposure times were used, resulting in 
increased background signals.
To further investigate the accessibility of the single-chain TCRA1M1 at the surface of 
the virus particles we performed an immunoprecipitation assay, in which the ability of 
the pIX_TCRA1M1 virus to bind to anti-TCR antibody-coated beads was analyzed (Fig. 
3d). The pIX_TCRA1M1 virus was mixed with a control virus and subsequently incubated 
with Vα12.1 or Vβ1 antibody precoated beads. Both antibodies specifically recognize 
the variable (V) domain of the TCRA1M1. After incubation, supernatant fraction, 
containing virus particles that were not bound to the beads, was applied to MEL2a 
cells, and the infection ratio of pIX_TCRA1M1 virus (containing the luciferase transgene) 
to control virus (containing the β-galactosidase transgene) was determined. As a 
result, significantly lower ratio for the Vα12.1- or Vβ1-treated samples was observed 
when compared to the ratio obtained from the samples without antibody treatment. 
This shows the binding of intact pIX_TCRA1M1 virus particles to the Vα12.1 and Vβ1 
antibodies. Thus, it can be concluded that the V domains of the TCRA1M1 at the surface 
of the virus particles are accessible, suggesting that the scTCR may be free to interact 
with the HLA-A1/MAGE-A1 complex at the cell surface.  
Targeting of the pIXscTCR-containing virus to HLA-A1/MAGE-A1 
positive MZ2-MEL3.0 tumor cells
To test the targeting potential of the HAdV-5/pIX_TCRA1M1 virus to HLA-A1/MAGE-A1 
expressing cells, transduction of MZ2-MEL3.0 melanoma cells (CARneg, HLA-A1pos, 
MAGE-A1pos) was analyzed and compared to control virus transduction. The absence 
of CAR expression is an important aspect to test the targeting potential of the pIX_
TCRA1M1 containing virus, since the virus is not ablated for its natural CAR-binding 
ability, which occurs via the fiber attachment protein. In parallel to the infection 
of MZ2-MEL3.0, the CAR-positive melanoma cell line MEL2a (CARpos, HLA-A1pos, 
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MAGE-A1neg) was infected with the viruses to analyze CAR-mediated transduction. 
Transduction efficiencies of the viruses were determined by measuring luciferase 
production 24 h after transduction. As represented in Fig. 4, presence of the pIX_
TCRA1M1 fusion protein in the virus capsid results in a highly increased transduction of 
the target cell line MZ2-MEL3.0. Whereas CAR-mediated transduction on the MEL2a 
cell line was highest for the pIXscTCR-lacking virus (indicated by a twofold higher 
luciferase activity), the opposite pattern was obtained for the target cell line MZ2-
MEL3.0, which was approximately fourfold better transduced by the pIXscTCR loaded 
virions. When setting the targeting ratio (MZ2-MEL3.0 / MEL2a) for HAdV-5 at one, 
the normalized targeting effect for HAdV-5/pIX_TCRA1M1 on the MZ2-MEL3.0 cell line 
is 9.5. The approximate 10-fold increase in transduction specificity on the target cell 
line did not significantly change by increasing (multiplicity of infection (MOI) = 10,000) 
or decreasing (MOI = 100) the MOI (results not shown).
Downmodulation of HLA-A1/MAGE-A1 availability results in 
decreased targeting by HAdV-5/pIX_TCRA1M1
To demonstrate that HAdV-5/pIX_TCRA1M1 mediates transduction through binding 
to HLA molecules at the cell surface, MZ2-MEL3.0 cells were incubated with anti-
HLA-ABC antibodies, prior to adding the virus. This resulted in a significant decrease 
in transduction with the pIXscTCR virus, whereas no decrease was observed for the 
control virus (Fig. 5a). This observation indicates that transduction of the MZ2-MEL3.0 
cells is inhibited by the binding of immunoglobulins to HLA molecules.
As an alternative blocking strategy, HLA class I presentation at the surface of MZ2-
MEL3.0 was downmodulated by the expression of the human cytomegalovirus (HCMV) 
US11 protein. The US11 protein causes rapid degradation of newly synthesized 
HLA class I heavy chains by mediating their retrograde transport or ‘dislocation’ 
from the endoplasmic reticulum (ER) into the cytosol, where they are degraded by 
proteasomes.34 MZ2-MEL3.0 cells were transduced using retroviruses encoding US11 























Figure 4. Targeting of HAdV-5/pIX_TCRA1M1 
to HLA-A1/MAGE-A1-presenting MZ2-
MEL3.0 cells. The target cell line MZ2-
MEL3.0 (HLA-A1pos/MAGE-A1pos, CARneg) 
was transduced with HAdV-5 and HAdV-5/
pIX_TCRA1M1. In parallel, transduction of the 
MEL2a cell line was performed to determine 
fiber-CAR-mediated transduction of both 
vectors. As transduction readout, luciferase 
production was determined 24 h after 
transduction. Multiplicity of infection was 
1000 virus particles per cell. The insert 
graph shows the ratio of MZ2-MEL3.0 to 
MEL2a transduction for the targeted virus 
HAdV-5/pIX_TCRA1M1, which is normalized to 
the ratio for the control virus. The presence 
of pIX_TCRA1M1 results in a 10-fold improved 
transduction of the MZ2-MEL3.0 cell line.
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5b). The MZ2-MEL3.0 cells were efficiently transduced with the retroviruses, since the 
majority of the cells was positive for the vector-mediated green fluorescent protein 
(GFP) expression. The downshift of the US11-expressing cells in the dotplots indicates 
the downregulation of HLA class I presentation. Next, luciferase production after 
HAdV-5/pIX_TCRA1M1 and HAdV-5 transduction was measured in the cell lines MZ2-
MEL3.0/US11.ires.GFP and MZ2-MEL3.0/ires.GFP (Fig. 5c). This revealed a decrease 




















































Figure 5. Downmodulation of human leukocyte antigen (HLA) availability results in decreased 
targeting. (a) Incubation of MZ2-MEL3.0 with anti-HLA-ABC antibody results in a significant decrease 
in HAdV-5/pIX_TCRA1M1 transduction. Transduction of the control virus is not downregulated after anti-
HLA-ABC loading. (b) Flowcytometric analysis shows downregulation of HLA class I presentation at 
the cell surface of MZ2-MEL3.0 cells after infection with the retroviral vector pLZRS.US11.ires.GFP or 
the control vector pLZRS.ires.GFP. The dot plots show for both transductions the presence of green 
fluorescent protein (GFP)-positive cells (shift to the right). The downshift in case of the pLZRS.US11.
ires.GFP transduction indicates the downregulation of HLA class I presentation (detection via B9.12.1 
antibody plus allophycocyanin (APC)-conjugated secondary antibody). (c) Decrease in HAdV-5/pIX_
TCRA1M1 targeting after US11-mediated downregulation of HLA class I molecules. Compared to the 
control cell line, the ratio HAdV-5/pIX_TCRA1M1 to HAdV-5 transduction is lower for the US11-expressing 
cell line (ratios of respectively 13.2 and 5.2). Multiplicity of infection was 1000 virus particles per cell. 
Luciferase production was measured 24 h after transduction.
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of targeting did not occur, probably as a result of incomplete downregulation of HLA 
class I expression.  
Further analysis on different cell lines to confirm specificity of 
targeting to HLA-A1/MAGE-A1
During the time course of our study, the cell line MZ2-MEL43 became available. This 
line is CARneg, HLA-A1pos, and MAGE-A1pos. Since the level of HLA-A1 expression 
Figure 6. Comparison of the targeting on multiple cell lines to further confirm HLA-A1/MAGE-A1 
specificity. (a) Flow cytometry analysis of human leukocyte antigen (HLA)-A1 expression at the surface 
of MZ2-MEL43 cells. The control plot represents incubation with secondary antibody only. (b) The 
targeting efficiency of the HAdV-5/pIX_TCRA1M1 virus on three different cell lines was determined, 
and normalized to the targeting on MZ2-MEL3.0 cells equal to 100%. Enhanced transduction of the 
pIXscTCR virus compared to the control virus was observed for the cell line MZ2-MEL43. This cell line 
was more efficiently targeted than the MZ2-MEL3.0 cells. No specific targeting was obtained on the 
melanoma-associated antigen (MAGE)-A1-negative cell line MZ2-MEL2.2. A decrease in targeting was 
obtained after incubation of the pIXscTCR virus with Vα12.1 antibody. (c) Improved transduction of 
MZ2-MEL2.2 cells after loading with MAGE-A1 peptide. MAGE-A1 peptide or an irrelevant peptide 
derived from influenza virus A nucleoprotein antigen was added to the wells 2 h before transduction with 
HAdV-5/pIX_TCRA1M1. Luciferase production was measured 24 h after transduction and was normalized 
to transduction on nonpeptide-loaded cells. (d) Flow cytometry analysis to compare the presentation 
of HLA-A1 and HLA-ABC at the cell surface of MZ2-MEL2.2 and MZ2-MEL3.0 cells. The control graphs 
represent incubation with secondary antibody only. The MZ2-MEL3.0 cell line had significantly more 
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appeared to be at least equal to the HLA-A1 level of the target cell line MZ2-MEL3.0 
(Fig. 6a), the targeting efficiency of HAdV-5/pIX_TCRA1M1 to MZ2-MEL43 and MZ2-
MEL3.0 was analyzed in parallel (Fig. 6b). A third cell line, MZ2-MEL2.2, which is a 
derivative from MZ2-MEL3.0 but does not express MAGE-A1, was included as well. As 
expected, transduction with the pIXscTCR virus was enhanced in cell line MZ2-MEL43. 
Interestingly, the targeting efficiency was 45% higher to MZ2-MEL43 than to MZ2_
MEL3.0. As expected, no targeting was obtained on the MAGE-A1-negative cell line 
MZ2-MEL2.2, demonstrating the absolute requirement for MAGE-A1 presentation. The 
enhanced transduction in the two HLA-A1/MAGE-A1-positive cell lines was blocked 
by incubation of the pIXscTCR virus with the antibody Vα12.1 (Fig. 6b), confirming 
that the targeting is dependent on the scTCR in the capsid.
To further analyze the specificity of targeting, MZ2-MEL2.2 cells (CARneg, HLA-A1pos, 
MAGE-A1neg) were loaded either with a control peptide (an irrelevant peptide derived 
from influenza virus A nucleoprotein), a MAGE-A1 peptide, or were mock treated, and 
were subsequently exposed to the pIXscTCR virus (Fig. 6c). Incubation of the cells with 
MAGE-A1 peptide, but not with the control peptide, resulted in a significant increase in 
transduction by HAdV-5/pIX_TCRA1M1. This effect did not occur in HAdV-5 transduction, 
confirming the dependency of HAdV-5/pIX_TCRA1M1 transduction on the presentation 
of the MAGE-A1 on HLA-A1. Compared to the MZ2-MEL3.0 cell line, the targeting 
efficiency to MAGE-A1-loaded MZ2-MEL2.2 cells was rather low. This can be explained 
by the significantly lower number of HLA-A1 molecules at the cell surface (Fig. 6d).
dIsCussIOn
We demonstrate successful targeting of HAdV-5 vectors to HLA-A1/MAGE-A1-
presenting tumor cells using an scTCR incorporated in the capsid as a genetic fusion 
with pIX. The pIX_TCRA1M1-loaded virions transduced HLA-A1/MAGE-A1-expressing 
cells and HLA-A1-expressing cells loaded with MAGE-A1 peptides. These findings 
warrant further exploration of minor capsid pIX as an anchor for the insertion of 
targeting moieties.
The fusion of targeting proteins to pIX has some potential advantages. The use 
of pIX allows the incorporation of larger numbers of targeting molecules since it is 
present in 240 copies whereas 36 fiber molecules are present per virion. Furthermore, 
incorporation of large targeting ligands in the fiber, such as scTCRs or scFv’s, may lead 
to a reduced number of fiber molecules per virion.35 Intriguingly, pIX fusion proteins 
with sizes of up to 120 kDa can be accommodated in the capsid, although incorporation 
efficiency of the modified pIX (linked to an HSV1-TK/luciferase fusion protein) was 
slightly decreased.36 However, this may be improved by the use of α-helical spacers.17
To produce our targeting virus, with pIX_TCRA1M1 incorporated in the capsid, we 
used pIX-producing helper cell lines generated via lentiviral transduction.37 By using 
this strategy of incorporation of pIX in a ΔpIX virus, the time-consuming process 
of making viruses with pIX modifications in the genome can be avoided. Efficient 
incorporation of modified pIX, for example, linked to single-chain antibody fragments, 
can be obtained.18 After transduction of 911 helper cells that produce the pIX_TCRA1M1 
protein, production of pIX_TCRA1M1 in the cells was verified by immunohistochemistry. 
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Infection of the transduced helper cells with ΔpIX virus resulted in the production of 
virus particles with close to wt level of the pIX_TCRA1M1 protein incorporated in their 
capsid, demonstrating the usefulness of this approach.
Interestingly, pIX_TCRA1M1 was detected predominantly in the cytoplasm of the 
LV.pIX_TCRA1M1-transduced 911 helper cells. This is in contrast to the location of the 
wt pIX, which is mainly nuclear.38 As can be concluded from our results, the aberrant 
subcellular localization of pIX_TCRA1M1 does not hamper incorporation in the virus 
capsid. Since adenovirus particles are assembled in the nucleus, these results imply 
that a sufficient amount of pIX_TCRA1M1 was present in the nuclei during formation of 
the HAdV-5/pIX_TCRA1M1 virus. Indeed, we could confirm by confocal microscopy that 
during the adenovirus infection significant amounts of pIX_TCRA1M1 are localized in the 
nucleus.
The targeting specificity to tumor cells expressing the MAGE-A1-derived epitope in 
the context of HLA-A1 was demonstrated via different approaches. First, transduction 
of the HLA-A1/MAGE-A1-positive MZ2-MEL3.0 cells was increased up to 10-fold 
by the incorporation of pIX_TCRA1M1 in the virus capsid. The targeting efficiency in 
another HLA-A1/MAGE-A1-positive cell line, MZ2-MEL43, appeared to be higher. 
Specificity was also evident from experiments in which HLA-A1-positive/MAGE-A1-
negative MZ2-MEL2.2 cells were loaded with MAGE-A1 peptides. This resulted in a 
significant increase in transduction efficiency. The targeting specificity was lower than 
achieved on MZ2-MEL3.0 cells. This may be due to distinct presentation of synthetic 
peptides when compared to endogenously processed and presented peptides at the 
cell surface. Also, MZ2-MEL2.2 cells express fewer HLA-A1 molecules at their cell 
surface than MZ2-MEL3.0 cells (Fig. 6d). Furthermore, the targeting efficiency to MZ2-
MEL3.0 could be reduced by blocking HLA, either via incubation of the cells with anti-
HLA-ABC antibody, or alternatively, via the expression of the HCMV US11 gene. The 
US11 causes degradation of newly synthesized MHC class I heavy chains by mediating 
their dislocation from the ER into the cytosol.34 For the antibody incubation, as well 
as the US11-mediated downregulation, the blocking of targeting was not 100%. 
Apparently, the incubation of cells with anti-HLA-ABC antibody was not sufficient to 
block all HLA-A1 molecules. In case of the US11-mediated downmodulation, flow 
cytometry analysis showed that a small but detectable fraction of the cell population 
had not been transduced (GFP negative), and thus did not downregulate HLA class I 
presentation, which probably explains the incomplete block of targeting.
We report successful targeting of HAdV-5 via fusion of a specific targeting moiety 
to capsid pIX. It has been speculated that targeting via pIX results in entrapment of 
the virions in the endosomes, caused by high-affinity interaction between the pIX 
fusion protein and the cellular receptor.16 However, binding of T-cell receptors to 
their target MHCI/peptide complex is known to have low affinity.39 This may allow 
the scTCR-containing virions to escape from the endosome. Alternatively, binding of 
the virus particles to the HLA-A1/MAGE-A1 complex may have resulted in a distinct 
internalization, that is, differing from the normal HAdV-5 internalization via clathrin-
coated vesicles. Cellular internalization mediated by binding to MHCI molecules is 
exploited by Simian virus 40, which enters the cell via a unique pathway that involves 
caveolae, rather than clathrin-coated pits.40 Interestingly, HLA class I has been 
suggested as an alternative receptor for HAdV-5.41
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The fact that the scTCR used in this study is biologically active at the surface of the 
adenovirus supports the feasibility of targeting adenovirus vectors by fusing complex 
polypeptide molecules, such as scTCRs or scFv fragments, to capsid pIX. Normally, 
such complex polypeptides are routed via the protein secretory pathway. This aspect 
might hamper functional incorporation in the capsid of adenovirus particles, which are 
assembled in the nucleus. The reducing environment in the cell prevents the formation 
of disulfide bridges, which may result in improper folding of these proteins.42 Another 
obstacle for the implementation of scTCRs in adenoviral vectors might be that the 
relatively large scTCRs hamper correct virion formation or might interfere with crucial 
processes necessary for virus propagation. Initial attempts to produce adenovirus 
vectors with an scTCR fragment genetically fused to a knobless fiber protein were 
unsuccessful.43 Incorrect folding and/or trimer formation of the fiber protein due to the 
presence of the scTCR fragment was reported to be the most likely explanation. The 
incorrect fiber formation might have caused the inability to rescue the virus, even though 
the mutated viral DNA was introduced into the target cell line. However, more recently 
the successful development of an scTCR-containing adenovirus has been reported.6 
Our results, with an scTCR bound to the minor capsid pIX, emphasize the potential of 
scTCRs for obtaining transductional specificity in adenoviral vectors. The pIX_TCRA1M1 
fusion protein was incorporated in the capsid with high efficiency. Although it remains 
to be established whether all scTCRs are functional if fused with pIX, our results clearly 
demonstrate the functionality of at least part of the scTCRs. The variable domains 
of the scTCR, which mediate binding to the HLA-A1/MAGE-A1 target complex, 
were accessible to antibodies in the context of intact virions, which was shown via 
immunoprecipitation of the virus on Vα12.1- or Vβ1-coated beads, and alternatively, 
via downregulation of transduction as a result of Vα12.1 incubation. The presence of 
the 75-Angstrom α-helical spacer17 in between the scTCR and pIX domains might have 
been crucial to generate sufficient flexibility for proper orientation of the scTCR at the 
capsid surface. Detailed studies on elucidating the process of scTCR folding during 
virus infection would be of great interest. Our immunohistochemistry analysis on the 
911/pIX_TCRA1M1 cell line yielded staining with the conformation-dependent antibody 
Vα12.1, only after adenovirus infection. It is tempting to speculate that the scTCR only 
adopts its proper conformation upon change of the intracellular milieu upon induction 
of adenovirus-induced cell death.
The pIXscTCR-containing virus used in this study was not de-targeted, as the 
CAR-binding elements, the heparan sulfate proteoglycans-binding elements and the 
plasma protein-binding elements are still present in the capsid. For the final aim of 
in vivo tumor therapy via delivery of an HAdV-5 vector, these elements should be 
abolished. Also, it would be interesting to test whether shortening of the fiber shaft or 
complete removal of the fiber improves targeting efficiency, for instance by reducing 
steric hindrance of the pIXscTCR molecules by the protruding fiber proteins. Currently, 
pIXscTCR targeting in the context of fiber mutations is under investigation.
Our approach as described here utilizes the targeting of CT antigen epitopes 
that are presented at the cell surface of tumor cells by HLA class I molecules. This 
principle differs from previously reported retargeting approaches of adenovirus-based 
vectors, which encompass the targeting of ‘overexpression’ receptors like Her2/neu44 
or the epidermal growth factor receptor.45 The expression profile of the CT antigens 
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is generally much more specific compared to the expression profile of the ‘more 
conventional’ target molecules such as the overexpressed receptors. The fact that 
HLA class I/CT antigen complexes can elicit a highly specific response of the immune 
system has prompted many studies on immune cell modifications with the aim to direct 
the modified cells toward tumor cells.4 However, tumor therapies via such approaches 
may not be feasible since the process of isolating, modifying and expansion of patient 
immune cells is likely to be difficult and time consuming. Viral vector-based cancer 
gene therapy might be a more suitable strategy. Genetic modification of adenoviral 
vectors, which are the most widely used virus vectors in clinical tumor gene therapy 
studies, is relatively easy. Besides, adenoviruses have a good safety profile and can be 
produced with high titers.
Our results show that HAdV-5 vectors can be genetically modified to mediate greatly 
enhanced gene delivery into tumor cells by targeting HLA class I/CT antigen complexes. 
The successful combination of two aspects with great potential in cancer gene therapy, 
adenovirus as a vector and CT antigens as a target, clearly warrants further exploration. 
Follow-up studies are under way, and especially the fusion of other scTCRs to pIX 
(directed against other HLA class I/CT antigen complexes), and the evaluation of in vivo 
performance of the modified HAdV-5 vectors will be of great interest.
MethOds
DNA constructs
The lentiviral vectors used in this study were described in earlier studies.37 Plasmid pLV.
CMV.pIXflag75AscTCRA1M1.bc.neo, abbreviated as pLV.pIX_TCRA1M1, was constructed 
by standard cloning procedures. The pLV plasmid contained a G418 resistance gene 
(neo) downstream of the pIX_TCRA1M1 sequence, separated by an internal ribosome 
entry site (bc). In between the pIX and scTCR sequence, sequences are present that 
encode a flag tag and a 75-Angstrom spacer. Insertion of this spacer has been shown 
to greatly enhance presentation of pIX-fused proteins at the virus capsid.17 The gene 
for pIXflag75 was obtained from the pcDNA3.1-based construct pAd5pIXflag75MYC.17 
The gene encoding scTCRA1M1 was subcloned from the retroviral vector pBullet.
VαVβCβ.46 The scTCRA1M1 sequence of pBullet.VαVβCβ was originally constructed from 
the Vα, Vβ and Cβ sequences from an HLA-A1/MAGE-A1-specific CTL clone MZ2-
82/30 of patient MZ2.47
Cells
All cell lines were maintained at 37 °C in a humidified atmosphere of 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco-BRL, Breda, the Netherlands) supplemented 
with 8% fetal bovine serum (FBS, Gibco-BRL) and penicillin-streptomycin mixture. Cell 
lines used for the adenovirus targeting experiments were the melanoma cell lines 
MEL2a, MZ2-MEL2.2, MZ2-MEL3.0 and MZ2-MEL43. Expression status of the CAR and 
HLA-A1/MAGE-A1 has been described before for the cell lines MEL2a (CARpos/HLA-
A1pos/MAGE-A1neg), MZ2-MEL2.2 (CARneg/HLA-A1pos/MAGE-A1neg) and MZ2-MEL3.0 
(CARneg/HLA-A1pos/MAGE-A1pos).6 The status of the previously uncharacterized cell 
line MZ2-MEL43 is CARneg/HLA-A1pos/MAGE-A1pos, as determined by flow cytometry 
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analysis and shown in Fig. 6a in this paper. The HAdV-5 E1-transformed cell line 911 
was used to propagate and titer adenovirus vectors.48
Lentiviral and retroviral transductions
The recombinant lentivirus LV.pIX_TCRA1M1 was produced as described elsewhere.37 
The lentivirus titer was determined by p24 enzyme-linked immunosorbent assay, 
assuming that 1 ng p24 equals 2.5 × 103 transducing units.49 To establish a helper cell 
line stably expressing pIX_TCRA1M1, 911 cells were transduced with the recombinant 
lentivirus, resulting in the cell line 911/pIX_TCRA1M1. Infection was done with five 
transducing units per cell. To select for stably transduced cells, the cell line 911/
pIX_TCRA1M1 was cultured in medium supplemented with 200 mg l−1 G418 (Invitrogen, 
Breda, the Netherlands).
The retroviral vector pLZRS-US11-IRES-EGFP was made by subcloning the 
HCMV US11 cDNA fragment into the pLZRS-IRES-EGFP vector.50 This construct was 
used, together with the wt enhanced green fluorescent protein (EGFP)-expressing 
retroviral vector, to produce amphotropic retrovirus by transfection of the Phoenix 
cell line with the calcium phosphate method (www.stanford.edu/group/nolan/
retroviral_systems/retsys.html). Transfected cells were grown under puromycin 
selection (2 μg ml−1), which was removed 24 h before collecting the virus. MZ2-MEL3.0 
cells, grown on retronectin-coated dishes (Takara, Japan), were transduced with the 
recombinant viruses to create cells stably expressing US11 and the control construct.
Adenovirus vectors
The 911/pIX_TCRA1M1 helper cell line was transduced with the replication-deficient 
adenoviral vector HAdV-5.CMVLUCΔE1ΔE3ΔpIX. Production and characteristics of 
this vector are described elsewhere.17 The vector carries a firefly luciferase transgene 
under control of the human CMV immediate-early promoter. In this vector the pIX 
gene had been deleted from the genome. Three days after transduction, the offspring 
virus was harvested and purified by CsCl banding, resulting in the virus HAdV-5.
CMVLUCΔE1ΔE3ΔpIX+pIX_TCRA1M1 (indicated in this paper as HAdV-5/pIX_TCRA1M1). 
Adenovirus particle titers were determined by measuring optical density at 260 nm, 
using a standard protocol.51 The control virus used in all retargeting experiments was 
HAdV-5.CMVLUCΔE1ΔE3 (indicated as HAdV-5).
Immunohistochemistry
Immunohistochemistry was performed on the helper cell line 911/pIX_TCRA1M1, with 
or without HAdV-5.CMVLUCΔE1ΔE3ΔpIX infection. Infection was performed with 
1000 virus particles per cell, 24 h before fixation. After washing with phosphate-
buffered saline (PBS), the cells were fixed in acetone/methanol (1:1) for 10 min at room 
temperature. Staining was performed with the antibodies anti-pIX (rabbit polyclonal 
(1:500), kindly provided by Dr Keith Leppard, University of Warwick, UK),52 Vα12.1 
(Pierce-Endogen Biotechnology, Rockford, IL, USA) and anti-hexon (clone BOD604, 
fluorescein isothiocyanate (FITC)-conjugated, Biodesign International, Saco, ME, USA). 
FITC-labeled antibodies (Jackson ImmunoResearch, France) were used as secondary 
antibody. Upon analysis of the uninfected cells, the nuclei were stained using propidium 
iodide. The exact detection procedure has been described previously.18
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Wide-field microscopy was performed with a Leica DM-IRBE microscope. Confocal 
laser scanning microscopy was performed on a confocal microscope system (model 
TCS/SP2; Leica). Z-series images (slice spacing 0.45 μm) were acquired with a 63_ NA 
1.4 plan Apo objective and were analyzed with Leica confocal software.
Immunoblotting procedures
Western analysis was performed to analyze production of pIX_TCRA1M1 in the helper 
cells and to analyze incorporation efficiency of pIX_TCRA1M1 in the virus capsid. Cell 
lysates were made in radioimmunoprecipitation assay lysis buffer (50 mM Tris (pH 
7.5), 150 mM NaCl, 0.1% SDS, 0.5% DOC, 1% NP40). Protein concentrations were 
measured with the bicinchoninic acid protein assay (Pierce Biotechnology, Perbio 
Science BV, Etten-Leur, the Netherlands). Virus lysates were prepared by adding 5 × 
109 virus particles directly to western sample buffer. The pIX variants were visualized 
with rabbit polyclonal anti-pIX serum (1:2000).52 Goat polyclonal anti-hexon (1:1000) 
(Abcam, Cambridge, UK) was used as a virus particle loading control. Secondary 
antibodies were horseradish peroxidase (HRP)-conjugated goat-anti-rabbit and 
rabbit-anti-mouse (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The western 
blotting and detection procedures have been previously described.17, 37
A spot-blot type analysis was used to detect viral capsid proteins in intact virus 
particles. Immobilon membrane (Millipore, Etten-Leur, The Netherlands) was activated 
with methanol, washed for 10 min with PBS and virus (3 × 109 particles) was spotted 
onto the membrane. Virus was spotted as intact particles (untreated) or as virus lysate 
(denatured through adding western sample buffer plus 5 min incubation at 98 °C). This 
was followed up by blocking for 1 h in Soja milk (Alpro soja, Breda, The Netherlands), 
and washing twice for 10 min with 0.2% Tween 20 in PBS. Thereafter, probing of capsid 
proteins was performed according to the same protocol as applied for the western 
analysis. The primary antibodies used were mouse monoclonal anti-fiber knob (1D6.14, 
1:1000),53 goat polyclonal anti-hexon (1:2000; Abcam), anti-flag (1:500) (anti-flag M2 
Affinity Gel Freezer-Safe; Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands), rabbit 
polyclonal anti-pIX (1:2000)52 and anti-pVII antibody (1:500) (kindly provided by Saw 
See Hong, Laboratoire de Virologie et Pathogénèse Virale, Lyon, France). Secondary 
antibodies used were HRP-conjugated goat-anti-rabbit and rabbit-anti-mouse (Santa 
Cruz Biotechnology).
Binding of virus particles to anti-TCR coated beads
The ability of the pIX_TCRA1M1 virus to bind to anti-TCR-coated beads was investigated 
through an immunoprecipitation assay. Protein G Sepharose beads (30 μl; Pierce 
Biotechnology) were incubated with 1 μg of antibody (Vα12.1 or Vβ1), for 2 h at 4 °C in 
600 μl cold PBS. Antibody-coupled beads were added to 1 ml DMEM without serum, 
containing two types of virus; HAdV-5.CMVLUCΔE1ΔE3ΔpIX (5 × 1010 particles), 
and HAdV-5.CMVLacZΔE1 (5 × 1010 particles). Control samples were incubated with 
beads only. After incubation for 12 h at 4 °C, 50 μl of the supernatant was added to 
450 μl DMEM (containing 8% FBS), which was subsequently applied on MEL2a cells 
in a 24-well plate. After 24 h, the expression levels of intracellular luciferase and 
β-galactosidase were determined. To this end, the cells were washed once with 
PBS, and lysed in 100 μl LUC-lysis mix (25 mM Tris-phosphate (pH 7.8), 2 mM CDTA, 
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2 mM DTT, 10% glycerol and 1% Triton-X in PBS). After shaking for 15 min at room 
temperature, lysates were centrifuged (10000 g, 10 min). Luciferase production was 
determined with Promega Luciferase Assay, and β-galactosidase production was 
determined with the Tropix Galacto-Light reporter gene assay (Applied Biosystems, 
Bedford, MA, USA). Light intensity measurement was performed in a Victor Wallac 2 
microplate reader (PerkinElmer, Inc., Waltham, MA, USA).
Virus transduction assays
Transduction efficiencies with HAdV-5/pIX_TCRA1M1 and HAdV-5 were analyzed by 
measuring luciferase production. For all virus transduction assays, transduction was 
performed in a 24-well plate, with 1000 viral particles per cell, in 500 μl DMEM/8% FBS. 
After 24 h, luciferase production was measured as described above (25 μl luciferase 
assay reagent was added to 10 μl lysate).
Incubation of cells with anti-HLA-ABC antibody (ascites) was performed to test 
downmodulation of targeting. The cells were incubated for 12 h with 20 μg ml−1 anti-
HLA-ABC (in medium), which was removed from the cells before adding the virus. TCR 
blocking analysis was performed by incubating the virus (108 particles) for 12 h (4 °C) 
with 150 ng Vα12.1 antibody in 100 μl PBS supplemented with 2% horse serum. After 
adding 400 μl medium, the virus was added to 105 cells (resulting in a titer of 1000 
particles per cell).
For peptide loading of the MZ2-MEL2.2 cells, 500 ng MAGE-A1 peptide, or 500 ng 
of an irrelevant peptide derived from influenza virus A nucleoprotein antigen54 was 
added per well 2 h prior to adding the virus.
Flow cytometry
To perform flow cytometry analysis on the different cell lines, the cells were trypsinized, 
resuspended in PBS (containing 0.5% bovine serum albumin and 0.02% sodium azide), 
and were incubated with antibodies. The cells were incubated with saturating conditions 
of anti-CAR antibody,55 anti-HLA-ABC antibody (W6/32, Cedarlane, ON, Canada) or 
anti-HLA-A1 antibody (One Lambda, CA, USA) for 30 min on ice, followed by incubation 
with phycoerythrin (PE)-labeled secondary antibody (Caltac Laboratories, Burlingame, 
CA, USA) for 30 min on ice. The status of HLA-ABCGE expression at the cell surface 
of the US11-expressing MZ2-MEL3.0 cell line and the control lines was performed by 
using anti-HLA-ABCGE (B9.12.1, Immunotech, Marseille, France) as primary antibody 
and allophycocyanin (APC)-conjugated goat-anti-mouse immunoglobulin G (Jackson 
ImmunoResearch) as secondary antibody. Flow cytometry data were analyzed with 
CellQuest software (Becton Dickinson).
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A CATHEPSIN-CLEAVAGE SITE BETWEEN THE 
ADENOVIRUS CAPSID PROTEIN IX AND A TUMOR-




Human adenoviruses have a great potential as anticancer agents. One strategy to 
improve their tumor-cell specificity and anti-tumor efficacy is to include tumor-specific 
targeting ligands in the viral capsid. This can be achieved by fusion of polypeptide-
targeting ligands with the minor capsid protein IX. Previous research suggested that 
protein IX-mediated targeting is limited by inefficient release of protein IX-fused 
ligands from their cognate receptors in the endosome. This thwarts endosomal escape 
of the virus particles. Here we describe that the targeted transduction of tumor cells 
is augmented by a cathepsin-cleavage site between the protein IX anchor and the 
HER2/neu-binding ZH Affibody molecule as ligand. The cathepsin-cleavage site did 
not interfere with virus production and incorporation of the  Affibody molecules in 
the virus capsid. Virus particles harboring the cleavable protein IX-ligand fusion in 
their capsid transduced the HER2/neu-positive SKOV-3 ovarian carcinoma cells with 
increased efficiency in monolayer cultures, three-dimensional spheroid cultures and 
in SKOV-3 tumors grown on the chorioallantoic membrane of embryonated chicken 
eggs. These data show that inclusion of a cathepsin-cleavage sequence between 
protein IX and a high-affinity targeting ligand enhances targeted transduction. This 
modification further augments the applicability of protein IX as an anchor for coupling 
tumor-targeting ligands.
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IntrOduCtIOn
Many clinical studies have demonstrated the feasibility and safety of cancer therapy 
with human adenovirus type 5 (HAdV-5)-derived vectors. However the efficacy of 
HAdV-5-based therapies still needs further enhancement. Several factors have been 
identified that limit the anti-tumor efficacy (reviewed in de Vrij et al.1). One of these 
is the inadequate penetration and spread of the therapeutic virus within the tumor. 
This might be attributable, at least in part, to the low or heterogeneous expression 
of the coxsackie and adenovirus receptor (CAR) on the tumor cells.2,3 Much effort has 
been invested in devising strategies to improve the transduction efficiency of tumor 
cells in situ. Such strategies include the replacement of the HAdV-5 fibers with those 
of non-CAR binding HAdV serotypes, the inclusion of an integrin-binding arginine-
glycine-aspartic acid (RGD) motif in the fiber to bypass the CAR dependency, and 
fusing capsid proteins with tumor-cell-binding polypeptides (reviewed in Bachtarzi 
et al.4). In the latter approach, adenovirus capsid proteins, such as fiber, penton-
base, hexon and protein IX, have been explored as sites for inclusion of targeting 
polypeptides. 
It has previously been demonstrated that fusion of peptides at the carboxy 
terminus of protein IX allows incorporation of peptides near the surface of the 
adenovirus capsid.5,6 Incorporation of an α-helical spacer between the targeting 
peptide and the protein IX anchor increases the accessibility of the protein ligands on 
the virus surface.6 The capsid-exposed domains of protein IX can be modified without 
negatively interfering with virus stability and infectivity, which is in contrast to fiber 
modifications.7 So far, it has been demonstrated that large and complex proteins, 
such as single-chain antibodies, single-chain T-cell receptors, fluorescent proteins and 
herpes simplex virus thymidine kinase, can be fused with protein IX without losing 
their function.8-10 
We have shown that enhanced transduction of tumor cells was obtained through 
fusing protein IX with an RGD domain,6 thereby targeting cellular integrins, or through 
fusing protein IX with a single-chain T-cell receptor directed against MAGE-A1 
cancer-testis antigens presented by HLA-A1 molecules.9 However, with other ligands 
targeting efficiency was rather low, which led to the hypothesis that a protein IX-linked 
ligand requires dissociation from its cellular receptor after cellular uptake, to enable 
efficient targeted transduction.11 In a normal infection the HAdV-5 particles are 
taken up in clathrin-coated endosomes after binding of the fiber-knob domains to 
the CAR receptor, and secondary binding of the penton-base RGD motifs to cellular 
integrins.12-14 Thereafter, the CAR-bound fiber proteins are released from the virus 
capsid, thereby disconnecting the virus from the endosomal membrane.15,16 This 
allows its release into the cytoplasm. During endosomal escape protein IX remains 
attached to the capsid without being subject of proteolytic degradation.16 As a result, 
high-affinity binding between the protein IX-fused ligand and the receptor may cause 
inefficient endosomal release of the virus in the endosome. 
Here we describe the development and evaluation of a mechanism for dissociation 
of the protein IX-fused ligand from the virus capsid. To facilitate the release of the 
vector particles from the cellular receptor, we introduced a cathepsin-cleavage site 
(ccs) between the protein IX anchor and the targeting ligand. Endosomes contain 
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high levels of cathepsin proteases, which become active upon acidification of the 
endosome (reviewed in Kirschke et al.17). The HER2/neu-binding ZH Affibody molecule 
was chosen as targeting ligand.18 HER2/neu is overexpressed in many cancers, 
including cancers from the breast and prostate, and is therefore a potential target for 
cancer gene therapies.19 The ZH Affibody molecule has been successfully employed 
for targeting of HAdV-5 to HER2/neu upon introduction in the fiber.20
Our assays revealed that introducing a ccs between protein IX and a ZH Affibody 
molecule does not interfere with virus production and incorporation of the ZH Affibody 
molecules into the virus capsid. The ccs-containing virus demonstrated significantly 
enhanced transduction of SKOV-3 ovarian carcinoma cells in cell culture models as 
well as in a chorioallantoic membrane (CAM) tumor model as compared to the non-
ccs-containing control virus.
results
In vitro cleavage analyses on protein IX-ccs-ligand proteins
We first set out to explore the possibility of functionally incorporating a cathepsin-
cleavable amino-acid sequence in a protein IX-ligand polypeptide fusion protein. 
To this end, the fusion proteins pIX.13R4.myc.his, pIX.ccsB.13R4.myc.his and pIX.
ccsL.13R4.myc.his were purified and tested for their cathepsin sensitivity. The 13R4.
myc.his polypeptide sequence (with 13R4 being a single-chain antibody fragment 
directed against β-galactosidase) has previously been successfully fused with protein 
IX.8 A schematic overview of the fusion proteins is depicted in Fig. 1a.
Lentivirus vectors were used to generate 911 cell lines stably expressing the protein 
IX fusion proteins. The histidine (his) tag fused to 13R4 enabled the subsequent 
isolation of the fusion proteins via binding to nickel beads. Thereafter, the  proteins 
were incubated with either cathepsin B or cathepsin L, and the cleavage products 
were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
immunoblotting (Fig. 1b). This revealed  cleavage of the cathepsin L-cleavage site 
(ccsL)-containing fusion protein, as indicated by the appearance of the 25 kDa-sized 
fragment. The cathepsin B-cleavage site (ccsB)-containing protein was not cleaved. 
Of note, minor adjustments to the protocol (for example, cleavage of pIX.ccsL.13R4.
myc.his after elution from the beads) resulted in pIX.ccsL.13R4.myc.his degradation 
without the appearance of a cleavage product (data not shown). Probably, the 
cathepsin L preparation (derived from human liver) contains contaminating levels of 
other proteases, which may degrade the cleavage protein. Cleavage of pIX.ccsL.13R4.
myc.his could be blocked by co-incubation with the cathepsin-specific inhibitor Z-FY(t-
Bu)-DMK (Fig. 1b). 
The pIX.13R4.myc.his and pIX.ccsL.13R4.myc.his fusion proteins were incorporated 
in the capsid of HAdV-5 (Fig. 1c). Incorporation efficiency was similar for both fusion 
proteins, and the presence of the ccsL site did not result in detectable levels of protein 
cleavage. Importantly, after incorporation of the pIX.ccsL.13R4.myc.his into the 
HAdV-5 capsid, the fusion protein was still sensitive to cathepsin L (Fig. 1d), indicating 
that the ccsL was functional and accessible in the adenovirus capsid.  
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Binding of Ad5/pIX.ccsL.ZH to the extracellular domain of HER2/neu
We and others have demonstrated that the HER2/neu-binding ZH Affibody molecules 
can be used for adenovirus targeting by incorporating these ligands in the HI loop of 
the adenovirus fiber.20 Fusion of these Affibody domains with protein IX was far less 
efficient in retargeting adenovirus infection to HER2/neu-positive cells (our unpublished 
data). To study whether protein IX-Affibody-mediated targeting could be improved, we 
generated adenoviruses with protein IX-ccsL-ZH fusion proteins incorporated in their 
capsid, with the ccsL site located in between the 75-Ångstrom spacer and the tandem 
sequence of ZH Affibody molecules. By using standard cloning, recombination, and 
virus-rescuing procedures, we produced replication-competent HAdV-5 viruses with 
the sequences for pIX, pIX.ZH, or pIX.ccsL.ZH incorporated in the genome. In the viral 
genomes, major part of the E3 region was replaced by an enhanced GFP expression 
cassette.21 The incorporation of the modified protein IX genes did not affect the titers 
(in physical particle (pp) ml-1 as well as plaque forming units (PFU) ml-1) of the purified 
virus preparations (data not shown). 
To investigate the functionality of the capsid-incorporated ZH Affibody molecules, 
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Figure 1. (a) Schematic representation of the pIX.13R4 fusion proteins. All polypeptide components are 
indicated (protein IX, flag tag, 75-Ångstrom spacer, ccs, 13R4 (single-chain antibody fragment directed 
against β-galactosidase), myc tag, his tag). (b) Western analyses after cathepsin cleavage of pIX.13R4 
fusion proteins bound to nickel beads. The left panel indicates pIX.13R4 (13R4), pIX.ccsB.13R4 (ccsB) 
and pIX.ccsL.13R4 (ccsL) protein levels after cathepsin B (catB), cathepsin L (catL) or mock incubation. 
The right panel indicates pIX.ccsL.13R4 protein levels after cathepsin L cleavage in the presence or 
absence of the cathepsin inhibitor Z-FY(t-Bu)-DMK. Analyses were performed using anti-protein IX 
antibody. (c) Western analysis of pIX.13R4 and pIX.ccsL.13R4 protein levels after incorporation in the 
capsid of the protein IX-deleted HAdV mutant dl313 (5 x 109 pp per lane). Detection was carried out 
with anti-protein IX and anti-hexon antibodies. (d) Western analysis of pIX.ccsL.13R4 incorporated in 
the dl313 virus after incubation with different concentrations of cathepsin L (0, 10, 20 and 30 ng ml-1) (5 
x 109 pp per lane). Detection was carried out with anti-protein IX and anti-hexon antibodies.
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immobilized virus particles were incubated with soluble HER2-ECD, after which virus-
bound HER2-ECD was detected by virtue of the his tag, which was fused with the 
HER2-ECD polypeptide. This experiment demonstrated binding of the HER2-ECD to 
Ad5/pIX.ZH and Ad5/pIX.ccsL.ZH particles. As expected, all viruses bound equivalent 
amounts of an antibody recognizing the fiber-knob domain. Also, the amounts of 
hexon antigen detected were similar, confirming equivalent particle loading in all 
samples.  From these data, we conclude that both viruses with protein IX-Affibody 
fusions are functionally capable of binding HER2/neu.
Improved transduction of SKOV-3 cell culture by Ad5/pIX.ccsL.ZH
Subsequently, we studied the capacity of the viruses to transduce cultured cells 
that lack CAR but overexpress HER2/neu. Analyses were performed on the cell lines 
SKOV-3 (HER2/neu-positive and CAR-negative) and 911 (HER2/neu-negative and 
CAR-positive). Infection of SKOV-3 cells in an agar-overlaid monolayer culture showed 
the appearance of larger plaques for Ad5/pIX.ccsL.ZH (mean 2.4 arbitrary surface units 
(ASU), range 0.5-5.5), as compared to Ad5/pIX (mean 1.4 ASU, range 0.5-2.5) and Ad5/
pIX.ZH (mean 0.9 ASU, range 0.5-2.5) (representative plaques are shown in Fig. 3a). 
No differences were observed between Ad5/pIX and Ad5/pIX.ZH, suggesting that the 
presence of the ccsL site had an effect on the efficiency of transduction of the HER2/
neu-positive cells. In contrast, the plaques observed on monolayers of 911 cells had 
a similar size distribution for all three viruses (mean 1.3 ASU, range 0.5-4.5 for Ad5/
pIX, mean 1.3 ASU, range 0.5-3.5 for Ad5/pIX.ZH, mean 1.4 ASU, range 0.5-3.5 for 
Ad5/pIX.ccsL.ZH). These data suggest that inclusion of the pIX.ccsL.ZH in the capsid 
enhanced the virus spread in monolayers of CAR-negative, HER2/neu-positive cells. 
To test whether the infection is also enhanced in three-dimensional tumor cell 
cultures, the viruses were applied on SKOV-3 and 911 spheroids (Fig. 3b). As in the 
SKOV-3 monolayer cultures, Ad5/pIX.ccsL.ZH displayed the highest transduction 
efficiency on SKOV-3 spheroids, with the GFP expression levels being significantly 































Figure 2. Slot-blot analyses of HER2-ECD binding to intact virus particles. HER2-ECD binding was 
assayed by subsequent incubation with his-tagged HER2-ECD and anti-HIS antibody. For loading-
control purpose, incubation with anti-fiber-knob and anti-hexon antibody was performed. Two virus 
concentrations (1010 and 109 pp) were applied to the membrane.
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Figure 3. (a) Plaque assay to compare Ad5/pIX, Ad5/pIX.ZH and Ad5/pIX.ccsL.ZH infection of 
monolayer cell cultures. The microscopy pictures show representative GFP-positive SKOV-3 plaques. (b) 
Transduction of 911 and SKOV-3 spheroids with Ad5/pIX, Ad5/pIX.ZH and Ad5/pIX.ccsL.ZH. Infection 
was performed at multiplicities of infection (MOI) of 1 and 10 PFU per cell. The graphs show the 
mean GFP intensities at 5 days post-transduction. Error bars represent s.d. (n = 3). Differences in GFP 
intensity are considered significant at P<0.05 for both MOIs.   Representative pictures (at 5 days post-
transduction) are shown on the left. (c) Transduction of SKOV-3 spheroids with Ad5/pIX, Ad5/pIX.ZH 
and Ad5/pIX.ccsL.ZH in the presence or absence of the cysteine protease inhibitor E64-D. The graphs 
show the mean GFP intensities at 5 days post-transduction. Error bars represent s.d. (n = 3).
no enhanced transgene delivery was observed for the Ad5/pIX.ccsL.ZH virus on 
the non-target 911 spheroids. Strikingly, the transduction efficiencies for both 
ZH-containing viruses appeared reduced on the 911 spheroids, as compared with 
the transduction efficiency for Ad5/pIX. This reduction is in contrast to the results 
obtained on the 911 monolayers, which showed identical plaque sizes for all three 
viruses. The cause for this discrepancy between the monolayer and the spheroid model 
remains to be elucidated. It is conceivable that the growth of the cells in such different 
conditions affects the cell surface expression or accessibility of the viral receptors CAR 
and integrins. Irrespective of the mechanism, the reduced transduction of Ad5/pIX.ZH 
and Ad5/pIX.ccsL.ZH on the non-target 911 spheroids may result from the presence 
of large targeting ligands fused with protein IX. This warrants further investigation.
The enhanced GFP expression upon Ad5/pIX.ccsL.ZH infection of SKOV-3 
spheroids could be inhibited by incubation with the cysteine-protease-specific 
inhibitor E64-D (Fig. 3c). Although the presence of the inhibitor resulted in a modest 
increase in transduction for Ad5/pIX and Ad5/pIX.ZH, the transduction efficiency for 
Ad5/pIX.ccsL.ZH was strongly decreased. Of interest, the addition of the cathepsin 
inhibitor resulted in a general effect on SKOV-3 spheroid morphology, with obvious 
changes in the cell density on the spheroid surface (results not shown). This effect 
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probably caused the modest increase in transduction for the Ad5/pIX and Ad5/pIX.
ZH viruses.
Analysis of transduction of SKOV-3 tumors on a CAM 
To gain insight into the performance of the viruses in vivo, the viruses were tested for 
their transduction efficiencies in human tumors grown on the CAM of embryonated 
chicken eggs. The engraftment of SKOV-3 cells at embryo development day 7 (EDD7) 
resulted in the rapid formation of tumors with a size of 4-6 mm at EDD14 (= day of 
virus injection), with obvious appearance of blood vessel sprouting (Fig. 4a). Western 
analysis was carried out at EDD14 to analyze the expression of cathepsin L in the CAM 
tumor lysate (Fig. 4b). Pro-cathepsin L (42 kDa) as well as the active form of cathepsin 
L (25 kDa) were detected. At EDD20 (=6 days post virus injection), the tumors were 
harvested and GFP signals were quantified (Fig. 4c). The insertion of the ccsL site 
significantly enhanced transduction, with the GFP expression level for Ad5/pIX.ccsL.





































Figure 4. Virus transduction of SKOV-3 cells grown on the CAM. (a) Representative pictures of CAM 
tumors at EDD 14 (before virus injection) and EDD 20 (before tumor isolation). (b) Western analysis of 
cathepsin L protein levels in lysates of SKOV-3 cells grown as CAM tumor. Detection was carried out 
with anti-cathepsin L antibody directed against pro-cathepsin L (42 kDa) as well as the active form of 
cathepsin L (25 kDa). (c) Biofluorescent imaging with the IVIS system of GFP expression in SKOV-3 
tumors retrieved from the CAM (EDD 20). The graph shows the mean GFP intensities. Error bars 
represent s.d. (n = 5). Representative IVIS pictures are included.
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dIsCussIOn
We studied the usability of cathepsin-cleavage sites in mediating the dissociation of 
HAdV-5 protein IX from fused tumor-targeting ligands. Inclusion of a ccsL in between 
protein IX and a HER2/neu-targeted ZH Affibody molecule enhanced the transduction 
of HER2/neu-positive SKOV-3 tumor cells. The enhanced delivery of an enhanced GFP 
reporter gene was observed in monolayer culture, three-dimensional spheroid culture, 
as well as in SKOV-3 tumors grown on the CAM of embryonated chicken eggs. These 
results provide a strategy to enhance the applicability of protein IX as an anchor for 
coupling high-affinity tumor-targeting ligands.
Varying efficiencies have been reported for protein IX-mediated retargeting 
approaches, with the targeted transduction efficiency depending on the type of ligand 
used.9,11,22 It was first suggested by Barry et al.11 that high-affinity binding between a 
protein IX-coupled targeting ligand and its receptor may prevent release of the virus 
particle from the targeted receptor, resulting in inefficient escape of the virus particle 
from the endosome to the cytoplasm. Such endosomal sequestration is in contrast to 
fiber-mediated targeting, as the fiber is released from the virus particle upon cellular 
uptake.15,16 To gain more insight into the phenomenon of endosomal entrapment of 
protein IX targeted HAdV-5 vectors, Corjon et al.22 fused protein IX with the RAP 
(receptor-associated protein) ligand, which is evolutionary designed for dissociation 
from its target receptor (LRP; LDL-receptor-related protein) at low pH. As intended, 
this strategy resulted in proper routing of the virus particles in the LDL-expressing 
target cells (from endosome to the nuclear periphery), and retargeting efficiency 
appeared to be equal to fiber-RAP-mediated retargeting of HAdV-5.    
To prevent the endosomal entrapment of protein IX-targeted HAdV-5, we set out to 
test whether insertion of a ccs can be used to circumvent this problem, by facilitating 
endosomal release of the vector. Such mechanism would mimic the strategies adopted 
by other viruses. Reovirus is disassembled by cathepsins B and L in the endosome. This 
is a crucial step in its infective pathway.23 The Ebola virus is dependent on cleavage of 
glycoprotein GP1 by cathepsins B and L to trigger membrane fusion and cell entry.24 
In addition, activation of the Nipah virus fusion protein (responsible for virus entry 
into the host cell) is mediated by endosomal proteases, presumably cathepsins.25 Ccs 
incorporation has already been introduced in radioimmunotherapy, which has revealed 
a decrease in hepatic toxicity when a cathepsin cleavable peptide is attached to the 
therapeutic-chelated radiometal.26
We first performed an in vitro cleavage assay to compare a ccsB and a ccsL site for 
their cleavage sensitivity if incorporated in between protein IX and a model ligand, 
that is, the hyper-stable single-chain antibody fragment 13R4.8 Cathepsins B and L, 
which belong to the papain-like family of cysteine proteases, are ubiquitous in the 
lysosomes of animals.27 The enzymes are endopeptidases, although cathepsin B was 
found also to be a dipeptidyl carboxypeptidase.28 Among the lysosomal cysteine 
proteases, cathepsin L was found to be the most active in degradation of protein 
substrates27,29,30 and cathepsin B the most abundant.27 The enzymes are optimally 
active at slightly acidic pH, that is, pH 6.0 for cathepsin B and pH 5.5 for cathepsin 
L (reviewed in Kirschke et al.17). This allows full activity within the lysosomal and 
endosomal compartments. Interestingly, and probably of relevance to our strategy 
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of using a ccs in HAdV-5 tumor targeting, cathepsins are frequently up regulated in 
human cancers, and have been implicated in distinct tumorigenic processes such as 
angiogenesis, proliferation, apoptosis and invasion (reviewed in Gocheva and Joyce31).
Our assays demonstrated that the pIX.ccsL.ligand fusion molecule was efficiently 
inserted in the HAdV-5 capsid. The ccsL site retained its sensitivity for cleavage 
with cathepsin L. Subsequently, the ccsL site was introduced in the genome of the 
replication-competent virus Ad5/pIX.ZH, between the protein IX and a tandem pair of 
ZH Affibody ligands. Binding of the soluble HER2-ECD to the particles was confirmed, 
demonstrating that the ZH Affibody molecules are located at an assessable location 
within the virus capsid. Furthermore, Ad5/pIX.ZH and Ad5/pIX.ccsL.ZH bound the 
HER2-ECD with similar efficiency, demonstrating that during virus production the virus 
particles were not exposed to active cathepsin L to an extend that leads to proteolytic 
removal of the targeting ligands. 
By quantifying GFP expression levels, we compared the transduction efficiencies 
of the viruses Ad5/pIX, Ad5/pIX.ZH and Ad5/pIX.ccsL.ZH in different SKOV-3 models. 
In all models the mere presence of the ZH Affibody molecule was insufficient for 
significantly improving transduction efficiency. Insertion of the ccsL site, however, 
resulted in a significantly enhanced transduction in all SKOV-3 models tested. The 
targeted transduction efficacy was moderately but significantly enhanced in the 
spheroid as well as in the CAM tumor model.
Of interest, the transduction efficiencies of the ZH-containing viruses were 
significantly reduced, as compared to the Ad5/pIX virus, on the non-target (CAR-
positive/HER2-negative)  911 cells in the three-dimensional spheroid model. The 
cause of this reduction, which is in contrast to the equal plaque sizes for all viruses 
in 911 monolayers, is unknown. One explanation might be that the wild-type 
HAdV-5 receptors (that is, CAR and/or integrins) are relatively poorly accessible on 
the cell surface in a 911-cell spheroid. As a consequence, extensive HAdV-5 capsid 
modification, such as the protein IX-ZH incorporation, might lead to changes in virion 
composition that restrict virus mobility to their receptors. Fusion of other ligands with 
protein IX can result in reduced transduction of 911 spheroids as well (our unpublished 
data), demonstrating that the effect is not specific for ZH Affibody molecules. It will 
be of interest to further analyze protein IX-ligand-targeted HAdV-5 vectors for their 
infection efficacy on non-target cells, for example, in human tumor xenografts in mice.
In this particular proof-of-principle study, the incorporation of a cathepsin 
L-cleavage site resulted in substantial improved transduction of SKOV-3 tumor cells. 
It remains to be established which ccs is optimally suited for a particular ligand and 
target combination. Tumor cell lines as well as primary tumors have been shown to 
strongly vary in their expression profile and expression level of the different types 
of cathepsins (BioGPS Gene Portal;32 NCI60 cell lines (U133A) data set33 and Human 
Primary Tumors (U95) data set34). Depending on the tumor type to target, the optimal 
ccs for incorporation in a pIX.ccs.ligand-containing HAdV-5 may vary, thereby 
necessitating preclinical ccs evaluations in oncolytic virus protocol development.
The causal mechanistic for the improved performance of the ccsL containing virus 
remains to be established. Although enhanced endosomal escape of the targeted 
viruses seems a plausible hypothesis, further studies are necessary to provide a definite 
answer. Despite these uncertainties on the mechanism, our results demonstrate the 
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feasibility of using a ccs for improving transgene delivery with protein IX-ligand-
targeted HAdV-5 vectors. Enhanced transduction was observed in a spheroid and 
CAM tumor model, which are highly suitable models for analysis of transgene delivery 
in a three-dimensional context. Nevertheless, future experiments, implementing bona 
fide tumor models that allow long-term follow-up, will be necessary to reveal whether 
incorporation of a ccs leads to enhanced anti-tumor efficacy of protein IX-ligand-
targeted viruses.
Our cathepsin-cleavage strategy enhances the potential for protein IX-mediated 
targeting of HAdV-based oncolytic viruses for cancer therapy. Also, the introduction of 
a ccs might be efficacy-improving for other (non-protein IX-based) HAdV-5 targeting 
approaches. It would be highly interesting to analyze the effect of introducing a ccs 
in fiber-ZH viruses,20 and to perform a side-by-side comparison between pIX.ccs.ZH 
viruses and fiber-ccs-ZH viruses. 
Future research will reveal whether protein IX-based targeting, in combination 
with other targeting (for example, fiber-ligand-based) and de-targeting approaches 
(for example, ablating CAR-binding by fiber knob modification or blood-coagulation 
factor X-binding by hexon modification35), can lead to improved oncolytic HAdV 
vectors. Such rational design strategies, as well as parallel strategies involving random 
mutagenesis and bioselection methodologies,36-39 will facilitate the derivation of new 
targeted adenoviruses with improved tumor-cell specificity and anti-tumor efficacy.
MAterIAls And MethOds
Cell lines
The human cell lines SKOV-3 (ovarian adenocarcinoma), A549 (carcinomic alveolar 
epithelium) and 911 (HAdV-5 E1-transformed embryonic retinoblasts)40 were 
maintained at 37°C in a humidified atmosphere of 5% CO2 in Dulbecco’s Modified 
Eagle’s Medium (Gibco-BRL, Breda, The Netherlands) supplemented with 8% fetal 
bovine serum (Gibco-BRL, Breda, The Netherlands) and penicillin-streptomycin.
Viruses
Overlap extension-polymerase chain reaction (PCR) (with oligonucleotides 1-4; Table 1) 
was used to fuse a tandem of ZH Affibody sequences derived from the plasmid FibR7-
ZHZH,20 with the sequence pIX.flag.75 derived from the plasmid pAd5pIX.flag.75.
MYC.6 Next, the resulting fusion fragment pIX.flag.75.(ZH)2 was flanked at both ends 
with a short sequence containing a restriction site (MluI upstream of the pIX.flag.75.
(ZH)2 start codon and BstZ17I downstream of the pIX.flag.75.(ZH)2 stop codon) by PCR. 
The pIX.flag.75.(ZH)2 sequence was ligated to the MluI- and BstZ17I-digested plasmid 
pLV-CMV-IRES-NPTII,41 resulting in the plasmid pLV-CMV-pIX.flag.75.(ZH)2-IRES-NPTII 
(pLV-pIX.ZH). Subsequently, a unique PacI restriction site was introduced between the 
75-Ångstrom spacer and the (ZH)2 sequence (with oligonucleotides 5 and 6; Table 1) 
by site-directed mutagenesis PCR, resulting in the plasmid pLV-CMV-pIX.flag.75.PacI.
(ZH)2-IRES-NPTII. The PacI site enabled introduction of a cathepsin L-cleavage site by 
ligation of the annealed oligonucleotides 7 and 8 (Table 1), resulting in pLV-CMV-pIX.
flag.75.ccsL.(ZH)2-IRES-NPTII (pLV-pIX.ccsL.ZH). The coding sequences of pIX.flag.75.
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(ZH)2 and pIX.flag.75.ccsL.(ZH)2 were isolated from, respectively, pLV-pIX.ZH and 
pLV-pIX.ccsL.ZH by PCR (oligonucleotides 9 and 10; Table 1). The sequence for HAdV-5 
protein IX was isolated from the plasmid pAd5pIX6 by PCR with oligonucleotides 9 and 
11 (Table 1). The ScaI-SpeI-flanked PCR products were cloned in pShuttle+E1+pIXScaI/
SpeI.42 The ScaI restriction site was restored by exchanging the E1B/protein IX sequence 
containing MfeI/HindIII region with the corresponding fragment from pTG3602. The 
resulting plasmids pSh+pIX, pSh+pIX.ZH and pSh+pIX.ccsL.ZH were recombined with 
the HAdV-5-based backbone plasmid pBB42 (containing the eGFP gene in the E3 region, 
based on the previously described pShuttle-DE3-ADP-EGFP-F221), followed by virus 
rescue in A549 cells. Recombination and virus rescue were as described elsewhere.42 
The viruses (named Ad5/pIX, Ad5/pIX.ZH and Ad5/pIX.ccsL.ZH) were purified by a 
standard double cesium chloride gradient protocol, dialyzed against sucrose buffer 
(5% sucrose, 140 mM NaCl, 5 mM Na2-HPO4.2H2O, 1.5 mM KH2PO4) and stored at 
−80 °C. The virus titer was determined by the PicoGreen-DNA binding assay43 (for 
Table 1. Oligonucleotide list.
Oligonucleotide Sequence (5’ to 3’)
1 FWD Tthiii-pIX TACGAGACCGTGTCTGGAACG
2 REV pIX75Å GGCGCCGTGTAAGGTTGGGTTGTGGCGTTTGAAGGCGGCTTC
3 FWD pIX75Å-ZH AACCCAACCTTACACGGCGCCGTAGACAACAAATTCAACAAA
4 REV DraI-ZH GTTTTAAACTTTCGGCGCCTGAGCATCATT
5 FWD PacI-ZH CAAACGCCACAACCCAACCTTAATTAAGGCCGTAGACAACAAATTC
6 REV PacI-ZH GAATTTGTTGTCTACGGCCTTAATTAAGGTTGGGTTGTGGCGTTTG
7 FWD CatL-ZH CGACGGCGGAGGGAGGAAGGAATTGGTGACGCCAGCACGAGA-CTTCGGTCATTTTGGATTATCCGGAGGCGGGAT
8 REV CatL-ZH CCCGCCTCCGGATAATCCAAAATGACCGAAGTCTCGTGCTGGCGT-CACCAATTCCTTCCTCCCTCCGCCGTCGAT
9 FWD ScaI-pIX CGCGGAAGTACTATGAGCACCAACTCGTTTGATGG
10 REV SpeI-ZH CGCACTAGTCTAAACTTTCGGCGCCTGAGCAT
11 REV SpeI-pIX CGCACTAGTTTAAACCGCATTGGGAGGGGAGG
12 FWD PacI-13R4 CAACCCAACCTTAAGCGCCGTCGACGGCTTAATTAACGGCG-GAGGGAGCATGG
13 REV PacI-13R4 CCATGCTCCCTCCGCCGTTAATTAAGCCGTCGACGGCGCTTA-AGGTTGGGT
14 FWD CatB-13R4 TCGACGGCGGAGGGGGCTTCCAGGGCGTGCAGTTCGCCG-GCTTCAT
15 REV CatB-13R4 GAAGCCGGCGAACTGCACGCCCTGGAAGCCCCCTCCGCCG
16 FWD CatL-13R4 TCGACGGCGGAGGGAGGAAGGAATTGGTGACGCCAGCACGAGA-CTTCGGTCATTTTGGATTATCCAT
17 REV CatL-13R4 GGATAATCCAAAATGACCGAAGTCTCGTGCTGGCGTCAC-CAATTCCTTCCTCCCTCCGCCG
Abbreviations: CatB, cathepsin B; CatL, cathepsin L; FWD, forward; pIX, protein IX; REV, 
reverse.
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pp ml-1 measurement), and a plaque assay on 911 cells (for PFU ml-1 measurement), 
as described in Fallaux et al.40 To compare the virus spread in monolayers of 911 and 
SKOV-3 cells, standard plaque assays were performed, followed by photographing 
GFP-positive plaques and measuring plaque size with ImageJ software (National 
Institutes of Health, Bethesda, MD, USA). The plaque surface area of Ad5/pIX.ZH and 
Ad5/pIX.ccsL.ZH was normalized to the plaque surface area of Ad5/pIX.
Western analyses
Cell lysates were made in radioimmunoprecipitation assay lysis buffer (50 mM Tris-
Cl, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% DOC, and 1% NP40) 
supplemented with protease inhibitors. Protein concentrations were determined 
with a BCA protein assay (Pierce, Etten-Leur, The Netherlands). Cell lysate samples 
for western analysis were prepared by boiling of 20 μg of total protein in reducing 
sample buffer (final composition: 33 mM Tris-Cl, pH 6.7, 9% glycerol, 2% sodium 
dodecyl sulfate and 2.2% β-mercaptoethanol, and 2.2% from a 1:20 dilution of a 
saturated bromophenol blue solution) for 5 min at 100°C. Virus samples for western 
analysis were prepared by adding purified viruses directly to the reducing sample 
buffer, followed by boiling. All samples were subjected to standard sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, with 15% polyacrylamide running gels, 
and subsequent protein transfer to polyvinylidene difluoride (PVDF) membranes 
(Immobilon-P transfer membrane; Millipore, Amsterdam, The Netherlands) by 
electroblotting. After immunological probing of the blots, horse radish peroxidase 
(HRP)-conjugated antibodies were detected by enhanced chemiluminescence. 
Primary antibodies used were goat polyclonal anti-hexon (1:2000, ab19998; Abcam, 
Cambridge, UK), rabbit polyclonal anti-protein IX (1:2000)44, and mouse monoclonal 
anti-cathepsin L (1:500, [33/2] ab6314; Abcam). Secondary antibodies used were HRP-
conjugated goat-anti-rabbit and mouse-anti-goat (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA).
In vitro cathepsin cleavage assay 
To test various protein sequences for their usage as ccs in the context of a protein 
IX-ligand incorporation, we introduced the sequences in our previously described 
pIX.13R4.myc.his fusion protein8 (Fig. 1a). To this end, PCR was carried out (with 
oligonucleotides 12 and 13; Table 1) to introduce a PacI site in the plasmid pLV-
CMV-pIX.flag.75.13R4.myc.his-IRES-NPTII (pLV-pIX.13R4.myc.his).8 Subsequently, 
oligonucleotides 14 and 15 (Table 1) were used for insertion of a ccsB45 and 
oligonucleotides 16 and 17 (Table 1) for insertion of a ccsL,23 resulting in the 
plasmids pLV-pIX.ccsB.13R4.myc.his and pLV-pIX.ccsL.13R4.myc.his. From the pLV 
plasmids recombinant lentiviruses were produced, which were subsequently used 
for transduction of 911 cells to establish the expression of proteins pIX.13R4.myc.
his, pIX.ccsB.13R4.myc.his, and pIX.ccsL.13R4.myc.his. Lentivirus production and the 
transduction of 911 cells were performed as described previously.41 
After lysing the 911 cells with radioimmunoprecipitation assay lysis buffer, the 
protein IX fusion proteins were bound to nickel beads (IBA, Qiagen, Valencia, CA, 
USA), enabled by the presence of the his tag fused to the 13R4 ligand. Cell lysates (40 
mg) were incubated overnight at 4°C with 20 ml NI-NTA beads and wash buffer (50 mM 
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Na2H2PO4, 300 mM NaCl, 20 mM immidazole, pH 8.0) was added to a final volume 
of 1 ml. After one washing step with 1 ml wash buffer, the beads were re-suspended 
in 50 ml cathepsin digestion buffer (50 mM sodium acetate buffer, 2 mM EDTA, 2 mM 
dithiothreitol, pH 5.0).
Purified virus particles with the protein IX-ligand proteins incorporated in the 
capsid were prepared by using our previously described strategy involving the 
infection of protein IX-producing cell lines with a protein IX gene lacking HAdV-5.41 
Briefly, the virus was prepared by infecting the protein IX-ligand-expressing 911 cell 
lines with the HAdV-5 dl313 mutant, followed by harvesting, purification, and storage 
of the offspring virus. The sucrose-based storage buffer of the virus preparation was 
exchanged for cathepsin cleavage buffer by filter centrifugation (Amicon Ultra-4 
filter tubes; Millipore). Aliquots of 50 ml, containing 5 x 109 pp (as determined by the 
PicoGreen-DNA binding assay) were prepared for cathepsin cleavage analysis. 
Cathepsin cleavage was tested by incubation with cathepsin L (human, liver; Merck 
KGaA, Darmstadt, Germany) (28,6 ng/ml) or cathepsin B (human, liver, Merck KGaA) 
(250 ng/ml) for 1 h at 37°C. The samples were subjected to western blotting for the 
analysis of protein cleavage. Cathepsin L cleavage was inhibited with 10 mM specific 
inhibitor Z-FY(t-Bu)-DMK (Merck KGaA).
Slot-blot-based assay for analysis of HER2-ECD binding to intact 
virus particles
Binding of purified virions to the HER2/neu ECD (HER2-ECD) was assessed by a slot-
blot-based protocol as described by Uil et al.46 In brief, the virions were diluted in PBS 
and blotted onto a polyvinylidene difluoride membrane (Millipore) using a slot-blot 
apparatus. Blocking was carried out with 2.5% bovine serum albumin, 2.5% protifar 
(Nutricia, Zoetermeer, The Netherlands) in PBS for 2 h. Functional presentation of HER2/
neu on the virion surface was analyzed by overnight incubation with HER2-ECD (300 ng/
ml) (Fox Chase Cancer Centre, Philadelphia, PA, USA). The presence of a his tag fused to 
HER2-ECD allowed the subsequent immunological staining with HRP-conjugated goat 
polyclonal anti-his tag antibody (ab1269; Abcam). In parallel, staining was performed 
with mouse anti-fiber-knob (1D6.14 (1:250))47 and goat anti-hexon antibody (1:2000, 
ab19998; Abcam), followed by incubation with HRP-conjugated secondary antibodies.
Spheroid analysis
Semiconfluent 911 cells and SKOV-3 cells were trypsinized, counted, and re-suspended 
in medium containing 2.4 mg/ml methylcellulose (Sigma Aldrich Chemie, Zwijndrecht, 
The Netherlands) at the concentration of 104 cells/ml. Cell suspension (100 ml) was 
added into each well of a U-bottom 96-well-plate allowing the formation of one 
spheroid (consisting of 103 cells) per well. Viral infection was initiated at two days after 
plating by exchanging the medium with infectious medium (multiplicity of infection =1 
or 10 PFU per cell). After 2 h, the infectious medium was replaced with normal medium. 
To test the dependency of transduction on cathepsin L activity, the cysteine protease 
inhibitor E64-D (Sigma Aldrich) was added to the infectious medium at a concentration 
of 5 mg/ml. Pictures were taken at 5 days after infection (Olympus Camedia Digital 
Camera C-3030, installed on an Olympus CK40 microscope) and transduction was 
quantified by measuring the mean GFP intensity using ImageJ software.
100
CATHEPSIN-CLEAVAGE SITE TO IMPROVE TARGETING
5
Chicken CAM assay
Human tumors were grown on the chicken CAM as described in detail by Durupt et al.48 
Briefly, fertilized chicken eggs (Gallus domesticus) were placed in a humidified incubator 
at 37°C without CO2 to induce embryogenesis (EDD 0). On EDD 4, a small hole was 
made with a 19G needle in the air sack and a window was cut using a forceps under 
sterile conditions. The shell membrane was humidified with sterile PBS and carefully 
removed. This window was then sealed with a 3 cm Petri dish and eggs were placed 
back to the incubator. At day 7 (EDD 7), viability of the embryos and the vasculature 
of the CAM were visually inspected and the CAM was gently lacerated with a sterile 
cotton swab to create a blood spot to facilitate engraftment of tumor cells. Tumor cells 
were collected by trypsinization, washed with culture medium and pelleted by gentle 
centrifugation. After removing the medium, 107 SKOV-3 cells were resuspended in 50 μL 
matrigel (Growth-Factor Reduced Matrigel; Becton-Dickinson, Breda, The Netherlands) 
and inoculated on the CAM. Eggs were sealed, placed back into the incubator, and 
tumor growth was inspected on a daily basis. Purified virus (1 ml, 104 PFU) was injected at 
EDD 14 in the center of each tumor mass using a 30G syringe. At EDD 20, the eggs were 
placed on ice for at least 2 h to euthanize the chick embryos by hypothermia and tumors 
were isolated and collected in a Petri dish for immediate analyses of GFP expression 
with a Xenogen IVIS 100 biofluorescence imaging system (Xenogen, Alameda, CA, 
USA). For the analysis of cathepsin L expression, three tumors (not infected with virus) 
were transferred at EDD14 to a tube with 2 ml radioimmunoprecipitation assay lysis 
buffer, followed by sonication at 4°C. The cell debris was removed by centrifugation, 
and the supernatants were stored at -20°C for western analysis.
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AN ONCOLYTIC ADENOVIRUS REDIRECTED WITH A 
TUMOR-SPECIFIC T-CELL RECEPTOR
AbstrACt
To improve safety and specificity of oncolytic adenoviruses, we introduced T-cell 
receptors (TCR) specific for a unique class of truly tumor-specific antigens into the 
adenoviral fiber protein. The adenoviral fiber knob responsible for attachment to the 
coxsackie-adenoviral receptor (CAR) on target cells was replaced by a single-chain 
TCR (scTCR) molecule with specificity for the melanoma-associated cancer-testis 
antigen MAGE-A1, presented by HLA-A1, and an extrinsic trimerization motif in a 
replicating Ad5 vector (Ad5.R1-scTCR). The production of the recombinant virus was 
initiated in a novel producer cell line that expressed an antibody-based hexon-specific 
receptor (293T-AdR) in the cell membrane. This new production system allowed CAR-
independent and target antigen-independent propagation of Ad5.R1-scTCR. Infection 
with adenovirus bearing the scTCR-based fiber resulted in an efficient killing of target 
tumor cells. The infection was cell type specific because only HLA-A1+/MAGE-A1+ 
melanoma cells were killed, and thus, this retargeting strategy provides a versatile tool 




A prerequisite for the safe and effective application of therapies that are based on 
antigen-driven tumor eradication is the nature of the target antigen, which has to be 
truly tumor specific. Studying tumor cell eradication by CTL immunologists identified 
such tumor-specific antigens that were targets for CTL while leaving healthy tissue 
intact.1,2 Tumor cells may express a group of antigens termed “cancer-testis antigens” 
that are presented as antigenic peptides by MHC molecules to CTL.3 In fact, cancer-
testis antigens are immunogenic in cancer patients as they may elicit an anticancer 
response.4-6 They exhibit highly tissue-restricted expression and are considered 
promising target molecules for immunotherapies. To date, 44 cancer-testis antigen 
gene families have been identified and their expression has been studied in numerous 
cancer types.7 For example, bladder cancer, non-small lung cancer, and melanoma are 
high cancer-testis antigen gene expressers, with 55%, 51%, and 53% of the cancer-
testis antigen transcripts examined by reverse transcription-PCR detected in 20% or 
more of the specimens examined, respectively. With the exception of testis-restricted 
cancer-testis antigen transcripts, all remaining cancer-testis antigen transcripts were 
expressed in normal pancreas. Other antigens that were shown to elicit potent 
antitumor responses in cancer patients include differentiation antigens, such as the 
melanoma antigens gp100, Mart-1, and tyrosinase, or antigens that are overexpressed 
on tumor cells, such as p53, Her-2/neu, and WT-1.7,8 Both groups of antigens are 
also expressed in healthy tissue and may therefore elicit autoimmune disease when 
targeted.
Oncolytic adenoviral vectors hold great promise for cancer gene therapy because 
they potently eradicate tumor cells.9 Therefore, efforts are currently invested in 
improving replication-competent adenoviruses with respect to safety and specificity to 
fulfill criteria for clinical application.10 Among several strategies, genetic modification 
of the adenoviral fiber, which is responsible for cell binding, may result in a logical and 
preferable site to carry structures that specifically bind to target antigens of choice, 
thereby changing viral tropism.
Application of adenoviruses in a tumor cell-specific fashion is highly hampered 
because the natural cellular receptor of adenovirus is widely expressed on normal 
tissues and, on the other hand, often reported to be down-regulated or even absent 
on tumor cells.11 To address this issue, one needs strategies to alter the tropism of 
adenoviral vectors and retarget them against tumor-specific antigens.
Recent developments to change the natural tropism of adenoviral vectors into 
tumor-specific recognition are based on the genetic engineering of capsid proteins, 
such as pIX,12,13 hexon, and fiber.14-19
Genetic modification of the fiber protein has been achieved either through 
exchange of the Ad5 fiber knob with the Ad3 knob,20,21 knob mutagenesis,22,23 or 
incorporation of small ligands into the knob domain.21,24 However, it should be noted 
that an effective and safe retargeting strategy should include complete ablation of the 
natural tropism, which is not guaranteed by the above-mentioned modifications, and 
preferably include deletion of the fiber knob. This can be accomplished by replacing 
the fiber knob by new antigen-binding structures and an extrinsic trimerization 
signal.18,21 Antibody or T-cell receptor (TCR) fragments [e.g., single-chain Fv (scFv) 
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and single-chain TCR (scTCR)] mediate tumor cell recognition and are able to redirect 
T cells25 and viruses26 and, as such, are candidate structures to genetically redirect 
adenoviruses to tumor cells. Previous attempts to produce adenoviruses with fibers 
that include scFv have failed, most likely as a consequence of improper folding of the 
chimeric fiber in the cellular cytoplasm.18
Here, we show that an oncolytic adenovirus bearing chimeric fibers, comprising an 
extrinsic trimerization signal and scTCR with HLA-A1–restricted MAGE-A1 specificity, 
can be produced. To this end, we generated a novel producer cell line expressing an 
anti-hexon receptor, which was needed to initiate production of virus that specifically 
infects HLA-A1/MAGE-A1+ melanoma cells but not MAGE-A1− or HLA-A1− target cells. 
The presented strategy to produce genetically retargeted oncolytic adenoviruses 
holds great promise to develop clinically applicable anticancer agents.
results
Construction of a replication-competent adenovirus with HLA-A1/
MAGE-A1 specificity
A knobless fiber containing fiber tail plus NH2-terminal first shaft repeat (R1, 61 amino 
acids), an extrinsic trimerization motif (NRP, 36 amino acids) from lung surfactant 
protein D, a linker derived from Staphylococcus protein A (13 amino acids), and scTCR 
VαVβCβ (377 amino acids), specific for the melanoma antigen MAGE-A1, presented by 
HLA-A1 (which replaced the natural fiber knob), was constructed (Fig. 1) and introduced 
into replication-competent adenovirus serotype 5 essentially as described.17,18 To 
construct the scTCR, TCR α and β chains were cloned from an HLA-A1–restricted, 
MAGE-A1–specific CTL clone, MZ2-82/30, and reformatted into the scTCR VαVβCβ 
as described.27 Specific binding of the scTCR was verified by expression on primary 
human T lymphocytes, which showed scTCR-directed immune functions such as 
specific tumor cell kill and cytokine production. The apparent molecular weight of the 
R1-scTCR fiber (54 kDa) is similar to that of the WT Ad5 fiber (59 kDa).
Generation of 293T-AdR cells to propagate fiber-modified adeno-
viruses
As a consequence of ablating the natural tropism, we expected that recombinant 
Ad5-scTCR virus would require the presence of its target antigen, HLA-A1/MAGE-
A1, on the surface of the producer cell line for the primary attachment and entry. 
Therefore, we generated 293T cells expressing the HLA-A1/MAGE-A1 antigen. 293T 
cells were infected with retroviral vectors pBullet HLA-A1 and pBullet MAGE-A1 (full-
length cDNA and minigene). Next to these antigen+ 293T cells, we also used MZ2-mel 
3.0 melanoma cells, which naturally present MAGE-A1 in the context of HLA-A1. 
Neither the antigen-transduced 293T cells nor MZ2-mel 3.0 cells were able to initiate 
production of the recombinant virus starting with transfection of the adenoviral DNA 
(data not shown). To support initiation of viral production and propagation of fiber-
modified adenoviruses that depend neither on CAR nor on MAGE-A1/HLA-A1 antigen 
(or any ligands of interest for that matter), we generated a novel producer cell line 
based on the introduction of an adenovirus-binding antibody into 293T cells.
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To this end, we constructed two membrane-anchored anti-adenovirus receptors, 
AdR and AdR-cMyc/ζ, from hybridoma cells producing a hexon-specific antibody (Fig. 
2a) that cross-reacts with many adenovirus subtypes and introduced it via retroviral 
transduction into 293T cells. Due to a lack of antibodies binding to the scFv directly, 
demonstration of cell surface expression of the anti-adenovirus receptors on 293T 
cells was only possible for AdR-cMyc/ζ using anti-c-Myc mAb (Fig. 2b).
The ability of AdR and AdR-cMyc/ζ to serve as universal receptors for Ad5 was 
analyzed in 293T cells. 293T cells with AdR, termed 293T-AdR, 293T cells with AdR-
cMyc/ζ, termed 293T-AdR-cMyc/ζ, or parental 293T cells were transfected with a 
fiberless Ad5 vector encoding the EGFP gene. We observed a severely impaired 
propagation of fiberless adenovirus in 293T cells in line with previous reports and 
most likely due to a lack of CAR-fiber knob interactions.21,28 We hypothesized that the 
presence of the AdR receptor would at least in part restore the ability of 293T cells to 
produce fiber-deleted viruses. As shown in Fig. 2c, on day 1 following transfection, 
the expression of EGFP was comparable in both 293T and 293T-AdR cells. The ratio of 
EGFP in normal 293T cells did not improve on day 2 or 3. However, in 293T-AdR cells, 
we observed a robust spread of the reporter gene together with comet-like formation 
that was most significant on day 3 after transfection. Production of virus particles in 
culture supernatant was confirmed by an adenovirus-specific ELISA (data not shown). 
When 293T cells were stably expressing the AdR-cMyc/ζ receptor, we also observed 
an increase in reporter gene expression and release of viral particles. However, the 
ability of 293T-AdR-cMyc/ζ to induce adenovirus production was significantly less than 
that of 293T-AdR cells (data not shown).
We then introduced the Ad5.R1-scTCR construct into 293T-AdR cells and showed 
that, 3 days following transfection, virus was produced at a titer of 6 × 107 particles/
mL (= physical particles, determined by ELISA), starting from 3 × 106 293T-AdR cells. 
Figure 1. Diagram of WT Ad5 fiber and R1-scTCR fiber. Distinct domains of the Ad5 WT fiber and 
R1-scTCR fiber as well as the amino acid (a.a.) composition of the distinct domains. Vα, variable domain 
of TCRα chain; Vβ, variable domain of TCRβ chain; Cβ, constant domain of TCRβ chain.
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Figure 2. (a) Diagram of expression vectors encoding the “adenoreceptor.” SS, Igκ signal sequence; 
γ, intracellular domain of FcεR1-γ chain. (b) Surface expression of AdR-cMyc/ζ on 293T cells. 293T 
cells were retrovirally transduced with the adenoreceptor fused to a c-Myc tag (AdR-cMyc/ζ). Cells 
were stained with FITC-conjugated c-Myc-specific mAb (9E10) and samples were measured by flow 
cytometry. Histograms represent nontransduced 293T cells (thin line) and receptor-positive 293T cells 
(thick line). (c) Infection of 293T cells by fiberless adenovirus requires the expression of AdR on the cell 
surface. 293T and 293T-AdR cells were seeded and transfected with fiberless pAdeasy EGFP construct. 
Kinetics of green fluorescent protein expression was monitored by fluorescence microscopy at days 1, 
2, and 3 after transfection. Representative images (×10 magnification) from one of three experiments.
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Ad5.R1-scTCR virus is produced, specifically binds to HLA-A1/
MAGE-A1 complexes, and replicates in HLA-A1+/MAGE-A1+ tumor 
cells
To show production, specific binding to peptide/MHC complexes, and fiber 
incorporation of adenoviral particles that incorporate the chimeric R1-scTCR fiber, 
we did the following experiments: (a) electron microscopy, to show presence of 
viral particles in MZ2-mel 3.0 cells (Fig. 3a); (b) flow cytometry analysis of HLA-A1/
MAGE-A1–specific binding of Ad5-R1-scTCR (Fig. 3b); (c) Western blot analysis, to 
show incorporation of the R1-scTCR fiber (Fig. 3c); and (d) ELISA, to show production 
of Ad5.R1-scTCR in 293T AdR and MZ2-mel 3.0 cells.
To show production of Ad5.R1-scTCR particles, MZ-2-mel 3.0 cells were infected 
with viral supernatant and analyzed by electron microscopy. Fig. 3a shows the presence 
of viral particles in the nucleus of MZ2-mel 3.0 cells 72 h after infection.
To show specific binding to HLA-A1/MAGE-A1, supernatant from 293T-AdR cells 
producing Ad5-R1-scTCR was incubated with magnetic beads that were loaded with 
HLA-A1/MAGE-A1 complexes or HLA-A1 complexes that present an irrelevant peptide 
derived from influenza virus A nucleoprotein. 
As shown, Ad5.R1-scTCR virus only bound to HLA-A1/MAGE-A1 complexes and 
not to HLA-A1 complexes presenting an irrelevant influenza virus peptide (Fig. 3b).
Ad5.R1-scTCR virus bound to HLA-A1/MAGE-A1–coated magnetic beads was 
then analyzed by Western blotting using fiber tail-specific mAb 4D2. As shown in Fig. 
3c, chimeric scTCR fibers were incorporated into adenoviral particles.
To determine whether Ad5.R1-scTCR virus is able to infect HLA-A1+/MAGE-A1+ 
tumor cells, we incubated MZ2-mel 3.0 melanoma cells with supernatant obtained 
from 293T AdR cells transfected with either Ad5.WT or Ad5.R1-scTCR DNA. MZ2-mel 
3.0 cells lack CAR expression (Table 1), making them refractory to infection by WT 
virus. As shown in Fig. 3d, Ad5.R1-scTCR virus produced by 293T AdR cells infected 
MZ2-mel 3.0 cells and was able to replicate in these cells, shown by the presence of 
viral particles in the tissue culture supernatant 3 days after infection. In contrast, WT 
virus at comparable virus particle-to-cell ratio did not result in adenoviral infection. 
Cellular localization of Ad5.R1-scTCR epitopes during replication
It has been suggested that only those recombinant fibers that assemble correctly in 
the nucleus may be incorporated into an infectious adenoviral particle.24 To analyze 
intracellular localization of adenoviral proteins, we infected MZ2-mel 3.0 cells with 
Ad5.R1-scTCR and did intracellular immunofluorescent staining with mAbs specific 
for hexon, fiber tail, and scTCR. Hexon and fiber tail molecules showed a comparable 
cellular distribution, localized almost exclusively to the nucleus 24 h after infection 
(Fig. 4, top). Interestingly, at that time point, hexon molecules were detected in the 
cytoplasm to some extent, whereas fiber molecules were not. In control experiments, 
we observed that adenoviruses displaying WT fiber showed similar cellular localization 
of hexon and fiber tail (data not shown). In contrast, staining for the R1-scTCR fiber 
with the anti-TCR-specific antibody did not result in any detectable fluorescent signal 
at 24 h after infection (Fig. 4, top). 





Figure 3. Characterization of Ad5.R1-scTCR particles. (a) Electron microscopic image of Ad5.R1-scTCR 
in MZ2-mel 3.0 cells. Presence of Ad5.R1-scTCR particles in the nucleus of MZ2-mel 3.0 cells was 
shown by electron microscopy 72 h after incubation of MZ2-mel 3.0 cells with viral supernatant. Right, 
a five times enlargement of a region of the left. (b) Ad5.R1-scTCR particles from 293T-AdR supernatant 
specifically bind to HLA-A1/MAGE-A1 complexes only. Tissue culture supernatants derived from 293T-
AdR cells producing Ad5.R1-scTCR particles were incubated with HLA-A1/MAGE-A1 or irrelevant 
HLA-A1/Flu complex-coated magnetic beads. Ad5.R1-scTCR particles were detected by flow cytometric 
analysis using anti-hexonFITC mAb. (c) Ad5.R1-scTCR viral particles incorporate the R1-scTCR fiber. 
Ad5.R1-scTCR virus bound to HLA-A1/MAGE-A1 complex-coated beads and cesium chloride-purified 
WT Ad5 were loaded on 7% SDS-PAGE, transferred to nitrocellulose membrane, and detected with 
anti-fiber tail antibody 4D2. Lane 1, Ad5.WT; lane 2, Ad5.R1-scTCR. (d) Adenovirus expressing the 
scTCR fiber infects and replicates in HLA-A1/MAGE-A1+ melanoma cells. MZ2-mel 3.0 cells were 
incubated with viral supernatant obtained from 293T AdR cells transfected with either Ad5.R1-scTCR or 
Ad5.WT DNA. Adenoviral titer in tissue culture medium was detected by ELISA after (a) transfection of 
the producer cell 293T-AdR with Ad5.WT (black columns) or Ad5.R1-scTCR (gray columns) and (b) 3 d 
after infection of MZ2-mel 3.0 cells by crude lysates from a.
Figure 4. Localization of adenoviral proteins during replication. MZ2-mel 3.0 cells were infected with 
Ad5.R1-scTCR at a virus particle-to-cell ratio of 50, and cell-associated adenoviral proteins were stained 
with mAbs against hexon (α-hexon), fiber tail (4D2.5), and scTCR Vα domain (Vα12.1) at 24 and 72 h 
after infection. Images were collected with a fluorescent microscope.
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Localization of both hexon and fiber proteins changed at 72 h after infection from a 
prominent nuclear localization to accumulation at the cell periphery, most likely at the 
plasma membrane. At this stage of replication, presumably on virus release, R1-scTCR 
could be detected with anti-TCR antibody and also located to the plasma membrane 
or to its proximity, indicating an identical cellular compartmentalization of hexon, fiber 
tail, and scTCR ( Fig. 4, bottom). 
Infection by Ad5.R1-scTCR is epitope specific
Specificity of infection of Ad5.R1-scTCR was analyzed by infecting the melanoma 
cells: MZ2-mel 3.0 (HLA-A1+/MAGE-A1+) and MEL.2A (HLA-A1+/MAGE-A1−). Also 
included were 293T and 293T-AdR cells. Target cells were infected at different virus 
particle-to-cell ratios and monitoring the production of hexon protein at 2 days after 
infection. In this assay, cells expressing the hexon molecule represent infected cells 
and constitute an indirect readout for viral titers as an alternative to plaque assay. As 
shown in Fig. 5, Ad5.R1-scTCR virus reached maximum infectivity at ∼20 virus particle-
to-cell ratio when infecting antigen+ MZ2-mel 3.0 cells and 293T-AdR, approximately 
corresponding to a MOI of 4. When using antigen− MZ2-mel 2.2 cells, Ad5.R1-scTCR 
infectivity remained low even at high virus particle-to-cell ratio and showed a similar 
titration curve when using 293T cells.
Specificity studies were expanded by the use of a larger panel of target cells, 
including the following melanoma cell lines: MZ2-mel 3.0; 9303-A; 518-A2; MZ2-mel 
2.2, a MAGE-A1 antigen lost mutant obtained from MZ2-mel 3.0; MEL.2A; and FM-3. 
We also included Nemeth renal cell carcinoma cell lines and the 293T cells. Five 
days after infection, surviving tumor cells were stained with methylene blue. HLA-A1/
MAGE-A1 expression as well as infectivity data of all target cells are summarized in 
Table 1. As shown in Table 1 only HLA-A1+/MAGE-A1+ melanoma cells were infected.
Figure 5. Ad5.R1-scTCR specifically infects melanoma cells expressing the HLA-A1/MAGE-A1 epitope 
at a low virus particle-to-cell ratio. Cells (5 × 105) of MZ2-mel 3.0 (solid line with black box), MEL.2A 
(solid thin line), 293T (solid line with triangle), and 293T-AdR (dashed line) were infected at various 
virus particle-to-cell ratios of Ad5.R1-scTCR. Cells were harvested 2 d after infection and stained with 





Our aim of this study was to provide oncolytic adenoviral vectors with a truly tumor 
cell specificity to improve safety and efficacy, which are major criteria for the clinical 
use of replicating vectors. TCR recognizing MHC-restricted cancer-testis antigens, 
such as MAGE-A1, which are distributed in a highly tumor tissue-specific manner, may 
constitute promising molecules to retarget adenoviruses. This study shows for the first 
time that even complex molecules such as TCR can genetically replace the fiber knob 
and be expressed on the adenoviral fiber, thereby ablating its natural tropism. The Ad5 
fiber knob was replaced by an extrinsic trimerization motif and an HLA-A1/MAGE-A1–
specific scTCR. Critical to the experimental use of this recombinant adenovirus was the 
generation of a novel producer cell line, 293T-AdR, which was successfully used to initiate 
production, starting by transfection with adenoviral DNA, and supported propagation 
of adenovirus, which depended neither on CAR nor on HLA-A1/MAGE-A1. Our failure 
to use 293T expressing the HLA-A1 and MAGE-A1 cDNA for the initiation of adenovirus 
production was most likely attributed to unstable expression of the HLA-A1 gene. Within 
3 days after infection with retrovirus encoding the HLA-A1 gene, HLA-A1 molecules 
disappeared from the cell surface, resulting in lack of MAGE-A1 antigen presentation to 
the chimeric fibers (data not shown). There may be more reasons why we were unable 
to initiate adenovirus production in MZ2-mel 3.0 cells. In general, the production of 
adenovirus after DNA transfection is inefficient because plasmid DNA does not contain 
the protein binding to the viral inverted terminal repeats and therefore requires several 
rounds of amplification.29 When DNA transfection efficiencies become limiting, as might 
be the case when using MZ2-mel 3.0 cells, low numbers of virus-producing cells may 
result in undetectable levels of virus even after serial amplification. In addition, MZ2-mel 
3.0 cells may produce lower numbers of viral particles than, for example, 293 cells.
Importantly, the retargeted viruses specifically bound to relevant HLA-A1/MAGE-A1 
complexes only (Fig. 3b), specifically infected target cells expressing HLA-A1–restricted 
MAGE-A1 antigen (Fig. 5; Table 1), and killed these melanoma cells.
Table 1. Antigen expression and infection of melanoma and renal cell carcinoma cell lines 
by Ad5.R1-scTCR.
Target cell HLA-A1 MAGE-A1 CAR Infection by Ad5.R1-scTCR*
MZ2-mel 3.0 + + - +
9303-A + + + +
518-A1 + + + +
MZ2-mel 2.2 + - - -
MEL2A + - + -
FM-3 - - + -
Nemeth - - + -
293T - - + -
* Represents infection of target cells analyzed by methylene blue staining. + or  -  is based on 
qualitative comparison with noninfected control cells.
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The initiation of production when starting from recombinant Ad5 DNA seemed 
to be a critical step during propagation. As a consequence of ablation of native Ad5 
tropism, the recombinant Ad5.R1-scTCR is not able to use the natural CAR-mediated 
cellular entry pathway during propagation in conventional packaging cell lines, such 
as 293 or 911. Although there are reports on possible solutions to overcome the 
limitations of fiber-modified adenoviral vector production,28,30 there is no precedent 
on virus retargeting via complex molecules, such as TCR or Igs, and an alternative 
strategy had to be developed. A major factor that can hamper genetic retargeting 
of adenoviral vectors, especially when including complex molecules into the viral 
genome, is the proper folding of these new molecules in the nucleus. According to 
Pecorari et al.,31 the formation of intrachain disulfide bridges, which are crucial for the 
correct folding and stability of IgG or TCR, is suboptimal in the reducing environment 
of the cytoplasm and nucleus. One could address this issue by using small molecules, 
such as affibodies, which possess the binding properties of an antibody but do not 
require intrachain disulfide bounds.16 Magnusson et al.18 reported that, although the 
scTCR fiber was able to form homotrimers and bound its ligand, the recombinant 
fiber protein misfolded, thereby possibly explaining the unsuccessful propagation 
of Ad5.R1-scTCR in MZ2-mel 3.0 melanoma cells. However, our studies on scTCR 
fiber expression suggest that at the proximity to the cell membrane (Fig. 4, bottom) 
proper folding of the scTCR fiber occurs, resulting in exposure of a fully functional 
scTCR fiber on the virus particle. We assume that at this stage of virus assembly 
restricting intracellular conditions no longer limits the formation of sulfide bridges. 
Furthermore, we now also succeeded in the initiation of production of two other 
recombinant viruses, one with a scTCR fiber and a virus equipped with an affibody 
fiber (data not shown), which shows the universal applicability of this production 
system.
These findings open new and safer strategies for cell-specific retargeting of 
oncolytic adenoviruses, providing a versatile tool for future clinical application.
MAterIAls And MethOds
Cells and antibodies
Target cell lines used in this study are the melanoma cell line MZ2-mel 3.0, MZ2-mel 
2.2, and MEL.2A (kindly provided by T. Boon and P. Coulie, Ludwig Institute for Cancer 
Research, Brussels, Belgium). The melanoma cell lines 9303-A, 518-A1, and FM-3; the 
renal cell carcinoma cell line Nemeth (kindly provided by Dr. E. Oosterwijk, University 
Medical Center Nijmegen, Nijmegen, the Netherlands); and the human embryonic 
kidney cell line 293T and its derivative 293T-AdR (further described in the Results 
section) were grown in DMEM (Life Technologies) supplemented with 10% fetal bovine 
serum (FBS; Hyclone). HLA-A1/MAGE-A1 and coxsackie-adenovirus receptor (CAR) 
expression status of the target cell lines is further described in Table 1 (see Results). 
Antibodies used in this study were against fiber tail (4D2.5; NeoMarkers), hexon 
(clone BOD604, FITC conjugated; Biodesign), rabbit polyclonal anti-Ad5 (Abcam), 
TCR Vα12.1 (FITC or nonconjugated; Endogen), CAR (USBiological), and c-Myc (9E10, 
FITC conjugated; Convance). FITC-conjugated rabbit anti-mouse IgG Fab fragment 
CHAPTER 6
118
(Jackson ImmunoResearch) or horseradish peroxidase–conjugated goat anti-rabbit 
IgG (Becton Dickinson Biosciences) was used as secondary antibodies. 
Infectivity assay with fiberless virus
293T and 293T-AdR cells were transfected with a fiberless pAdeasy-EGFP construct 
(a kind gift of Wim Jongmans, University Medical Center, Nijmegen, the Netherlands) 
using the CellPhect Transfection kit (Amersham Biosciences). The expression of 
the reporter gene EGFP was monitored using a Leica DMIL inverted fluorescence 
microscope (Leica Microsystems). At time points indicated, culture supernatant was 
collected and virus release (particle count) was analyzed using the IDEIA Adenovirus 
ELISA kit (DakoCytomation). 
DNA constructs
Ad5.R1-scTCR adenoviral DNA was generated as described.18 Briefly, recombinant 
fiber genes were constructed using methods based on ligation, PCR, and splicing by 
overlap extension. The gene encoding the Ad5 wild-type (WT) fiber was obtained from 
pAB26 (Microbix, Inc.) by PCR introducing an upstream BamHI and downstream XhoI 
site, respectively. The knob domain in recombinant fibers was deleted and replaced 
by a 36-amino acid extrinsic trimerization motif derived from the neck region peptide 
(NRP) of human lung surfactant protein D.18 The NRP sequence followed by a linker 
sequence from Staphylococcus protein A was ligated to the COOH-terminal end of 
fiber shaft with one repeat and named R1, and the scTCR VαVβCβ was added to 
the COOH-terminal end of the Staph-A linker. The resulting R1-scTCR fiber was then 
cloned into a fiberless Ad5 genome as described.18 
Retroviral vectors encoding the HLA-A1 gene, MAGE-A1 complete cDNA, or 
MAGE-A1 minigene (encoding the 9-amino acid antigenic epitope EADPTGHSY) were 
generated as follows: HLA-A1 and MAGE-A1 cDNA cloned in pCDNA-3 (a kind gift 
from Pierre van der Bruggen, Ludwig Institute for Cancer Research, Brussels, Belgium) 
were reamplified to introduce NcoI and XhoI sites and cloned into the retroviral vector 
pBullet. The MAGE-A1 minigene was introduced into a version of pBullet that contains 
a signal sequence from the G250 antibody heavy chain32 by ligation of a small linker 
encoding the MAGE-A1 minigene next to the signal sequence. 
To construct the membrane-bound adenovirus-specific receptor (AdR), first an 
scFv was generated from the hexon-specific hybridoma 2Hx-2 (American Type Culture 
Collection). In short, RNA isolated from the 2Hx-2 hybridoma was reverse transcribed 
using SuperScript II (Invitrogen) and amplified using Ig variable heavy and variable 
light chain primers (Amersham scFv module, Amersham Biotech). The variable heavy 
and variable light chain DNA fragments were then reamplified to fuse them together 
by introducing a linker sequence between the two fragments and to introduce SfiI 
and NotI restriction sites. The resulting scFv was then introduced into the retroviral 
expression cassette pBullet-CD4γ, and pBullet-cMyc/ζ, which allows for membrane 
expression of the scFv.32,33 
Generation of the recombinant virus
293T-AdR cells were transfected with PacI-digested recombinant adenovirus plasmid 
(Ad5.R1-scTCR), and after 3 days, culture supernatant was harvested and used 
ONCOLYTIC ADENOVIRUS REDIRECTED WITH A TCR
6
119
immediately for infection or further analysis. Adenovirus particle count (semiquantitative) 
was determined by IDEIA Adenovirus ELISA kit. Infectious adenovirus particle number 
[multiplicity of infection (MOI)] was determined by the Adeno-X Rapid titer kit (BD 
Clontech) on 293T-AdR cells. 
Analysis of adenoviral particles
Electron microscopy
For electron microscopy, MZ2-mel 3.0 cells were fixed in 1.5% glutaraldehyde in 0.1 
mol/L cacodylate buffer for 1 h at room temperature, postfixed in 1% OsO4 in the 
same buffer for 1 h at 4°C, dehydrated in a graded ethanol series, and embedded 
in epon. Ultrathin sections were poststained with uranyl acetate and lead citrate and 
viewed with a Tecnai 12 electron microscope at 80 kV (FEI). 
Flow cytometry
Supernatant derived from Ad5.R1-scTCR–producing 293T-AdR cells (12.5 mL 
containing 108 particles/mL) was incubated overnight with magnetic beads (Dynal 
Biotech ASA) that were loaded with in vitro-generated HLA-A1 complexes (1 μg total) 
presenting the MAGE-A1 nonapeptide (EADPTGHSY) or an irrelevant peptide derived 
from influenza virus A nucleoprotein (CTELKLSDY). After three wash steps with PBS, 
the beads were incubated with a saturating concentration of anti-hexonFITC monoclonal 
antibody (mAb) and incubated for 30 min at 4°C. Specific binding of Ad5.R1-scTCR 
virus to the beads was then analyzed by flow cytometry on a Cytomics FC-500 flow 
cytometer (Beckman Coulter). 
Western blotting
Ad5.R1-scTCR virus bound to the HLA-A1/MAGE-A1–coated magnetic beads was 
eluted from the beads by addition of high-affinity Fab fragments that specifically bind 
to HLA-A1/MAGE-A1 (15 min at room temperature, 39 μg total in 1 mL PBS).34 Excess 
high-affinity Fab fragments were then removed by addition of Ni-NTA agarose (Qiagen) 
that binds to the 6× His tag present in the Fab fragment. Purified Ad5.R1-scTCR virus 
was then separated on SDS-PAGE, immobilized on a nitrocellulose membrane, and 
detected with fiber tail–specific mAb (4D2). 
Detection of adenoviral infection
Flow cytometry of infected cells
One million cells were infected at indicated virus particle-to-cell ratios using virus 
supernatant diluted in DMEM supplemented with 10% FBS for 2 h at 37°C/5% CO2. 
After infection, cells were seeded in six-well plates. Cells were harvested 2 days after 
infection by scraping, after which they were spinned and permeabilized in FACSPerm2 
solution (Becton Dickinson). Following a PBS wash, cells were incubated in the 
presence of FITC-hexon mAb (1:10 dilution) for 30 min at room temperature in the 
dark, washed again, and analyzed on a Cytomics FC-500 flow cytometer. 
Methylene blue staining of infected cells
Half a million cells were infected using virus supernatant as described above. After 
infection, cells were seeded in gelatin-coated (0.1% gelatin in PBS) six-well plates 
in the presence of 2 mL 1.25% agar in DMEM culture medium. Cells were stained 
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with methylene blue 5 days (after infection) and photographed (LEICA DMIL inverted 
microscope). 
Expression and localization of adenoviral proteins
A quarter of a million cells were infected using virus supernatant (at virus particle-to-
cell ratio of 50) as described above. After infection, cells were seeded in 24-well plates 
and cultured for the indicated times. Cells were carefully washed with PBS and fixed 
with a 1:1 solution of ice-cold methanol and acetone for 10 min on ice. After repeated 
washing steps with PBS, cells were blocked using 1% bovine serum albumin in PBS 
for 30 min at room temperature. Cells were then shortly air dried and stained with 
primary and secondary antibodies (diluted in blocking buffer). Kinetics of expression 
and cellular localization of fluorescently labeled adenoviral proteins were monitored 
(LEICA DMIL inverted fluorescence microscope).
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ENHANCED TRANSDUCTION OF CAR-NEGATIVE 
CELLS BY PROTEIN IX-GENE DELETED  
ADENOVIRUS 5 VECTORS
AbstrACt
In human adenoviruses (HAdV), 240 copies of the 14.3-kDa minor capsid protein IX 
stabilize the capsid. Three N-terminal domains of protein IX form triskelions between 
hexon capsomers. The C-terminal domains of four protein IX monomers associate 
near the facet periphery. The precise biological role of protein IX remains enigmatic. 
Here we show that deletion of the protein IX gene from a HAdV-5 vector enhanced the 
reporter gene delivery 5 to 25-fold, specifically to Coxsackie and Adenovirus Receptor 
(CAR)-negative cell lines. Deletion of the protein IX gene also resulted in enhanced 
activation of peripheral blood mononuclear cells. The mechanism for the enhanced 
transduction is obscure. No differences in fiber loading, integrin-dependency of 
transduction, or factor-X binding could be established between protein IX-containing 
and protein IX-deficient particles. Our data suggest that protein IX can affect the cell 





Protein IX is a non-essential protein in the capsid of human adenoviruses (HAdV). The 
protein has a size of 14.3 kDa, is present at 240 copies per virion, and has three highly 
conserved regions present in the amino (N) terminus, the central part (alanine-rich), 
and the carboxy (C) terminus (leucine-rich). The location and function of protein IX 
in the virus capsid has been the subject of investigation and debate for many years.1 
Recent work by different groups has brought consensus on its location and topology 
in the capsid.2,3 The N-terminus of the protein is located in between hexon cavities of 
the groups of nine (GON) hexons, presumably stabilizing the GONs. The C-terminus of 
the protein forms an alpha helix and is exposed on the capsid surface in close contact 
with hexon hypervariable region 4 (HVR4).3 C-terminal domains of three protein IX 
molecules associate in a parallel orientation, whereas a fourth domain binds in an 
antiparallel orientation.2 The role of protein IX in the capsid remains enigmatic. In vitro 
analysis revealed the N-terminus of protein IX to confer a thermostable phenotype 
on HAdV-5 capsids.4 Propagation of protein IX gene deleted HAdV-5 in cell culture 
yields wild-type like virus titers, demonstrating that protein IX is dispensable for virus 
replication in vitro.
Protein IX has potential as an anchor for the attachment of different types of 
polypeptides to the viral capsid. Targeting of HAdV-5 to tumor cells has been 
achieved by genetically fusing protein IX to a single-chain T cell receptor directed 
against MHC class I in complex with MAGE-A1 peptides.5 Similarly, integrin-binding 
arginine-glycine-aspartate (RGD) peptides, as well as single-chain antibody fragments 
have been incorporated in this way.6,7 Alternatively, targeting ligands can be coupled 
to protein IX via the genetic inclusion of cysteine residues and subsequent chemical 
coupling of ligands to the reactive thiol groups.8 Multiple polypeptides can be 
incorporated simultaneously.9 A triple-mosaic HAdV-5 vector was developed with a 
poly-lysine motif, the herpes simplex virus type 1 (HSV-1) thymidine kinase, and the 
monomeric red fluorescent protein fused with protein IX, thereby combining targeting, 
therapeutic, and imaging modalities. Recently, it was demonstrated that HAdV-5 
vaccine vectors with pathogen-specific antigens fused to pIX can stimulate robust 
protective immune responses in animals, suggesting a new route for the development 
of improved HAdV-5 based recombinant vaccines.10,11 
Here we report on the enhanced delivery of transgenes into CAR-negative cell lines 
as a result of protein IX-gene deletion from a HAdV-5-based vector. Furthermore, the 
protein IX-deficient particles demonstrated enhanced activation of peripheral blood 
mononuclear cells (PBMCs), and had a different in vivo distribution after intravenous 
delivery in a mouse model. The exact molecular mechanism behind this ‘DpIX effect’ 
remains to be delineated. Our data suggest that protein IX can affect the cell tropism 
of HAdV-5, and may function to dampen the innate immune responses against HAdV 
particles.




Enhanced transgene expression in CAR-negative cells with Ad5D-
E1DpIX
To study the role of protein IX in the HAdV-5 transduction of cells, we compared the 
vectors Ad5DE1+pIX and Ad5DE1DpIX for luciferase transgene expression in a panel of 
cell lines (Fig. 1a). Cell lines with varying expression levels of CAR were included (Fig. 
1b). Whereas similar expression levels were obtained with both vectors in the CAR-
positive cell lines HeLa, A549, and MEL2A, the vector Ad5DE1DpIX yielded higher 
levels than Ad5DE1+pIX in the CAR-negative cell lines MZ2-MEL3.0 and VH10. Since 
these results suggested a specific role of the protein IX lacking vector in mediating 
relatively higher transduction in the absence of CAR, Ad5DE1+pIX and Ad5DE1DpIX 
were analyzed for reporter gene expression in MZ2-MEL3.0 cells versus MZ2-MEL3.0/
CAR cells (Fig. 2B). MZ2-MEL3.0/CAR cells stably expressed CAR via transduction 
with a recombinant lentivirus, which was confirmed by flow cytometry and immune-
fluorescence staining (Fig. 2A). In MZ2-MEL3.0 cells the reporter gene expression 
upon infection with Ad5DE1DpIX was found to be ten-fold increased compared to 
infection with Ad5DE1+pIX, while in MZ2-MEL3.0/CAR cells the difference was a mere 
two-fold (Fig. 2b). The enhanced transgene expression for Ad5DE1DpIX on the CAR-
negative cell line MZ2-MEL3.0 appeared to be not affected by the establishment of 
protein IX expression in the cells (by using the recombinant lentivirus LV-CMV-pIX-
IRES-NPTII12) prior to the transduction) (result not shown).
As a next step, the involvement of the C-terminal region of protein IX in the 
observed phenomenon was investigated. This domain, which is rich in leucine amino 
acids and is exposed on the HAdV-5 capsid as an alpha-helical structure,2,3 is highly 
conserved in human adenoviruses. The biological function of this conserved domain 
of protein IX is unknown. We analyzed the vector Ad5DE1pIXDLEU, which lacks a major 
part of the C-terminal region of protein IX (amino acids 100 to 114) for reporter gene 
expression in MZ2-MEL3.0 and MZ2-MEL3.0/CAR. Ad5DE1pIXDLEU demonstrated 
enhanced transduction of the CAR-negative cell line, very similar to the Ad5DE1DpIX 
vector (Fig. 2c). 
To assess the appearance of the vector particles and to check for the absence 
of microaggregation, electron microscopy was performed on Ad5DE1+pIX and 
Ad5DE1DpIX vector batches. This showed identically shaped virus particles (Fig. 3a). 
No signs of microaggregation were observed. The Ad5DE1DpIX stock appeared to 
contain more small particulate matter, possibly virus debris. As previously described, 
pIX-deficient HAdV-5 particles have an enhanced tendency to partly dissociate into 
fiber- and penton base- lacking particles.13 However, our vectors had similar capsid 
incorporation levels of fiber and hexon proteins, as evident from immunoblot analyses 
(Fig. 3b), thus ruling out differences in particle dissociation for the vector preparations.
Transduction with Ad5DE1DpIX is integrin-dependent 
Wild-type HAdV-5 enters cells via high affinity binding of the fiber knob domain to 
CAR.14 Subsequently low affinity interaction of the penton base with cellular integrins 
αVβ3 and αVβ5 promotes virus internalization in clathrin coated pits.
15,16 To answer 
the question if Ad5DE1DpIX still uses integrins for cellular uptake, we analyzed 
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Ad5DE1+pIX and Ad5DE1DpIX for transgene expression (GFP) in the presence or 
absence of bivalent cations, which are necessary for integrin-mediated uptake of wild-
type HAdV-5 into cells16 (Fig. 4a). This experiment again displayed a stronger reporter 
gene expression of Ad5DE1DpIX in MZ2-MEL3.0 cells compared to Ad5DE1+pIX. For 
both vectors the transduction appeared to be totally dependent on the presence of 
bivalent cations, with a complete reduction to background GFP levels for the cation-
negative incubation. This is consistent with integrin-mediated uptake for both vectors. 
More specifically, the integrin-dependency of Ad5DE1DpIX was confirmed by a small 
but significant (approximately two-fold) decrease in transduction after incubation of 
MZ2-MEL3.0 cells with antibodies directed against αVβ3 and αVβ5 integrins (Fig. 4b). 
Similar antibody-blocking (1.5-fold reduced transduction for anti-αVβ3 and anti-αVβ5) 
was observed for Ad5DE1+pIX. Incubating the cells with higher concentrations of 
antibodies did not result in further reductions in transduction levels (data not shown). 
Anti-integrin mediated blocking of transduction was also observed on A549 cells (Fig. 
4b). From these data we conclude that the vector Ad5DE1DpIX still uses integrins for 
cell internalization in CAR-deficient cells. 
Reduced virus spread of the replication competent virus Ad5DpIX
Our data from the comparative transduction analysis suggest an alternative interaction 
of HAdV-5 particles lacking protein IX with the cell surface. In parallel to cell tropism 
extending capsid modifications described for other viruses17, it is likely that protein 
IX deletion from a replication competent HAdV-5 virus would result in a modified 
ability to spread in monolayer cell cultures. To investigate this, we constructed the 
replication-competent HAdV-5 viruses Ad5+pIX and Ad5DpIX. Both viruses expressed 





































































Figure 1. (a) Transduction of CAR-positive and CAR-negative cells with the replication deficient vectors 
Ad5DE1+pIX and Ad5DE1DpIX. At 24 hours post transduction (at 10 pp/cell) the luciferase expression 
was measured as indicated by the relative luciferase units (RLU) (NS signifies Not Significant, *p<0.02 
versus Ad5DE1+pIX). Error bars represent S.D. (n=3). (b) Flow cytometry with anti-CAR antibody and 
PE-labeled secondary antibody to analyze cell surface expression level of CAR (white histograms). The 
gray histograms represent incubation with secondary antibody only.
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Figure 2. Transduction assays on MZ2-MEL3.0 and MZ2-MEL3.0/CAR (a) Detection of CAR expression in 
MZ2-MEL3.0 cells by immune-fluorescence staining with anti-CAR antibody and FITC-labeled secondary 
antibody. The insets represent flow cytometry histograms after staining with anti-CAR antibody and 
PE-labeled secondary antibody. (b) Luciferase expression in MZ2-MEL3.0 and MZ2-MEL3.0/CAR after 
Ad5DE1+pIX and Ad5DE1DpIX transduction. Error bars represent S.D. (n=3). (c) Fold enhancement of 
MZ2-MEL3.0 transduction with Ad5DE1DpIX and Ad5DE1pIXDLEU as compared to the transduction with 
Ad5DE1+pIX. The fold enhancements are normalized to the vector transduction ratios on MZ2-MEL3.0/
CAR (*p<0.05, **p<0.005 versus Ad5DE1+pIX). Errors bars represent S.D. (n=3).
the Ad5DpIX virus (median 30 arbitrary surface units (ASU), range 20-170) appeared 
to be significantly smaller than the plaque size for Ad5+pIX (median 100 ASU, range 
30-290). A similar difference in plaque size was observed on the CAR-negative cell line 
VH10, with Ad5DpIX (median 50 ASU, range 30-150) yielding much smaller plaques 
compared to Ad5+pIX (median 100 ASU, range 75-280). From these analyses we 
conclude that protein IX-gene deletion from the genome of the replication competent 
virus results in a decrease in virus spread in CAR-positive (A549) as well as CAR-
negative (VH10) monolayer cell cultures.      
Enhanced activation of peripheral blood mononuclear cells by 
Ad5ΔE1DpIX 
Our findings on the modified transduction characteristics of protein IX-deficient 
HAdV-5 vectors are of relevance for: (1) fundamental adeno-virology (as the findings 
point towards a novel biological function of protein IX), and (2) the development of 
protein IX-modified HAdV-5 vectors for gene therapies. For both these aspects, it will 
be highly interesting to determine the effect of protein IX-deletion on the interaction 























Figure 3. (a) Electron microscopy on Ad5DE1+pIX and Ad5DE1DpIX samples with negative staining 
of the vector particles in phosphotungstic acid. (b) Immunoblot detection on Ad5DE1+pIX and 








































Figure 4. The effect of integrin blocking on transduction of cells with Ad5DE1+pIX and Ad5DE1DpIX. (a) 
MZ2-MEL3.0 cells were treated with EDTA to remove bivalent cations necessary for HAdV-5 interaction 
with integrins. Subsequent transduction was performed in the presence (PBS++) or absence (PBS) of 
bivalent cations and GFP expression was measured, as indicated by the mean fluorescence intensity 
(MFI). Error bars represent S.D. (n=3). (b) Vector mediated luciferase expression in MZ2-MEL3.0 and 
A549 cells in the presence or absence of antibodies directed against αVβ3 or αVβ5 integrins in the 
infection medium (*p<0.05 versus control treatment). Error bars represent S.D. (n=3).
human peripheral blood mononuclear cells with Ad5DE1+pIX and Ad5DE1DpIX, 
and analyzed GFP expression and the expression of cellular activation markers. This 
revealed relatively high levels of GFP expression in the monocyte population. The 
percentage of GFP-positive monocytes was similar for both vectors, varying between 
10% and 30% at 100 pp/cell, depending on the donor (data not shown). For both 
vectors, the GFP expression in the T cell, B cell, and NK cell populations was very low 
(<1% GFP-positive cells). Although Ad5DE1+pIX and Ad5DE1DpIX showed identical 
GFP expression levels in the monocytes, the incubation with Ad5DE1DpIX resulted 
in a remarkably higher level of monocyte activation, as indicated by enhanced CD86 
expression (Fig. 5a). The percentage of CD86 positive monocytes as well as the mean 
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fluorescence intensity for CD86 was significantly higher for the protein IX-lacking vector. 
This enhancement in monocyte activation was observed for monocytes derived from 
PBMCs of three different donors and with different virus batches. The up-regulated 
CD86 level involved the entire Ad5DE1DpIX-incubated monocyte population, not only 
the GFP-positive cells (Fig. 5a). Incubation with Ad5DE1DpIX also resulted in enhanced 
activation of NK cells, as demonstrated by an increase in CD69 expression (Fig. 5b). 
Interferon-gamma (IFN-γ) ELISA of PBMC supernatants revealed higher levels of IFN-γ 
production after incubation with Ad5DE1DpIX at the higher input virus levels (Fig. 5c).
Enhanced liver transduction upon intravenous administration of 
Ad5DE1DpIX
To study the functional consequences of protein IX gene deletion on biodistribution in 
mice, Ad5DE1+pIX and Ad5DE1DpIX viruses were administered via tail vein injection. 



















































































Figure 5. Activation of peripheral blood mononuclear cells (PBMCs) after incubation with Ad5DE1+pIX 
and Ad5DE1DpIX for two days. (a) Activation of the monocyte population. The graphs on the left show 
the percentage of CD86 positive cells and the mean CD86 expression levels (MFI) for three different 
donors. The flow cytometry figures on the right illustrate the CD86 up-regulation for transduced (GFP-
positive) monocytes and non-transduced (GFP-negative) monocytes (from donor 1). (b) Activation of 
the NK cell population. The percentage of CD69 positive cells and the mean CD69 expression levels 
(MFI) are shown for three different donors. (c) Measurement of IFN-γ levels in PBMC supernatant (from 
a single donor) after incubation with Ad5DE1+pIX and Ad5DE1DpIX. The data represent mean values 
of two independent measurements.
CHAPTER 7
132
The vector lacking protein IX yielded a more than ten-fold higher luciferase activity in 
the liver (Fig. 6a). These data show that the absence of protein IX in the viral capsid 
strongly affected the biodistribution of HAdV-5 particles.
Recent reports have described the involvement of plasma proteins, such as the 
blood coagulation factor X (FX), in HAdV-5 transduction of the liver.18,19 To study 
whether removal of protein IX influences the effects of clotting-factor binding, we 
compared the FX-mediated transduction for Ad5DE1+pIX and Ad5DE1DpIX (Fig. 
6b). In vitro incubation of A549 cells and HepG2 cells with FX resulted in a similar 
enhancement in transduction for Ad5+pIX and Ad5DpIX. As expected, no effect on 
transduction was observed after incubation with the mutant FX (FXMUT), which lacks the 
domain necessary for binding to the HAdV-5 capsid.19 From these data we conclude 
that the absence of protein IX does not affect the binding of coagulation factor X.
dIsCussIOn
From our data we conclude that the omission of protein IX from HAdV-5 vectors 
enhances viral transduction of cell lines that are low in expression of the adenovirus 
receptor CAR. This finding is of relevance for the development and implementation of 









































Figure 6. (a) Distribution of Ad5DE1+pIX and Ad5DE1DpIX in mice after tail vein injection of 109 vector 
particles. Prior to vector injection, pre-dosing was performed with the vector HAdV-5.CMV to saturate 
Kupffer cell macrophages. Organs were harvested three days post injection and the luciferase expression 
per total protein was measured (*p=0.057, **p=0.006 versus Ad5DE1+pIX). Error bars represent S.D. 
(n=2). (b) Luciferase expression in HepG2 and A549 cells after transduction with Ad5DE1+pIX and 
Ad5DE1DpIX in the presence of coagulation factor X (FX), Gla-domainless mutant factor X (FXMUT), or no 
coagulation factors (mock). Error bars represent S.D. (n=3).
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on HAdV-5 biology and evolution, which especially becomes clear if stating our 
conclusion in a  ‘backwards’ manner: the introduction of protein IX in HAdV-5 (making 
it wild-type HAdV-5) decreases viral transduction of cell lines that are low in CAR 
expression. Although speculative, it is very well possible that the presence of protein 
IX in the HAdV-5 capsid negatively interferes with non-specific cell transduction, and 
thereby plays a role in determining the virus tropism.  Noteworthy, the extended cell 
tropism of the Ad5DE1DpIX vector, as presented by its enhanced transduction of 
CAR-negative cells, did not come with a loss in ability of CAR-mediated transduction 
of cells. This is clear from the comparison on MZ2-MEL3.0 and MZ2-MEL3.0/CAR. 
Introduction of CAR in the CAR-negative cells significantly increased transduction 
levels with Ad5DE1DpIX. It is conceivable that in CAR-expressing cells the protein 
IX-deficient particles can use either the CAR/fiber-dependent mechanism, or the CAR-
independent pIX-dependent mechanism. Quantifying the relative contribution of each 
of these mechanisms to the total transduction requires tools for specifically blocking 
the new pathway. Such inhibitors remain to be identified.
Interestingly, the vector Ad5DE1pIXDLEU had Ad5DE1DpIX-like properties, 
implicating the importance of the C-terminal domain of protein IX in inhibiting 
transgene expression in CAR-negative cell lines. The specificity for the C-terminal 
domain of protein IX excludes differences in viral capsid stability as a cause for the 
observed phenomenon, since deletion of this domain does not result in reduced 
capsid stability.4
Wild-type HAdV-5 enters cells via high affinity binding of the fiber knob domain 
to CAR,14 followed by interaction of the RGD motif of the penton base with cellular 
integrins αVβ3 and αVβ5 promoting rapid adenovirus cell entry into clathrin-coated 
vesicles.15,16 Similar to the Ad5DE1+pIX control virus, Ad5DE1DpIX requires the 
presence of bivalent cations for its transgene delivery, indicating the usage of cellular 
integrins for cell internalization.16 More specifically, blocking cells with anti-integrin 
antibodies resulted in a decrease in transduction for Ad5DE1DpIX, thereby confirming 
the integrin-dependency. Unfortunately, our efforts to compare the vectors for a 
general difference in cell binding affinity, using Alexa488-TFP (tetrafluorophenyl) 
labeled vector particles, were not conclusive as a result of strong and reproducible 
negative effects of the labeling procedure on the pIX-deficient vector particles. The 
effects were not identical for protein IX-positive and protein IX-negative particles, 
making the results obtained with these particles in comparative binding assays 
unreliable. Alternative protocols for fluorescent- or radio-labeling of vector particles 
might be more suitable for comparing the cell-binding affinity. Labeled vector particles 
might also be used for analysing differences in cell surface motility between protein 
IX-containing and protein IX-lacking vectors. Through largely unknown mechanisms 
HAdV-5 particles migrate on the cell surface and alterations in viral movement can 
result in modified transduction.20 
The removal of the protein IX gene from a replication competent HAdV-5 virus 
results in a small-plaque phenotype on CAR-positive as well as CAR-negative cell 
lines. This suggests the tropism modifying mutation affects the virus’s capacity to 
spread from cell to cell. Such small-plaque phenotypes of extended tropism mutants 
is not unprecedented: similar phenotypes have been described for murine corona 
virus mutants that acquired the capacity to bind heparin.17 
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To investigate the effect of protein IX-gene deletion on the interaction of HAdV-5 
with human mononuclear leukocytes, we compared the vectors Ad5DE1+pIX and 
Ad5DE1DpIX for GFP expression in PBMCs. Flow cytometry analyses demonstrated 
GFP expression almost exclusively in monocytes, with similar expression levels for 
both vectors. However, increased activation of the entire monocyte population (so not 
exclusively restricted to the GFP-positive population) was observed for Ad5DE1DpIX, 
as demonstrated by an enhancement in CD86 expression. CD86 is an activation 
marker on antigen-presenting cells such as monocytes, macrophages, dendritic cells, 
and B cells, and is important for co-stimulation of T cells.21 The increased activation of 
monocytes despite similar levels of transduction (GFP expression) could be due to a 
direct effect on the monocytes themselves or indirectly via a more efficient stimulation 
of T cells or NK cells. Uptake of the protein IX-deleted vector may be increased 
and/or may follow different intracellular trafficking routes.22,23 As a consequence, 
more efficient viral antigen loading onto human leukocyte antigen (HLA) molecules, 
or an increase in CD86 expression, could lead to more T cell activation, and e.g. 
IFN-γ secretion. Of note, most healthy adult donors have HAdV specific T cells.24 
Indeed, Ad5DE1DpIX incubation resulted in enhanced production of IFN-γ. Protein 
IX-gene deletion appeared to affect NK cell activation as well, resulting in increased 
expression levels of CD69, which is an activation marker for lymphocytes including NK 
cells.25 Increased T cell activation could have been accompanied by increased levels 
of other T cell cytokines like interleukin-2 (IL-2). IL-2 is a known activating cytokine of 
NK cells.26,27 Alternatively, the increased production of IFN-γ in the supernatant would 
also be consistent with increased activation of NK cells by the vector lacking protein 
IX, without the involvement of T cells. 
Irrespective of the mechanism, the increased activation of monocytes and NK cells 
as a result of protein IX deletion is likely to have important consequences for the in 
vivo implementation of protein IX modified HAdV-5 vectors, since monocytes (after 
differentiation to Kupffer macrophages in the liver) as well as NK cells are important 
players in the sequestration of HAdV-5 vectors from the blood after systemic delivery 
(reviewed by Muruve28). Furthermore, the observed differences in PBMC activation 
between Ad5DE1+pIX and Ad5DE1DpIX suggest a biological function of protein IX in 
diminishing the immune response against HAdV-5. Further studies will be necessary 
to fully determine the effects of protein IX deletion from HAdV-5 on the activation of 
immune cells.
Omission of protein IX from the capsid resulted in a remarkable difference 
between Ad5DE1+pIX and Ad5DE1DpIX upon intravenous administration in mice. 
Administration of Ad5DE1DpIX yielded more than ten-fold higher luciferase activity in 
the liver, for reasons that remain to be clarified. Extensive research has been devoted 
to defining the molecular mechanisms behind the sequestration of intravenously 
administered HAdV-5 in the human liver, with the aim to eventually improve the 
therapeutic efficacy of intravenously delivered HAdV-5 vectors (reviewed by Di Paolo 
and Shayakhmetov29). The uptake of HAdV-5 in the liver has been found to occur 
in a CAR-independent manner and involves binding of the virus particles in the 
blood to complement factors and immunoglobulins (mediating uptake in Kupffer cell 
macrophages),18,30 and coagulation factors (resulting in hepatocyte transduction).18,19 
The enhanced transduction of the liver with Ad5DE1DpIX observed in our mouse 
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model seems not to be a result of more efficient binding of the vector to coagulation 
factor X (FX), as can be concluded from our in vitro FX-binding assay. An alternative 
explanation might be that the absence of protein IX extends the HAdV-5 tropism, 
enabling the transduction of cells in the liver that do not present CAR. Of interest, 
primary human hepatocytes were recently found to have CAR localized at cellular 
junctions that are inaccessible to the hepatic blood flow.31 This localization is in 
contrast to the CAR molecules on hepatocellular carcinoma cells (like HepG2), being 
highly available for HAdV-5 binding.31,32
Protein IX is strongly conserved in all primate adenoviruses indicating the 
importance of the protein. A biological role for protein IX in HAdV-5 capsid stabilization 
has been proposed, based on in vitro heat-stability assays.4 Our findings point toward 
other biological functions of protein IX in (i) determining the cell tropism of HAdV-5, 
and (ii) negatively interfering with the innate immune response against HAdV-5. More 
insight into the mechanisms by which the presence of protein IX affects gene transfer 
and activation of immune cells may be of use for enhancing the efficiency of current 
(e.g. 33) and future gene therapies involving protein IX modified HAdV-5 vectors.
MAterIAls And MethOds
Cell lines
All cell lines were maintained as monolayers at 37°C in a humidified atmosphere of 5% 
CO2. The human cell lines HeLa (cervical cancer), A549 (carcinomic alveolar epithelium), 
MEL2A (melanoma), MZ2-MEL3.0 (melanoma),5 VH10 (primary foreskin fibroblasts),34 
HepG2 (hepatocellular carcinoma), and 911 cells (HAdV-5 E1-transformed human 
embryonic retinoblasts)35 were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Gibco-BRL, Breda, The Netherlands) supplemented with 8% fetal bovine 
serum (FBS) (Gibco-BRL, Breda, The Netherlands) and penicillin-streptomycin mixture.
Lentivirus transduction was used to create a MZ2-MEL3.0 cell line stably expressing 
human CAR. To this end, the CAR gene was PCR-amplified by using primers 1 and 2 
(Table 1) from plasmid pCMV_hCAR (kindly provided by Dr. J.M. Bergelson14). The 
PstI+NheI digested PCR product was ligated in between the corresponding restriction 
sites of pLV.CMV.IRES.PURO36, resulting in pLV.CMV.CAR.IRES.PURO. The virus 
LV.CMV.CAR.IRES.PURO was produced by a previously described procedure involving 
cotransfection of pLV.CMV.CAR.IRES.PURO together with helper plasmids encoding 
HIV-1 gag-pol, HIV-1 rev, and the VSV-G envelope37. The methods for determining the 
titer of the LV.CMV.CAR.IRES.PURO vector stock and the procedures for transduction 
of the MZ2-MEL3.0 cells have been described before36. Selection for antibiotic 
resistance was achieved by seeding the cells in medium with 0.6 μg/ml puromycin (MP 
Biomedicals, Amsterdam, The Netherlands).
Viruses
The vectors HAdV-5.CMV.GFP/LUC12 (Ad5DE1+pIX) and HAdV-5DpIX.CMV.GFP/
LUC12 (Ad5DE1DpIX)  contain a green fluorescent protein (GFP) gene as well as a 
firefly luciferase (LUC) gene, which are both driven by a human cytomegalovirus (CMV) 
promoter. The vector HAdV-5pIXD100-114.CMV.LUC (Ad5DE1pIXDLEU), encoding LUC 
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only, was described previously as well.4 Titration of the vector stocks was performed 
by a PicoGreen-DNA binding assay to determine the concentration in physical vector 
particles per ml (pp/ml).38 A standard agar overlay plaque assay on 911 cells was used 
to determine the infectious virus concentration in plaque forming units per ml (pfu/
ml).35 The pp/pfu ratios of the three vectors were very similar, within the range of 10 
to 12. 
The replication-competent viruses HAdV-5.DE3.ADP.eGFP (Ad5+pIX) and HAdV-5.
DE3.ADP.eGFP.DpIX (Ad5DpIX) were constructed by recombination of the shuttle 
plasmids pShuttle+E1+pIX (pSh+pIX) and pShuttle+E1DpIX (pShDpIX) with a HAdV-5 
backbone plasmid containing the eGFP gene in the E3 region (pBB). The plasmids 
pSh+pIX, pShDpIX and pBB were constructed as follows. The wild-type HAdV-5 
BsrGI-MfeI fragment containing the E1 genes (nucleotides 193-3925) was isolated 
from pTG3602 (kindly provided by Dr. M. Luski, Transgene, Strasbourg, France), 
and cloned into the BsrGI-MfeI digested pTrackCMV-GFP/LUC,12 thereby replacing 
the GFP/LUC genes with the HAdV-5 E1 region. By using site-directed mutagenesis 
(QuikChange site-directed mutagenesis kit; Stratagene) (primers 3, 4, 5, 6 (Table 1)) 
two restriction sites were introduced in the protein IX gene; a ScaI site at the start 
codon of protein IX and a SpeI site upstream of the protein IX stop codon, thereby 
creating pShuttle+E1+pIXScaI/SpeI. Next, the pShDpIX plasmid was constructed by ScaI/
SpeI digestion and re-ligation of the protein IX gene-deleted fragment. The pSh+pIX 
plasmid was created by introducing the protein IX sequence (amplified from pAd5pIX7 
by using primers 7 and 8 (Table 1)) into the ScaI/SpeI linearized pShuttleE1+.pIXScaI/SpeI. 
The ScaI-site was restored to the wild-type HAdV-5 sequence by exchanging the ScaI-
overlapping MfeI/HindIII fragment with the corresponding fragment from pTG3602. 
The SpeI site and the downstream ‘pIX-remainder sequence’ were left intact, since 
part of this sequence forms a hairpin-loop structure situated over the polyA site of the 
E1B transcript, which might be essential for efficient polymerase slippage needed for 
polyadenylation.39
The pBB backbone plasmid was constructed by replacing the E3-lacking SpeI-
PacI fragment (nucleotides 27238-33443) of pAdEasy-140 with the corresponding 
SpeI-PacI fragment of pShuttle-DE3-ADP-EGFP-F241, thereby introducing eGFP in 
the E3 region under control of the viral major late promoter. The coding sequence 
for the E3 Adenovirus Death Protein (ADP) was retained. The kanamycin resistance 
gene (inserted with the pShuttle-DE3-ADP-EGFP-F2 fragment) was removed by ClaI 
digestion and re-ligation of the two largest fragments.   
Recombination of pBB with pSh+pIX and pShDpIX in E.coli and subsequent virus 
rescue in A549 cells were performed as described elsewhere.40 Virus was purified by 
a standard double cesium chloride gradient protocol, dialyzed against sucrose buffer 
(5% sucrose, 140 mM NaCl, 5 mM Na 2HPO4.2H2O, 1.5 mM KH2PO4) and stored at 
-80°C. The virus titer was determined by the PicoGreen-DNA binding assay38 (for pp/
ml measurement), and a plaque assay on A549 cells35 (for pfu/ml measurement). For 
analysis of virus spread, GFP positive plaques were photographed (Olympus Camedia 
Digital Camera C-3030, installed on an Olympus CK40 microscope) and the plaque 
size was determined in arbitrary units (Olympus DP-soft v.5.0 Soft imaging System 
software). The median plaque size of Ad5DpIX was normalized to the plaque size for 
Ad5+pIX. 
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Analysis of CAR presentation on the cell surface
Flow cytometry was performed to determine the levels of CAR presentation on the 
cell surface. Cells in suspension (in PBS with 0.5% bovine serum albumin and 0.02% 
sodium azide) were incubated with mouse monoclonal anti-CAR antibody (clone RmcB, 
Upstate Biotechnology, Lake Placid, NY, diluted 1:1000) for 30 min on ice, followed by 
incubation with phycoerythrin (PE)-conjugated rabbit-anti-mouse secondary antibody 
(Caltac Laboratories, Burlingame, CA, USA) for 30 min on ice. Flow cytometry data 
were analyzed with CellQuest software (Becton Dickinson).
Immunohistochemistry was performed on the cell line MZ2-MEL3.0/CAR. After 
washing with phosphate-buffered saline (PBS), the cells were fixed in acetone/
methanol (1:1) for 10 min at room temperature. Staining was performed with the anti-
CAR antibody (clone RmcB, Upstate Biotechnology, Lake Placid, NY, diluted 1:500). 
Fluorescein isothiocyanate (FITC)-conjugated rabbit-anti-mouse antibody (Jackson 
ImmunoResearch, France) was used as secondary antibody.
Virus transduction assays
(1) Luciferase expression
The transduction efficiency of CAR-positive (HeLa, A549, MEL2A, MZ2-MEL3.0/CAR) 
and CAR-negative (MZ2-MEL3.0, VH10) cell lines by Ad5DE1+pIX and Ad5DE1DpIX 
was compared by measuring luciferase expression. Transduction was performed in 
triplicate in 24-well plate wells in 500 ml DMEM/8% FBS. After a two-hours incubation 
the virus-containing medium was replaced with fresh medium without virus. At 24 
hours post transduction the cells were washed once with PBS and lysed in 100 ml 
LUC-lysis mix (25 mM Tris-phosphate (pH 7.8), 2 mM CDTA, 2 mM DTT, 10% glycerol 
and 1% Triton-X in PBS). Luciferase production was determined with the Promega 
Luciferase Assay by adding 25 ml luciferase assay reagent to 10 ml lysate. Light intensity 
measurement was performed in a Victor Wallac 2 microplate reader (PerkinElmer, Inc., 
Waltham, MA, USA).
(2) Integrin blocking
Indirect blocking of integrin-mediated virus uptake was performed by incubating 
cells with EDTA. MZ2-MEL3.0 cells were harvested from semi-confluent tissue culture 
plates, washed three times in PBS with 5 mM EDTA, and resuspended in standard PBS 
Table 1. Oligonucleotides used in the cloning procedures.
FWD CAR_PstI 5’-GATGTACTGCAGATGGCGCTCCTGCTGTG-3’









or PBS supplemented with 0.9 mM CaCl 2
 and 0.5 mM MgCl2 (PBS
++). The Ad5DE1+pIX 
and Ad5DE1ΔpIX stocks were adjusted to equal pp concentrations by adding sucrose 
buffer and were diluted 1:1 in a 5 mM EDTA solution in PBS. Virus (100 pp/cell) 
was added to 500,000 cells in 1 ml PBS or PBS++ and incubation was performed for 
60 min at 37°C under constant agitation. Subsequently, the cells were pelleted by 
centrifugation, dissolved in 5 ml medium and transferred to 24-well plate wells (500 ml 
per well). Cells were incubated for 24 hours and analyzed for GFP expression by flow 
cytometry. Data were analyzed with CellQuest software (Becton Dickinson).
The anti-human CD51/61 monoclonal antibody (MAb LM609), an αVβ3 integrin 
antagonist, and MAb P1F6, an αVβ5 integrin antagonist (both obtained from Millipore) 
were used to test the inhibitory effect of anti-integrin antibodies on virus transduction. 
Cells grown as monolayers were pre-incubated with medium only or with medium 
containing integrin function-blocking MAbs (10 mg/ml). After 30 min of incubation, 
the excess antibody was removed by gentle washing followed by virus transduction 
(100 pp/cell). Reporter gene expression was measured 24 hours post transduction by 
performing a standard luciferase assay.
(3) Virus incubation with coagulation factor X (FX)
HepG2 and A549 cells were plated in 24-well plate wells. After a PBS wash step, 
Ad5DE1+pIX or Ad5DE1DpIX (100 pp/cell) was added in serum-free medium 
containing 8 mg/ml Factor X (FX) (HCX-0050, Haemotologic Technologies Inc.), 8 mg/
ml Gla-domainless Factor X (FXMUT) (HCX-GD, Haemotologic Technologies Inc.) or 
no FX/FXMUT. After 2 hours the medium was replaced by normal medium. Luciferase 
expression was measured 24 hours post transduction.
Immunoblot analysis and electron microscopy
Immunoblot analyses were performed to assess the incorporation of proteins into the 
capsid of Ad5DE1+pIX and Ad5DE1DpIX. The western blotting and detection procedures 
were described previously.5 Virus lysates were prepared by adding 5x109 virus particles 
directly to western sample buffer. Capsid proteins were visualized with rabbit polyclonal 
anti-protein IX serum (1:2000,42 goat polyclonal anti-hexon (1:1000, ab19998, Abcam, 
Cambridge, UK), and mouse monoclonal anti-fiber (1:5000, 4D2, Abcam).43 Secondary 
antibodies were horseradish peroxidase (HRP)-conjugated goat-anti-rabbit and rabbit-
anti-mouse (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Electron microscopy was performed on Ad5DE1+pIX and Ad5DE1DpIX samples 
adsorbed into glow-discharged carbon coated copper grids and negatively stained 
for 30 seconds with 2% phosphotungstic acid (pH 7). The viruses were examined with 
a FEI Tecnai Spirit BioTwin transmission electron microscope operating at 120 kV. 
Images were recorded on a 4k × 4k Eagle CCD camera.
PBMC analysis
Buffy coats were obtained from healthy donors after consent (Sanquin Bloodbank, 
Leiden, The Netherlands) and centrifuged on a Ficoll gradient to obtain PBMC. PBMC 
(1 x 106) were added to a well of a 24-well plate in 0.5 ml medium (RPMI/10%FCS) and 
virus was added at the indicated MOI in 0.5 ml medium. After incubation at 37oC and 
5% CO2 for two days, the supernatants were isolated for interferon gamma (IFN-γ) 
measurement, and the cells were prepared for flow cytometry analysis. Cells were 
ENHANCED TRANSDUCTION THROUGH PROTEIN IX DELETION
7
139
washed twice with PBS/0.02% sodium azide, fixed for 10 min in 4% paraformaldehyde, 
washed twice with PBS/0.5% BSA/0.02 sodium azide, and stained with antibodies. 
Antibodies used were anti-CD3-PerCP-Cy5.5, anti-CD4-PE, anti-CD14-APC, anti-
CD14-PerCP-Cy5.5, anti-CD19-PE, anti-CD19-PerCP-Cy5.5, anti-CD69-PE and 
anti-CD86-PE (Becton Dickinson, Franklin Lakes, NJ, USA), anti-CD8-APC and anti-
CD56-APC (Beckman Coulter, Brea, CA, USA). Activation of NK cells was evaluated 
as increased CD69 expression on CD3-, CD14-, CD19-, CD56+ cells. Monocyte 
activation was analyzed as increased CD86 expression on CD3-, CD19-, CD14+ 
cells. Fluorescence was measured by flow cytometry on a FACS Calibur (Becton 
Dickinson) and data were analyzed with CellQuest software (Becton Dickinson). IFN-γ 
in supernatants was measured by ELISA using the PeliPair reagent set for human IFN-γ 
(Sanquin, Amsterdam, NL).
Viral distribution after intravenous delivery  
Ad5DE1+pIX or Ad5DE1DpIX (109 pp) was injected in the tail vein of 6-week-old 
athymic nude mice (NMRI nu/nu; Taconic M&B A/S, Ry, Denmark), followed by 
sacrificing the animals and harvesting of multiple organs at 3 days post injection. Four 
hours before Ad5DE1+pIX and Ad5DE1DpIX injection, pre-dosing was performed with 
the empty vector HAdV-5.CMV (replication-deficient and not encoding a transgene) 
(5x1010 pp) to saturate Kupffer cell macrophages. Tissue samples from each organ were 
lysed in LUC-lysis mix and the luciferase expression was measured according to the 
Promega Luciferase Assay. The protein concentration in the lysates was determined 
by using the bicinchoninic acid protein assay (Pierce, Perbio Science BV, Etten-Leur, 
The Netherlands), enabling the calculation of luciferase expression per total protein. 
The experiment was performed under the Dutch Experiments on Animals Act that 
serves the implementation of “Guidelines on the protection of experimental animals” 
by the Council of Europe (1986), Directive 86/609/EC, and only after a positive 
recommendation by the Animal Experiments Committee.
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Human adenovirus type 5 (HAdV-5)-derived vectors are among the most promising viral 
vectors for cancer gene therapy. Although clinical trials have shown safety for anti-tumor 
therapy with HAdV-5 vectors, the efficacy in general remains limited. A variety of efficacy-
limiting aspects has been identified, as outlined in Chapter 2 of this thesis. A major 
problem is the poor penetration of the tumor due to the paucity of the coxsackievirus 
and adenovirus receptor (CAR) on the surface of the tumor cells.1,2 Genetic modification 
of HAdV-5 capsid proteins might lead to the development of vectors that are specifically 
targeted to tumor cells, thereby improving efficacy as well as safety. Development of 
genetically modified vectors that can infect CAR-negative cells has mainly focused 
on the incorporation of heterologous ligands in the fiber knob, or on replacement of 
the entire knob domain by a heterologous ligand.3 The complexity of incorporating 
ligands into the adenovirus fiber locale has prompted the identification of other capsid 
proteins amendable for ligand incorporation.4 These approaches have the potential to 
incorporate an increased number of complex ligands per virion.
Major part of this thesis describes proof-of-principle studies on the usability of the 
minor capsid protein IX for targeting HAdV-5 to tumor cells (Chapters 3, 4, 5). Different 
ligands (single-chain antibody fragments (scFv’s), single-chain T-cell receptors (scTCRs) 
and Affibody molecules) were efficiently incorporated in the virus capsid after genetic 
fusion to the carboxyl terminus of protein IX. This leads to enhanced transgene delivery 
to the targeted tumor cells. Also, a variety of analyses was performed on HAdV-5 vectors 
lacking the protein IX gene, motivated by the fact that the biological role of protein IX 
has not been fully elucidated (Chapter 7). This revealed aberrant characteristics for the 
protein IX-deficient vectors, such as enhanced transgene expression in CAR-negative 
cell lines, and enhanced activation of immune cells. Besides the assessment of protein 
IX-based tumor targeting, Chapter 6 of this thesis involves an alternative tumor-targeting 
methodology, i.e. through the fusion of ligands (scTCRs) to the fiber protein.
In this section, the major conclusions from the work presented in this thesis are 
summarized and recommendations for further research are provided. Furthermore, 
a general perspective is given on the future directions of developing oncolytic 
adenoviruses.
8.2 COnClusIOns
From the work presented in this thesis, we can draw the following major conclusions: 
1. Large and complex polypeptide moieties with proven potential for tumor 
targeting, such as single-chain antibody fragments, single-chain T-cell receptors, 
or Affibody molecules, can be efficiently incorporated in the capsid of HAdV-5.
2. HAdV-5 can be targeted in vitro to cancer-testis (CT) antigens through fusing a 
single-chain T-cell receptor with protein IX or fiber molecules.
3. HAdV-5 can be targeted in vitro to Human Epidermal growth factor Receptor-2 
(HER2) expressing tumor cells through fusing ZH-Affibody molecules with protein 
IX. This methodology requires the introduction of a cathepsin-cleavage site in 




4. Deleting the protein IX gene from HAdV-5 vectors results in enhanced delivery 
of transgenes into CAR-negative cells and enhanced activation of immune cells
8.3 PersPeCtIVes On PrOteIn IX-lIGAnd 
MedIAted tuMOr tArGetInG Of AdenOVIruses
Our studies present novel strategies for targeting HAdV-5 to tumor cells, which may 
be of great value for the future development of oncolytic adenovirus technology with 
improved efficacy and/or safety. The applicability of protein IX as an anchor for fusing 
large and complex polypeptides opens new opportunities for tumor cell targeting, 
as an alternative or in addition to the currently used fiber modification strategies. Of 
special interest, our studies also demonstrate the feasibility of targeting HAdV-5 to CT 
antigens through the fusion of scTCRs to protein IX or fiber. This significantly extends 
the number of tumor cell-specific molecules that can be targeted. Although these 
results are highly promising, a variety of further studies is needed to delineate the true 
clinical potential.   
One important aspect will be to introduce the protein IX-ligand modifications 
in the genome of replication competent adenoviruses. Our studies mainly involved 
assessments of transduction efficiencies using replication deficient vectors. However, 
it is currently anticipated that the clinical anti-tumor efficacy of replication deficient 
vectors remains insufficient, irrespective the type of foreign transgene delivery.5 This 
has lead to the ongoing development and clinical testing of different variants of 
Conditionally-Replicating Adenoviruses (CRAds), such as the HAdV-5.RGD.D24 virus 
that is tested for its anti-tumor efficacy and specificity in ovarian carcinoma and glioma 
patients.6 Future work may include the incorporation of protein IX-attached targeting 
ligands in CRAds to further improve their efficacy or specificity.
One aspect probably hampering the efficacy of oncolytic adenoviruses, and 
possibly all other types of oncolytic viruses, is the heterogeneity of tumor cells within 
a solid tumor mass. As such, highly differentiated tumor cells exist beside (a minor 
percentage of) tumor stem cells, which differ in the amount and type of cell surface 
receptor presentation. As a consequence of the heterogeneities, a significant fraction 
of a tumor might escape from infection with an oncolytic adenovirus. As a solution, 
‘mosaic’ adenovectors might be developed, that are harnessed with multiple tumor 
targeting ligands. Protein IX offers new potential for the establishment of mosaic 
HAdV-5 vectors, for example combining fiber- with protein IX-mediated targeting. 
Also, vectors might be developed that have protein IX fused to different targeting 
ligands in a single virus particle. Proof-of-principle of creating protein IX-polypeptide 
mosaic viruses has already been shown through simultaneously incorporating a 
targeting, imaging, and therapeutic motif in the capsid of HAdV-5.7
Alongside our applied studies on the feasibility of using protein IX as an anchor 
for the attachment of tumor targeting ligands, aberrant characteristics were found 
for protein IX-gene deleted vectors (Chapter 7). Most strikingly, protein IX-deficient 
vectors showed increased transgene expression in a variety of cell types, as compared 
to the control vectors. The highest enhancements were observed on CAR-low/negative 
cells. Also, protein IX deletion appeared to lead to increased activation of cellular 
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subsets of peripheral blood mononuclear cells (PBMCs), as demonstrated by changes 
in cell surface marker expression. Although our experiments ruled out various aspects 
as causative mechanism, the exact molecular mechanism could not be elucidated. 
Recently, Strunze et al. reported an essential role for protein IX in facilitating access 
of viral DNA to the cellular nucleus.8 Upon infection of a cell, the HAdV-5 particle 
successively travels towards the nucleus, binds with hexon epitopes to a nuclear pore 
complex (NPC), uncoats, and inserts its DNA into the nucleus. Protein IX molecules 
were found to link the virus with microtubule motor kinesin-1 molecules after docking 
to the NPC. This results in nuclear access of viral genomes through compromising 
the integrity of the NPC and uncoating of the virus particles. Infection of cells with a 
protein IX-gene lacking HAdV-5 was shown to be less efficient as compared to wild-
type HAdV-5 infection, as demonstrated by the formation of lower levels of progeny 
virus particles. These findings by Strunze et al. do not necessarily contradict our 
observations. Reduced microtubule motor binding of protein IX-lacking adenoviruses 
likely causes enhanced innate inflammatory responses, such as the interferon response, 
as a result of cytoplasmic sequestration and/or altered movement kinetics of the 
virus particles. In support of this, we observed enhanced activation of PBMCs. The 
cellular inflammatory responses might have had serious consequences on our protein 
IX-lacking vector’s luciferase and GFP expression levels, since both transgenes were 
driven by the cytomegalovirus (CMV) promoter. The activity of this promoter is known 
to be stimulated by the cellular interferon response.9 Still, it remains to be investigated 
why CAR-negative cell lines display the strongest increase in transgene expression for 
protein IX-gene deleted HAdV-5 vectors.
Obviously, translation of protein IX-mediated tumor targeting towards the clinic 
requires the performance of studies in models that resemble the eventual application 
in humans, including animal studies. This will reveal the anti-tumor efficacy of protein 
IX-ligand viruses in the complex environment of a tumor, which consists of a large 
variety of cell types and extracellular matrix components. These studies should include 
careful analyses on the interactions of protein IX-liganded viruses with non-tumor 
cells, such as immune cells or hepatocytes.
Our studies suggest inefficacious protein IX-mediated targeting after the 
attachment of high-affinity binding ligands. To obtain definite answers, it will be 
informative to perform a side-by-side comparison between vectors containing protein 
IX-linked ligands with different affinities for a certain receptor. Also, further studies 
are necessary to determine the most suitable type of polypeptide ligand to be fused 
with protein IX, e.g. comparing single-chain antibody fragments with single-chain T 
cell receptors. Again, it is recommended to use relevant model systems, since the 
outcome of such experiments probably depends on the tumor (micro)environment.
8.4 GenerAl PersPeCtIVes On the future 
deVelOPMent Of OnCOlytIC AdenOVIruses
Recent years have witnessed the publication of a large variety of preclinical 
improvements on HAdV-5 vectors. These developments, as summarized in Chapter 




performance in humans (through evaluation of clinical trial data), improved insights 
into tumor biology, and improved vector modification techniques.
Clearly, this plethora of ‘next generation oncolytic AdV techniques’ needs 
extensive evaluation in the near future. Performing well-designed studies (for example 
comparing different vectors) will facilitate translation of the technology to the clinic. 
Preclinical studies suggest differences in the performance of various oncolytic viruses, 
with certain viruses outperforming others, depending on the tumor type or the delivery 
technique.10 Therefore, it will be important to compare AdV-derived oncolytic viruses 
with other oncolytic viruses, such as Reovirus,11 Newcastle Disease Virus vectors,12 
and Herpes Simplex Virus vectors.13 Also, it will be essential to use testing models 
that resemble the eventual clinical setting. With this respect, important lessons can 
be learned from previous studies, which demonstrated remarkable differences in 
the in vivo behavior of HAdV-5 vectors between animals and humans. HAdV-5 binds 
extensively to human erythrocytes, thereby hampering systemic delivery. This is in 
contrast to rodents.14,15 Important differences occur between animal species as well. It 
has been found that tissues and cells of mice do not support HAdV-5 replication, whilst 
other species (e.g. cotton rats and Syrian hamsters) are permissive.16 For this reason, 
mouse models are less suitable for studying aspects on the specificity of oncolytic 
HAdV-5 vectors, such as liver toxicity and immune cell activation.
The existence of ‘human versus animal’ discrepancies makes human models more 
suitable to answer certain research questions. Various human models have been 
developed that are of special interest for the evaluation of oncolytic vectors. Vectors 
might be tested in ex vivo blood circulation models, a model that has already been used 
with success to compare blood circulation times and binding to blood components 
between AdV vectors.17 Also, oncolytic AdV testing is anticipated to benefit from 
the recent developments of ex vivo human tumor models.18 As an example, novel 
methodologies enable the ex vivo culturing of primary tumor material resected from 
brain tumors, including tumor stem cell cultures in specialized growth media (either 
as three-dimensional spheres,19 or as two-dimensional monolayers20) and organotypic 
brain slice cultures.21 To simulate the heterogeneity of a solid tumor, efforts are 
undertaken to create spheres that consist of co-cultures of tumor cells with stromal 
cells, like fibroblasts or endothelial cells.22 These systems require further optimization, 
mainly to prevent the stromal cells from rapidly losing their viability or phenotype. 
Of additional benefit, ex vivo culturing of primary tumor material opens 
opportunities for the design of ‘personalized therapeutics’. In theory, therapeutic 
vector regimens can be screened on patient-derived tumor material before initiating 
a therapy. Personalizing viral gene therapy might improve the clinical success rate, 
taking into account that most tumor types consist of a ‘family’ of tumor subtypes. It 
is unlikely that all patients suffering from a single tumor type respond similarly to an 
oncolytic virus therapy.
Besides the above mentioned requirements for vector testing in appropriate tumor 
models, it will be important to investigate the effects of combining oncolytic AdV 
therapy with other therapies. Combining chemotherapy with oncolytic virus treatment 
can lead to enhanced or even synergistic therapeutic efficacy, as demonstrated in 
animal models.23,24 Moreover, oncolytic virus treatment might enable the usage of 
lower concentrations of certain chemotherapeutics, thereby reducing the toxicity.
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Taken together, the availability of improved experimental models and improved 
viral vectors offers great opportunities for the development of ‘next generation 
oncolytic AdV therapies’. As a response on the previous identification of treatment 
efficacy-limiting aspects, a large plethora of novel vectors and strategies has been 
developed. Transductional targeting via attachment of ligands to protein IX offers 
a methodology for further improvements on oncolytic AdV vectors. Future studies 
in well-designed preclinical and clinical settings will teach whether the regained 
expectations for oncolytic adenoviruses as therapeutic regimens for cancer treatment 
will be fulfilled. 
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Recombinant viral vectors hold great promise in the field of cancer gene therapy. While 
a plethora of viruses is being evaluated as oncolytic agents, human adenoviruses of 
serotype 5 (HAdV-5) are among the most popular of viruses to be developed. Although 
clinical studies have demonstrated safety of cancer gene therapy with HAdV-5-derived 
vectors, the efficacy still needs further enhancement. Several factors have been 
identified that limit the anti-tumor efficacy, as reviewed in Chapter 2 of this thesis. 
One major bottleneck is the inadequate penetration and spread of the virus within the 
tumor. This is attributable, at least in part, to the low or heterogeneous expression of 
the coxsackie and adenovirus receptor (CAR) on the tumor cells. This thesis describes 
the development and preclinical evaluation of novel tumor-targeted HAdV-5 vectors, 
through implementing the genetic fusion of capsid proteins (protein IX and fiber) with 
a variety of tumor-targeting polypeptides.
Chapters 3, 4, and 5 describe the usability of the HAdV-5 minor capsid protein IX 
as a locale for genetically fusing tumor targeting ligands. At first, proof-of-principle is 
described of fusing protein IX with hyper-stable single-chain antibody fragments (scFv’s) 
(Chapter 3). Hyper-stable scFv’s are anticipated to be highly suitable for incorporation 
in adenovirus capsids, as a result of their ability to fold correctly in the reducing 
environment of the cytoplasm. A hyper-stable scFv directed against β-galactosidase 
(13R4) was fused with protein IX. To ensure enhanced protrusion of the scFv at the 
virus surface, a 75-Ångstrom α-helical spacer was included between protein IX and 
the 13R4. The protein IX-13R4 fusion proteins were efficiently incorporated in the 
HAdV-5 capsid and, importantly, 13R4 appeared to preserve its functionality in terms 
of β-galactosidase binding.
Next, protein IX also appears to be suitable for fusing tumor cell-directed single-
chain T cell receptors (scTCRs) (Chapter 4). Tumor cell targeting was established via 
the fusion of protein IX with a scTCR (scTCRHLA-A1/MAGE-A1) directed against the cancer 
testis (CT) antigen MAGE-A1, presented on the cell surface in complex with human 
leukocyte antigens of haplotype A1 (HLA-A1). HAdV-5 vector particles loaded with 
protein IX-scTCRHLA-A1/MAGE-A1 fusion proteins transduced melanoma target cell lines 
with at least 10-fold higher efficiency than the control particles. Importantly, specificity 
of targeting could be shown as well. These results underscore the potential of using 
protein IX for targeting HAdV-5, and demonstrate the feasibility of targeting HAdV-5 
vectors to intracellularly-derived CT antigens. The highly specific expression profiles 
of CT antigens, which are expressed in a variety of cancerous tissues and are generally 
silent in normal tissues (except for the testis), make them interesting target molecules 
for cancer therapies.
Chapter 5 describes protein IX-mediated tumor targeting of HAdV-5 through 
fusing Affibody molecules. Affibody molecules might be valuable moieties for virus 
targeting, because of their relatively small size and high binding affinity. Previous 
reports, however, showed limited targeting efficacies after fusing ‘high-affinity binders’, 
such as Affibody molecules, to protein IX, which has been suggested to be the result 
of inefficient release of the virions from their targeted receptors in the endosome. Our 
studies demonstrate that the transduction of tumor cells is augmented by incorporating 




directed against the Human Epidermal growth factor Receptor 2 (HER2). Virus particles 
harboring the protein IX-CCS-ZH in their capsid transduced HER2 positive SKOV-3 
ovarian carcinoma cells with increased efficiency in monolayer cultures, 3-dimensional 
spheroid cultures, and in SKOV-3 tumors grown on the chorioallantoic membrane 
of embryonated chicken eggs. These findings further augment the applicability of 
protein IX as an anchor for coupling tumor-targeting ligands.
An alternative HAdV-5 targeting strategy is described in Chapter 6, concerning 
the genetic fusion of a scTCR with the fiber capsid protein. In the genome of wild-
type HAdV-5, the sequence encoding for the fiber knob domain was replaced by 
sequences encoding a scTCR (identical to the scTCR molecule as described in Chapter 
4) and an artificial trimerization domain. The resulting virus was, as anticipated, 
detargeted from Coxsackie- and Adenovirus Receptor (CAR) binding, and targeted to 
HLA-A1/MAGE-A1 molecules on tumor cells. Efficient and specific killing of targeted 
melanoma cell cultures was observed.
Finally, Chapter 7 provides information on functional consequences of deleting 
the protein IX gene from HAdV-5 vectors. Various effects of protein IX deletion are 
reported, including enhanced reporter gene delivery to CAR-negative cell lines and 
enhanced activation of peripheral blood mononuclear cells. These findings suggest 
that protein IX can affect the cell tropism of HAdV-5, and may function to dampen the 
innate immune responses against HAdV particles. This may be of relevance for future 




Genetisch gemodificeerde virale vectoren hebben potentie voor gebruik als oncolytisch 
therapeuticum. In het scala aan virussen dat geëvalueerd wordt, neemt humaan 
adenovirus serotype 5 (HAdV-5) een voorname plaats in binnen het onderzoek naar 
oncolytische virustherapie. Uit klinische studies is gebleken dat kankergentherapie 
met HAdV-5 vectoren veilig is, maar de effectiviteit blijkt vooralsnog beperkt te zijn. 
Verscheidene factoren belemmeren de effectiviteit, zoals samengevat in Hoofdstuk 2 
van dit proefschrift. Een voornaam probleem wordt gevormd door het onvermogen 
van het virus om tot de gehele tumormassa door te dringen. Dit wordt onder meer 
veroorzaakt door de lage en heterogene expressie van de coxsackie- en adenovirus 
receptor (CAR) op het oppervlak van de tumorcellen. In dit proefschrift wordt de 
ontwikkeling en preklinische evaluatie beschreven van nieuwe oncolytische HAdV-5 
vectoren. Deze vectoren zijn gericht tegen tumorcellen door middel van het koppelen 
van virale manteleiwitten (IX en fiber) aan verschillende typen polypeptiden.        
In de hoofdstukken 3 tot en met 5 wordt de ontwikkeling en evaluatie beschreven 
van een nieuw HAdV-5 ‘tumor-targeting’ systeem, gebaseerd op het fuseren van 
polypeptiden aan het kleinste HAdV-5 manteleiwit, eiwit IX. In Hoofdstuk 3 wordt de 
haalbaarheid aangetoond van het fuseren van eiwit IX met hyperstabiele enkelstrengs 
antilichamen (scFv’s). In tegenstelling tot normale antilichamen nemen hyperstabiele 
scFv’s een functionele vouwing aan in het reducerende milieu van het cytoplasma, 
waardoor ze in potentie zeer geschikt zijn om in te bouwen in de mantel van 
adenovirussen. We beschrijven de fusie van eiwit IX met een hyperstabiel scFv gericht 
tegen β-galactosidase (13R4), waarbij een 75-Ångstrom α-helix is geïncludeerd om de 
presentatie van 13R4 op het virusoppervlak te optimalizeren. Het 13R4 polypeptide 
bleek efficiënt te worden geïncorporeerd in de mantel van HAdV-5, en bleek de juiste 
vouwing aan te nemen gezien de binding aan β-galactosidase.
In het volgende hoofdstuk (Hoofdstuk 4) wordt aangetoond dat eiwit IX tevens 
geschikt is voor het beladen van HAdV-5 met enkelstrengs T cel receptoren (scTCRs). 
Infectie van tumorcellen kon worden verbeterd door middel van het koppelen van eiwit 
IX aan een scTCR (scTCRHLA-A1/MAGE-A1) die gericht is tegen het kanker-testis antigeen 
MAGE-A1, welke gepresenteerd wordt op het celoppervlak door humaan leukociet 
antigenen met haplotype A1 (HLA-A1). Ten opzichte van een controle virus bleken 
virusdeeltjes geladen met scTCRHLA-A1/MAGE-A1 in staat om HLA-A1/MAGE-A1-positieve 
melanoma cellen te transduceren met een tienmaal hogere efficiëntie. Tevens werd 
specificiteit van de HLA-A1/MAGE-A1 binding aangetoond. Deze resultaten laten zien 
dat eiwit IX potentieel heeft voor het richten van HAdV-5 vectoren naar kanker-testis 
antigenen op tumorcellen. Het principe van kanker-testis antigeen targeting, gericht 
tegen tumor-specifieke peptides die afkomstig zijn uit het cytoplasma van een cel, 
wijkt af van de conventionele targeting van oncolytische (adeno)virale vectoren, welke 
gericht is tegen celoppervlakte-eiwitten die tot overexpressie komen op tumorcellen. 
Kanker-testis antigenen zijn mogelijk zeer geschikt om als target te dienen voor 
kankertherapieën, doordat deze moleculen tot expressie komen op het celoppervlak 





In Hoofdstuk 5 wordt uiteengezet hoe eiwit IX gebruikt kan worden voor de 
koppeling van Affibody eiwitten. Door het relatief kleine formaat en de hoge 
bindingsaffiniteit aan receptoren worden Affibody eiwitten beschouwd als interessante 
structuren voor tumortargeting van virussen. Eerdere publicaties duiden echter op 
een inefficiënte targeting na het fuseren van eiwit IX met ‘hoog-affiniteit liganden’, 
zoals Affibody eiwitten, doordat het virus niet kan loskoppelen van de receptor in 
het endosoom. Onze studies laten zien dat de infectie van tumorcellen verbeterd kan 
worden door het incorporeren van een cathepsin-knipsequentie (CKS) tussen eiwit IX 
en het Affibody eiwit ‘ZH’, welke gericht is tegen de Humane Epidermale groeifactor 
Receptor 2 (HER2). Het includeren van de CKS bleek noodzakelijk te zijn om 
tumortargeting te bewerkstelligen van eiwit IX-ZH beladen virusdeeltjes. Verbeterde 
infectie vond plaats van HER2-positieve targetcellen (SKOV-3 eierstokkankercellen) 
in verschillende modellen, zijnde monolaagkweken, 3-dimensionale spheroidekweken 
en tumorkweken op de chorioallantoïsche membraan van bevruchte kippeneieren. 
Deze vindingen vergroten het potentieel van eiwit IX voor het koppelen van anti-
tumor liganden.     
In Hoofdstuk 6 wordt een alternatieve targetingstrategie beschreven, door middel 
van het fuseren van een scTCR (scTCRHLA-A1/MAGE-A1) met het fiber manteleiwit. In het 
genoom van een wildtype HAdV-5 is de sequentie coderende voor het globulaire 
deel van de fiber vervangen door sequenties coderende voor de scTCRHLA-A1/MAGE-A1 
en voor een kunstmatig trimerizatie domein. Door de afwezigheid van het globulaire 
fiberfragment bleek het gemodificeerde virus niet meer in staat tot binding aan de 
Coxsackie- en Adenovirus Receptor (CAR). In plaats hiervan vond binding plaats aan 
HLA-A1/MAGE-A1. Als gevolg werd een sterkere en meer specifieke doding van 
verschillende melanoma targetcellen waargenomen.
Tot slot wordt in Hoofdstuk 7 een studie beschreven naar de functionele gevolgen 
van eiwit IX deletie in het genoom van HAdV-5 vectoren. Verschillende effecten 
vinden plaats, waaronder een verhoogde afgifte van transgenen in CAR-negatieve 
cellen en een verhoogde activatie van bepaalde typen cellen van het aangeboren 
immuunsysteem. De bevindingen suggereren dat eiwit IX een rol speelt in de 
totstandkoming van het cellulaire tropisme, en dat het eiwit een functie heeft bij 
vermindering van de aangeboren immuunrespons. Deze aspecten verdienen nader 
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